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Brain tumours kill more children and adults under 40 than any other cancer.  
Approximately half of primary brain tumours are high-grade malignancies called 
glioblastoma multiforme (GBM).  The current treatment regime for GBM combines 
de-bulking surgery with radiotherapy and the chemotherapeutic temozolomide.  
However, mean survival for patients is approximately 15 months, with less than 5% 
achieving 5 year survival.  Unfortunately, this devastating prognosis has improved 
little over the last 40 years, highlighting the need for new strategies to improve the 
treatment of these tumours. 
To identify potential novel drug targets that could augment the cytotoxicity potency 
of temozolomide, a dual approach was taken in temozolomide resistant T98G GBM 
cells; a kinome-wide siRNA screen and two small molecule repurposing drug 
screens.  Cell viability was calculated by high-content microscopy and algorithm-
based scoring of Hoechst-positive cells.  Target validation studies were carried out 
using additional siRNA libraries and small-molecule compound dose-escalation 
studies in additional GBM cell lines and primary glioma stem-like cultures.   
These screens identified the targeting of Extracellular Regulated Kinase 5 (ERK5) or 
Fibroblast Growth Factor Receptor 4 (FGFR4), as well as the use of butamben to 
augment temozolomide sensitivity.  We also find that ERK5 is upregulated (mRNA 
and protein) in GBM compared to normal brain tissue, offering a potential 
therapeutic window for tumour specificity. 
Furthermore, the combination of EKR5 inhibition and temozolomide caused an 
increase in DNA damage combined with a reduction in homologous recombination 
and an increase in non-homologous end joining, likely to be potentiated through 
mitotic progression, inducing chromosomal aberrations and heightened cell death. 
These exciting data provide a platform for further pre-clinical and clinical 
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Chapter 1 – Introduction 
1.1 Cancer 
 
Between 2013 and 2015 in the UK, almost 990 people were diagnosed with cancer 
each day and in 2016 cancer was classified as one of the top ten leading causes of 
death by the World Health Organisation (CancerResearchUK, 2011b, 
WorldHealthOrganisation, 2018b).  In 2018, more than 9 million people were 
diagnosed with either lung, breast, colorectal, prostate, skin or stomach cancer, the 
most common types of cancer throughout the world (WorldHealthOrganisation, 
2018a).  Although cancer treatment and survival has improved vastly, with an 
average of 50% of all cancer patients surviving 10 years or more, there is a need for 
research into and identification of novel treatments that can deliver improved 
treatment for currently difficult to treat and incurable tumours (CancerResearchUK, 
2015).   
Cancer is an extremely diverse disease, however, the development of all cancers is 
thought to be initiated through the progressive accumulation of mutations in DNA, 
conferring a selective survival advantage over normal cells, inevitably causing the 
death of the patient if left untreated (NationalCancerInstitute, 2015).  Mutations 
which confer the progression and growth of cancer are termed ‘driver’ mutations, 
with the exact number of such mutations differing between cancer types, as 
reflected by a recent study across 29 cancer types showing up to 10 mutations, 4 on 
average, are required to cause and sustain cancer (Martincorena et al., 2017).  
Driver mutations are commonly associated with tumour suppressor genes, proto-
oncogenes and DNA repair genes.   
Tumour suppressor genes are also known as anti-oncogenes and their role is to 
limit cell proliferation whereas proto-oncogenes regulate normal cell proliferation.  
Loss of tumour suppressor genes and gain of function in proto-oncogenes, termed 
oncogenes following oncogenic mutations, leads to uncontrolled cell proliferation.  
Examples of tumour suppressor genes are TP53 and Rb and examples of oncogenes 
are HER2, hTERT, MYC and RAS.  However, some genes can be both proto-
oncogenes and tumour suppressors, for example NOTCH which is proto-oncogenic 
in acute lymphoblastic leukaemia but acts as a tumour suppressor in skin cells, with 
loss of function resulting in spontaneous basal cell tumours in mice (Grabher et al., 
2006, Nicolas et al., 2003).   
DNA repair genes, such as BRCA1/2 and MGMT, maintain genomic integrity and 
mutations in these genes causes deficiencies in DNA damage repair leading to 
genetic instability and mutagenesis.  These mutations may confer a selective 
growth advantage, driving uncontrolled cell proliferation (Stratton et al., 2009).  As 
tumour cells proliferate the number of mutations in their DNA accumulates which 
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not only results in different genetic mutations in tumours between patients but also 
different mutations within one tumour, termed intratumoural heterogeneity (ITH)  
(De Grassi et al., 2010).  This accumulation of mutations in oncogenic cells is called 
the mutator phenotype, and was first hypothesised in 1974 when the increase in 
DNA mutations in cancer cells compared to normal cells was connected to 
tumorigenesis (Loeb et al., 1974).  Originally, defective DNA polymerases were 
thought to cause the mutator phenotype, however, mutations in DNA damage 
genes were later included.  For example, mutations in the nucleotide excision repair 
pathway, such as those present in xeroderma pigmentosum, increases the risk of 
UV-induced skin cancer up to 10,000 times (Bradford et al., 2011, Loeb, 2016).  In 
hyperplasic pre-cancerous cells, the DNA damage response (DDR) has been shown 
to be activated, detected by markers such as ɣH2AX, CHK2, 53BP1 and ATM.  This 
dysregulation of the DDR is thought to promote proliferation, replication stress, 
genome instability and carcinogenesis (Bartkova et al., 2005, Gorgoulis et al., 2005).   
The number of mutations within one tumour can be anywhere from around 500 in 
acute myeloid leukaemia (AML) and up to 100,000 in GBM, with the majority being 
single-nucleotide substitutions, also called single-nucleotide polymorphisms (SNPs), 
of which transitions from GC to AT account for more than 60% of the mutations 
(Loeb, 2016).  SNPs can be found within exons, introns, promoter regions and also 
untranslated regions (UTRs), however, SNPs found in genes encoding factors with 
important functions within cellular metabolism and immunity, DNA mismatch 
repair and cell cycle progression can result in a genetic predisposition to cancer 
(Deng et al., 2017).  Although SNPs can increase the risk of cancer, there are around 
5 million which can be found throughout the human genome, and most do not 
affect the expression and/or function of genes (The Genomes Project et al., 2015).    
Mutations within DNA can be caused by exogenous sources, such as carcinogenic 
chemicals, as investigated in 1918 following the identification of epidemic scrotal 
cancer in chimney sweeps where coal tar, containing the yet to be identified 
carcinogen benzopyrene, was used to induce cancer in the ears of rabbits  (Loeb 
and Harris, 2008).  Other exogenous sources such as ionising radiation, viruses and 
chemicals, as well as endogenous sources such as oxidative damage which occur as 
a result of normal metabolism, and errors in DNA replication also cause mutations 
in DNA (Bartkova et al., 2005, Gorgoulis et al., 2005, Mandal et al., 2011).   
The accumulation of driver mutations results in the formation of cancers which all 
share ten established ‘hallmarks’, irrespective of their diverse complexities 
(Hanahan and Weinberg, 2011).  The first six hallmarks included sustaining 
proliferative signalling, evading growth suppressors, resisting programmed cell 
death, enabling replicative immortality, inducing angiogenesis and activating tissue 
invasion and metastasis (Hanahan and Weinberg, 2000).  The additional hallmarks 
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included downregulation of cellular energetics and avoiding immune destruction, as 
well the inclusion of two hallmarks, tumour promoting inflammation and genome 
instability, which facilitate the accumulation of other hallmarks as cancer 
progresses (Hanahan and Weinberg, 2011).  The importance of these hallmarks has 
been highlighted by the development of therapeutic approaches which target each 
trait, for example, telomerase inhibitors to reduce replicative immortality and VEGF 
inhibitors to reduce angiogenesis (Hanahan and Weinberg, 2011). 
 
1.2 DNA Damage Response 
 
Each day, the human genome is subject to thousands of DNA lesions which can 
cause errors in DNA replication and if these errors are not repaired, deleterious 
aberrations which can effect cell viability and subsequent progeny (Jackson and 
Bartek, 2009).  These lesions are identified and repaired by the DNA damage 
response (DDR), which is comprised of individual enzymes through to complex 
pathways, all designed to promote the repair of any lesions which could potentiate 
mutations, thereby ensuring the preservation of genomic integrity (Pagès and 
Fuchs, 2002, Rouse and Jackson, 2002).   
In cancer cells, DDR pathways are often dysregulated which results in continuous 
genomic instability and the accumulation of mutations contributing to the 
progression and malignancy of the tumours e.g. mutator phenotype.  In order to 
survive and replicate in such a highly mutagenic background, tumours can be 
influenced by their tumour microenvironment (TME), as seen in colorectal cancer 
where deficiencies in the DDR pathway mismatch repair (MMR), which 
subsequently effect patient survival and response to treatment, are altered in 
response to the microbiome surrounding the tumour (Hale et al., 2018, Nik-Zainal, 
2019).   
In order to continue replicating with such a high mutational load, tumours can also 
become dependent on certain features, such as loss of checkpoint regulation, high 
dependence on oncogenes, or over reliance on DDR pathways that can still be 
functional even within their highly mutagenic background (Nik-Zainal, 2019).  These 
dependencies can be selectively targeted, leaving normal, healthy cells relatively 
unaffected by such treatments.  As molecular targeting acts in a more specific 
manner than traditional radiotherapy and chemotherapy treatments, normal tissue 
toxicity is reduced and patients are able to tolerate the reduced side effects (Ke and 
Shen, 2017).  A successful example of molecular targeting of oncogenes can be seen 
in chronic myeloid leukaemia (CML), where imatinib is effective at treating 95% of 
patients (Roskoski Jr., 2003). The fusion gene BCR-Abl, which is responsible for the 
malignancy of the disease, is inhibited by imatinib and subsequently patients 
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achieve remission with undetectable levels of BCR-Abl (de Klein et al., 1982, 
Roskoski Jr., 2003).   
 
1.3 Brain Cancer 
 
In the UK, brain cancer kills around 5,000 people every year, reducing life 
expectancy by 20 years (Burnet et al., 2005), and in 2014, brain cancer was 
classified as a cancer of unmet need by Cancer Research UK.  On average 50% of all 
patients diagnosed with cancer will achieve at least a 10 year survival, however, for 
patients with brain cancer, 10 year survival is only achieved by 13.5% 
(CancerResearchUK, 2011a, CancerResearchUK, 2011b).   
Tumours of the nervous system include both central (CNS) and peripheral nervous 
systems (PNS) tumours, with brain tumours arising within the CNS.  Most nervous 
system tumours are derived from non-neural glial cells which support and protect 
nerve cells (figure 1.1).  This is most likely due to the ability of glial cells to grow and 
divide in a developed and mature nervous system, unlike nerve cells which are 
largely non-proliferative.  Glial derived tumours are called gliomas and include 















Figure 1.1: CNS Tumour Origins  
Neural stem cells are believed to produce two progenitor cells: glial-restricted progenitor cells 
and neuronal-restricted progenitor cells.  Astrocytes and oligodendrocytes are derived from 
glial-restricted progenitors and neurons from neuronal-restricted cells.  However, there has 
been evidence supporting an alternative theory, whereby oligodendrocytes and motor neuron 
cells are derived from the same neuronal progenitor cells (Lu et al., 2002).  Glial tumours of 
the CNS are defined by the cell from which they arise; astrocytes form astrocytomas, 
oligodendrocytes form oligodendrogliomas and both cell types form oligoastrocytomas.  There 
are also CNS tumours which are formed from neural cells, such as medulloblastoma, however 
these generally present in children. 
 
Figure adapted with  permission from (Zhu and Parada, 2002) 
License number: 4463600514905 
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Interestingly, there appears to be a link between immune system activity and the 
risk of gliomas.  An increase in IgE levels, as seen with allergic disorders such as 
asthma, and cytomegalovirus titre are both associated with a decreased glioma risk 
(Bondy et al., 2008, Linos et al., 2007, Weller et al., 2015).  Infection has also been 
associated with a decreased risk of glioma, however, conflicting reports highlight 
the uncertainty of this association (Weller et al., 2015).  Post-operative infection 
has also been investigated in relation to survival in high-grade glioma patients 
across several studies; however, conclusive evidence showing any survival benefit 
has not yet been found (De Bonis et al., 2011). 
Along with alterations in the immune system, genetic and epigenetic mutations 
have also been studied in relation to gliomas.  Genome-wide analysis has enabled 
the identification of genetic and epigenetic changes which are found in certain 
types of gliomas, not only improving tumour classification, but also improving 
prediction of patient survival and response to treatment, all of which will positively 
impact the future of clinical trials and the personalisation of medicine (Reifenberger 
et al., 2017).  These alterations are now part of the World Health Organisation 
(WHO) integrated diagnostic classification of gliomas, where gliomas are scored 
from grade I through to IV based on malignancy determined by both histopathology 
and the newly identified diagnostic biomarkers (Reifenberger et al., 2017, Zhu and 






Figure 1.2: Integrated Diagnosis (Histology and Molecular Diagnostics) for WHO Grade II, III 
and IV Gliomas 
Histological examination determines tumour type (astrocytomas, oligodendrogliaomas, 
glioblastomas) and grade (I - IV) which correlates with malignancy, however, molecular 
biomarkers have proven to be more accurate predictors of clinical outcome.  IDH status, ATRX 
status, 1p/19q status and H3-K27M status can all be investigated in the process of classifying 
a tumour. 
 
Figure copied with permission from (Reifenberger et al., 2017) 
License number: 4463631369520 
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The biomarkers which were included by WHO as part of the integrated diagnosis 
pathway for gliomas include: IDH mutations, 1p/19q co-deletion and H3F3A or H3-
K27M mutations, however, the biological role of some of the biomarkers, such as 
1p/19q co-deletion, is not yet evident (Reifenberger et al., 2017).  There are other 
biomarkers which may be included as requisites in future, such as ATRX loss, TERT 
promoter mutations and BRAF fusions/mutations (Reifenberger et al., 2017).   
IDH mutant glial tumours which also have 1p/19q co-deletion and morphology 
similar to oligodendrocytes are predicted to have the best patient survival, with IDH 
mutant tumours which do not have a 1p/19q co-deletion and are astrocytic in 
morphology are predicted to have the next best patient survival and finally IDH 
wild-type tumours, found in higher grade gliomas, have the worst predicted patient 
survival (Weller et al., 2015).  IDH mutations are important predictors of survival as 
these tumours are more susceptible to oxidative stress due to changes in 
metabolism, improving patient response to treatment, however, mutant IDH alone 
cannot initiate the development of gliomas (Reitman and Yan, 2010, Sasaki et al., 
2012).  ATRX and TP53 mutations or 1p/19q co-deletion and TERT promoter 
mutations are also required for the formation of astrocytomas and 
oligodendrogliomas respectively (Reitman and Yan, 2010).  Various other genetic 
aberrations will also accumulate before grade II or III astrocytomas can progress in 
to grade IV GBMs (Reifenberger et al., 2017) (see 1.3.1). 
Of all the CNS tumours which occur in adults, astrocytomas are the most common 
and account for around 60% of all primary brain tumours (Adamson et al., 2009).  
Glioblastoma multiforme (GBM), the most common glioma, is a highly malignant 
grade IV astrocytoma, which is characterised by disease reoccurrence and 
resistance to treatment (Zhu and Parada, 2002).   
 
1.4 Glioblastoma Multiforme 
 
GBM, the most common high-grade glioma, accounts for around half of all primary 
adult brain tumours (Adamson et al., 2009, Kleihues et al., 2000).  GBM tumours are 
extremely aggressive and fast growing, with around 95% of GBM tumours arising 
prior to detection of a lesser grade tumour (Ohgaki and Kleihues, 2013).  GBM 
tumours that have progressed from a less malignant astrocytoma (grade II or III) 
have better patient prognosis due to differences in the genetic profiles (Ohgaki and 
Kleihues, 2013).   
Between 2007 and 2011, almost 11,000 people were diagnosed with GBM in 
England, with a median survival of just over 6 months and 5 year survival achieved 
by only 3.4% (Brodbelt et al., 2015).  Currently, the most aggressive treatment for 
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GBM is de-bulking surgery followed by radiotherapy and chemotherapy in the form 
of temozolomide (TMZ) (Stupp et al., 2009).  The heterogeneity and complexity of 
the disease biology combined with rapid treatment resistance needs to be further 
investigated and understood in order to improve treatment regimes and 
consequently patient survival.   
 
1.4.1 Genetic Aberrations in Glioblastoma 
 
The number of mutations within one tumour varies across tissue types, ranging 
from around 500 in acute myeloid leukaemia (AML) up to more than 100,000 in 
GBM (Loeb, 2016).  In order to begin to understand this complex, highly mutated 
disease, The Cancer Genome Atlas (TCGA) piloted a GBM study in 2008 
investigating aberrations in DNA and mRNA of 206 GBM patients 
(CancerGenomeAtlasResearchNetwork, 2008).  This investigation was built upon 
and in 2013 more than 500 GBM tumours were analysed, identifying somatic 
mutations and transformed pathways (Brennan et al., 2013). 
Around 5 to 10% of GBM cases are secondary tumours, arising from a less 
malignant, lower grade astrocytoma (grade II or III) (Ohgaki and Kleihues, 2013).  
IDH mutations are associated with the development of low grade gliomas and are 
often found in combination with mutations in TP53, a tumour suppressor, and 
ATPX, involved in gene regulation via chromatin remodelling and also telomere 
maintenance (Reifenberger et al., 2017).  Every IDH mutant tumour has a mutation 
in IDH1 at amino acid 132, where arginine is replaced by histidine (R132H) (Cohen 
et al., 2013). IDH mutations enable cells to convert α-ketoglutarate (αKG) to R(-)-2-
hydroxyglutarate (2-HG) instead of NADPH (Cohen et al., 2013).  This leads to 
abnormal methylation of DNA and histones and eventually the formation of CpG 
islands, also known as the glioma CpG island methylator phenotype (G-CIMP) and 
the reduced NADPH production increases the susceptibility of these tumours to 
oxidative stress, improving patient response to treatment (Reitman and Yan, 2010).  
To progress to a grade IV GBM, there are various aberrations that occur; CDKN2A 
and CDKN2B loss (cell cycle regulation) and 19q loss.  Other mutations found in IDH 
mutant GBM tumours include activation of the MYC and RAS/PI3K pathway 
(survival and proliferation), FOXM1 (cell cycle progression) and E2F2 (transcription 
factor controlling cell cycle progression and tumour suppressors), as well as 
silencing of PRC2 (chromatin modifications) (Reifenberger et al., 2017).  The outlook 
for patients with secondary mutant IDH GBM is better than that of those with 
primary GBM, with a median survival of 31 months (Ohgaki and Kleihues, 2013).  
This is due to several factors including prevalence of mutant IDH GBM tumours in 
younger adults (20-50 years) and a higher proportion of MGMT promoter 
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methylation (90% compared to 40%) (Reifenberger et al., 2017).  This renders the 
tumours more sensitive to the cytotoxic effects of the mainstay chemotherapeutic 
alkylating agent temozolomide.   
GBM IDH wild type (WT) tumours also have associated genomic aberrations 
including: PTEN mutations or deletions (tumour suppressor), CDKN2A and CDKN2B 
loss, TERT promoter mutations (telomere maintenance), gain of chromosome 7, 
loss of chromosome 10 and amplification in EGFR (growth, survival, and 
proliferation). There are also several mutations, which are less prevalent, including 
those in the tumour suppressor TP53 and several proteins involved in survival and 
proliferation e.g. PIK3CA, PIK3R1 and NF1. There are also some less common 
amplifications including: MDM2 and MDM4 which are inhibitors of TP53 activity 
and CDK4 and CDK6 which regulate cell cycle progression. Receptor amplification is 
also seen in a subset of IDH WT tumours and includes PDGFRα and HGFR, which 
both have roles in cell survival and proliferation (Reifenberger et al., 2017) and 
amplification in EGFR is found in around 50% of all GBM cases diagnosed.  Around 
half of the EGFR mutations which occur have a deletion of exons 2 to 7 and this 
generates the EGFR variant III (EGFRvIII), a constitutively active receptor which has 
no ligand binding domain (Aldape et al., 2015).  EGFR mutations have been shown 
to be insignificant in determining overall survival (Hartmann et al., 2013). A 
combination of EGFR amplification, combined with two of the following 3 
mutations: TERT promoter, gain of chromosome 7 or loss of chromosome 10 is 
sufficient to diagnose a IDH WT GBM tumour (Stichel et al., 2018).   
 
1.4.2 Molecular Classification of Glioblastoma Subtypes 
 
As well as investigating genomic aberrations, gene expression data has been used 
to subtype GBM tumours based on dominant gene expression or mutations.  TP53, 
RB1 and receptor tyrosine kinases have previously been identified as being mutated 
in a high proportion of GBM tumours and have therefore been implicated in  the 
development of GBM, however, further investigation into molecular classification 
has identified four sub-groups: proneural, neural, classical and mesenchymal (figure 
1.3) (CancerGenomeAtlasResearchNetwork, 2008, Verhaak et al., 2010).  
Of the 4 subtypes, the proneural group was found to have the best survival due to 
the presence of IDH mutations and a lower overall age at diagnosis, encompassing 
secondary GBMs which progress from lesser grade astrocytomas.  Proneural GBM 
subtypes were also shown to have amplification of PDGFRA and neural stem cell 
genes such as SOX2.  Neural subtypes were found to express nerve associated 
genes such as NEFL1 and GABRA1.  Classical subtypes had chromosome7 
amplification and chromosome 10 loss combined with high levels of EGFR 
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amplification, and although TP53 is the most commonly mutated gene in GBM, this 
mutation was not found in the classical subtype.  Mesenchymal subtypes had a 
significant increase in NF1 deletions, as well as PTEN co-mutations (Verhaak et al., 
2010).  The subtyping of GBMs will likely be important therapeutically as different 
subgroups may require different targeted approaches in order to treat patients 









1.5 Multimodal Treatment of GBM 
1.5.1 De-bulking Surgery 
 
The standard treatment for GBM involves de-bulking surgery to remove the 
majority of the malignant tumour, followed by radiotherapy and concomitant and 
adjuvant chemotherapy, in the majority of cases this is the DNA alkylating agent 
temozolomide. The importance of de-bulking surgery is reflected by a multivariate 
analysis study which showed removal of less than 98% of the tumour can 
significantly reduce survival from a median of 13 months to 8.8 months (Lacroix et 
al., 2001).  However, tumour margins are extremely difficult to accurately identify 
Figure 1.3: Molecular Classification of Glioblastoma Subtypes 
Gene expression from 200 GBM tumours and 2 normal brain samples were analysed across 3 
platforms, with 840 genes identifying 4 sub-groups of GBM: proneural, neural, classical and 
mesenchymal.  This molecular selection data was then validated using publicly available data 
sets (A and B) and glioblastoma xenografts established from patient specimens implanted 
after surgery (C).  Validation showed GBM subtyping to be reproducible across the three 
datasets.  
 
Figure adapted with permission from (Verhaak et al., 2010) 
License number: 4464810890816 
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due the limited imaging techniques and the migratory nature of GBM cells which 
have been discovered up to 6cm away from CT imaged tumour margins.  MRI is also 
unable to identify GBM tumour margins effectively with tumour cells identified 
2.5cm away from the imaged boundaries (Price and Gillard, 2014). This inability to 
image the tumour margin accurately inhibits complete resection of the tumour, 
enabling the disease to recur.  The extent of tumour removal that can be achieved 
by surgery is also highly influenced by the location of the tumour, as surgery could 
potentially cause damage to or removal of healthy brain tissue.  For example, 
patients with frontally located tumours were found to have a longer median 
survival compared to those with tumours located elsewhere (101 weeks compared 
to 47 weeks) (Jeremic et al., 1994). 
There have been various innovations in order to improve the outcome of surgical 
removal of brain tumours including the use of intraoperative MRI (iMRI) and 5-
aminolevulvinic acid hydrochloride (5-ALA) which enables surgeons to identify 
tumour cells as they fluoresce (Kuhnt et al., 2011, Teixidor et al., 2016).  However, 
even with these advances, GBM is a highly migratory and infiltrative disease making 
it still extremely difficult to remove all traces of the cancer cells without 




Treating GBM by postoperative radiotherapy has been the standard procedure for 
almost half a century, with a comparison study in 1980 expressing the efficacy of 
radiotherapy in prolonging survival post-surgery whilst also highlighting the need to 
‘continue the search for an effective chemotherapeutic’ (Walker et al., 1980).  
Radiotherapy uses ionizing radiation in the form of high energy x-rays to cause DNA 
damage and eventually cell death within the precise tumour location.  The central 
nervous system, however, is formed of tissues that are highly resistant to 
radiotherapy meaning a higher dose is often needed to cause cell death (Cassidy et 
al., 2015).   
In the 1970s, 60Gy of whole brain radiotherapy was shown to increase survival by 
2.3 times in GBM patients compared to ≤45Gy and is still the dose used today, 
however, now GBM patients receive 60Gy in once daily fractions of 2Gy for 30 days 
post-surgery (Gzell et al., 2017).  Hyper-fractionated radiotherapy (60Gy over 30 
days in more fractions i.e. twice daily) was shown to have adverse effects on GBM 
patient survival (Barani and Larson, 2015).  
Intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy 
(VMAT) are the techniques used to treat GBM patients today.  IMRT enables the x-
32                                                                                                                   Natasha Carmell 
 
rays to be targeted more directly at the tumour resulting in less toxicity to the 
surrounding eloquent brain tissue but does rely heavily on MRI.  There are few 
studies regarding VMAT in GBM, however, it is a dynamic radiotherapy which is 
able to specifically target the tumour giving a similar dose to IMRT but in a shorter 
period of time (Gzell et al., 2017).  
Magnetic Resonance Linear Accelerators (MR Linac) are a relatively new 
technology, with the UK’s first scan taking place in a healthy volunteer in November 
2017.  The MR Linac is able to ‘precisely locate tumours, tailor the shape of X-ray 
beams in real time and accurately deliver doses of radiation to moving tumours’, 
aiming to limit radiation damage to healthy tissues and maximise the dose to the 
tumour (TheRoyalMarsden, 2017).  It will therefore be interesting to see if clinical 
implementation of these new and emerging imaging techniques will be bought into 




In 1987, a meta-analysis used randomised trial data to determine the effect of 
adjuvant nitrosoureas chemotherapy on GBM patient survival when compared to 
treatment with radiotherapy alone (Stenning et al., 1987). Nitrosoureas 
chemotherapeutics are drugs (e.g. carmustine and lomustine) which are able to 
cross the blood brain barrier and cause alkylation damage to both DNA and RNA 
(Schabel, 1976).  Their findings showed a 9% increase in 1 year survival when 
patients were treated with both radiotherapy and adjuvant chemotherapy, 
however, due to the small data set their conclusions were tentative (Stenning et al., 
1987).  Published nearly two decades later, a larger meta-analysis which compared 
randomised trial data from 3004 patients found similar results; a modest 6% 
increase in one year survival (GMTGroup, 2002).  Although the effects of 
nitrosoureas chemotherapy still remain unclear, implants in the form of carmustine 
(BiCNU) wafers are used by the NHS to treat GBM patients following de-bulking 
surgery, however, they are associated with increased complications and are 
therefore used infrequently (Bregy et al., 2013, NICE, 2007). 
Synthesised in the 1980s, temozolomide is a cytotoxic alkylating agent which causes 
methylation of DNA, and is now used as an adjuvant and concomitant 
chemotherapeutic to treat GBM.  When exposed to the slightly alkaline pH of the 
blood, temozolomide is metabolised to 3-methyl-(triazen-1-yl)imidazole-4-
carboxamide (MTIC), which is further metabolised into a methyldiazonium ion.  
Methyldiazonium methylates DNA at several places, however, O-6-methylguanine is 
believed to be the most cytotoxic adduct yet only accounts for less than 8% of all 
lesions caused by temozolomide (Kaina et al., 2007, Newlands et al., 1997).   
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O-6-methylguanine adduct is directly repaired by the enzyme O-6-methylguanine 
DNA methyltransferase (MGMT) (Agarwala and Kirkwood, 2000, Newlands et al., 
1997).  MGMT repairs the damage by transferring the methyl group from O-6-
methylguanine to itself, permanently inactivating the enzyme and leading to its 
degradation.  If the level of methylation exceeds the level of MGMT enzyme and 
the damage cannot be repaired, O-6-methylguanine can be paired with dT 
(deoxythymidine) causing transition mutations from a GC pairing to O-6-methylG T 
pairing.  The inability of the mismatch repair pathway (MMR) to repair the damage 
is potentially why this lesion is so cytotoxic.  The transition mutation causes a futile 
cycle of base excision and base insertion which results in perpetual single strand 
breaks in DNA.  Replication forks can stall when they reach these lesions and this 
may result in reduced replication rates or fork collapse and generation of DNA 
double strand breaks (continued under Associated DSB Repair Pathways) and 
subsequent apoptotic mechanisms are activated (figure 1.4). If cells have a deficient 
mismatch repair (MMR) pathway they can continue through the cell cycle with 
methylated DNA bases (Harris et al., 2015, Noonan et al., 2012). Translesion 
synthesis (TLS) polymerases can also be activated in order to bypass the O-6-
methylguanine lesion, allowing the cell to tolerate the damage and continue DNA 
replication.  However, this mechanism is less faithful in its replication abilities and 
can result in point mutations (Fu et al., 2012).   
N-3-methyladenine and N-7-methylguanine are the most common DNA lesions 
caused by temozolomide treatment; however, these are readily repaired by the 
Base Excision Repair (BER) pathway and were initially believed to play no role in 



































Before approval for treatment of GBM, promising preclinical data for temozolomide 
showed anti-tumour activity in mouse models of various cancers, an excellent oral 
bioavailability of 98%, rapid activation and the ability to infiltrate the blood brain 
barrier (BBB) (Newlands et al., 1997).  Important data from a randomised trial were 
published in 2005, showing that treatment with both radiotherapy and adjuvant 
temozolomide for newly diagnosed GBM patients significantly increased survival by 
2.5 months when compared to radiotherapy alone.  An increase in 2 year survival of 
Figure 1.4: Processing of TMZ induced O-6-methylguanine Lesions  
O-6-methylguanine is directly repaired by MGMT, however, if the level of methylation exceeds 
the level of MGMT enzyme, unrepaired O-6-methylguainine will be incorrectly paired with 
thymine and TLS polymerases can be activated to bypass this lesion enabling replication to 
continue. The incorrect base pairing is detected by the mismatch repair (MMR) pathway 
which recognises the damage, resulting in futile cycles of MMR causing single strand gaps or 
breaks in DNA.  In the subsequent cycle of replication, replication fork collapse can cause 
double strand DNA breaks (DSB).  DSBs can be repaired by HR or NHEJ; however, mutations 
can occur as a result of these pathways or alternatively apoptosis is induced. Initial detection 
of the O-6-methylguanine lesions can also immediately induce apoptosis by activation of ATR-
ATRIP pathway.    
 
Figure adapted with permission from: (Fu et al., 2012) 
License number: 4474130220785 
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GBM patients from 10.4% to 26.5% lead to temozolomide being NICE (National 
Institute of Health and Care Excellence) approved, and in 2007, patients diagnosed 
with primary brain tumours in the UK could receive this treatment (Arney, 2013, 
Stupp et al., 2005).  A further study comparing survival of patients treated with 
radiotherapy combined with carmustine and those treated with adjuvant 
temozolomide showed the later treatment to be superior, with a higher median 
value of 15.9 months compared to 11.5 months (Vinjamuri et al., 2009).  Both 1 and 
2 year survival post diagnosis were also higher for patients treated with adjuvant 
temozolomide by 20% and 27% respectively. However, on average the patients 
treated with adjuvant carmustine had larger tumours and there was also no 
difference in progression free survival. This could mean temozolomide may not be 
more beneficial in halting disease progression but as it has a much lower toxicity 
than carmustine, it may be a better treatment choice (Vinjamuri et al., 2009). 
The current treatment regime for newly diagnosed patients with GBM is de-bulking 
surgery followed by concomitant temozolomide (75mg/m2 for 42 days) and 
radiotherapy (60Gy over 30 fractions) 4 weeks post-surgery. 4 weeks after 
concomitant temozolomide chemo-radiotherapy finishes, 6 28 day cycles of 
adjuvant temozolomide are given (100-200mg/m2 on days 1-5 depending on 
haematological tolerance) (ClinicalTrials.gov, 2018). 
 
1.5.4 Tumour Treating Fields 
 
Tumour Treating Fields (TTF) are low intensity alternating current fields which 
disrupt tumour cell proliferation by acting as an anti-mitotic agent (Gzell et al., 
2017).  A randomised phase III trial between July 2009 and 2014 investigated the 
effect of TTF in combination with adjuvant temozolomide in almost 700 patients 
with GBM.  In a report published at the end of 2017, median progression free 
survival was significantly improved by 2.7 months (6.7 months: 4.0 months 
TTF+TMZ: TMZ) and overall survival was also significantly improved by 4.9 months 
(20.9 months: 16.0 months TTF+TMZ: TMZ). Importantly, the combination of TTF 
with adjuvant temozolomide was tolerated well and there was no increase in 
adverse effects when compared to patients who received temozolomide only.  
However, the device must be worn on a shaved scalp for >18 hours every day, 
which of course could create issues for some patients and it is unfortunately not yet 
NICE approved so would cost a patient upwards of £18,000 per month (Stupp et al., 
2017).  Currently, NICE do not endorse the use of TTF for patients who have been 
newly diagnosed with GBM as ‘they are not an efficient use of NHS resources’ 
(NICE, 2018a). 
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1.5.5 Proton Beam Therapy 
 
Proton bean therapy (PBT) utilises beams of protons which cause DNA damage via 
ionising radiation, however, PBT is a more accurate alternative to traditional x-ray 
radiotherapy (Jäkel, 2007).  The energy of the protons can be adjusted in order to 
target tumours deeper within the body, making it preferable for harder to reach 
tumours such as those in the CNS, sarcomas and cancers of the head and neck 
(Frisch and Timmermann, 2017).  Due to the limited side scatter of protons, normal 
tissue toxicity is also reduced which is desirable for paediatric patients as the 
irreversible side effects of traditional x-ray based radiotherapy are well established 
and include both physical and mental defects (Armstrong et al., 2010, Paulino et al., 
2000).  There is currently a phase II clinical trial recruiting newly diagnosed GBM 
patients in order to investigate whether there is any survival benefit for patients 
who receive PBT in combination with temozolomide to both IMRT and traditional 
radiotherapy, a trial which is now feasible in England due to the NHS commission of 
two PBT centres (ClinicalTrials.gov, 2018, NHSEngland).  
  
1.6 Blood Brain Barrier 
 
One key issue with treating GBM tumours is the blood brain barrier (BBB).  The BBB 
is formed by endothelial tight junctions and it is vital in maintaining brain 
homeostasis.  The protective role of the BBB makes it difficult for systemically 
delivered drugs to pass into the brain and target brain tumours (Ballabh et al., 
2004).  Unlike many drugs, temozolomide is lipophilic and has a relatively low 
molecular weight, meaning it is readily able to cross the BBB (Kelly et al., 2005).  
Aiming to improve drug delivery to the brain, drugs such as mannitol that cause a 
short term disruption of the BBB have been trialled; however, the results were not 
promising and there were many dangerous side effects including neurological 
toxicity (Siegal et al., 2000). Drug efflux transporters within the central nervous 
system also contribute to brain homeostasis, pumping nutrients into and toxins out 
of the brain.  Inhibition of these transporters has been shown to increase the ability 
of a drug to pass into the brain without damaging the integrity of the BBB. 
However, little development has occurred following disappointing clinical trial 
results (Siegal et al., 2000, Van Tellingen et al., 2015).    
Delivery of drugs directly into the brain is one way to overcome the BBB without 
the risks of BBB disruption, however, there are still many issues associated with 
methods of direct delivery.  An intraventricular catheter, such as an Ommaya 
reservoir, allows drugs to be delivered directly into cerebral spinal fluid (CSF) which 
surrounds the entire CNS.  As the drugs are delivered directly into the CSF, they are 
now contained within the CNS by the BBB and therefore will have reduced systemic 
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toxicity.  Once the drugs are delivered, their ability to diffuse is ultimately affected 
by their size.  Small molecules diffuse quickly resulting in a reduced drug 
concentration, conversely, large molecules have extremely poor diffusion abilities 
(less than 1 mm over 72 hours), both resulting in reduced treatment efficacy.  To 
overcome the inability of large molecules to diffuse, convection-enhanced delivery 
(CED) stents have been developed to deliver drugs over a continuous pressure 
gradient allowing a more even distribution of drugs throughout the brain tissue 
(Zhou et al., 2012).  The PRECISE trial, which compared the use of CED stents to 
deliver bacterial toxins to treatment with carmustine wafers, showed no difference 
in patient survival.  However, this could be due to a variety of factors including drug 
efficacy and variation in stent positions (Kunwar et al., 2010).    
Even if effective drug delivery into the brain could be achieved, it will not 
necessarily be able to effectively target GBM due to the recurrent and highly 
invasive nature of the tumour.   The tumour blood brain barrier has been shown to 
be compromised in GBM tumours detectable on MRI scans, however, the more 
invasive tumour cells which are outside the compromised tumour blood brain 
barrier and are migrating into healthy brain tissue have an intact and effective 
barrier against drugs.  These malignant cells would be able to evade exposure to 
drug treatments, continue to proliferate and cause recurrence of GBM  (Van 
Tellingen et al., 2015).   
 
1.7 Resistance to Treatment 
1.7.1 MGMT Promoter Methylation and Mismatch Repair  
 
Resistance to treatment is a characteristic of GBM tumours which leads to the 
recurrence of the tumour and consequently patient death.  Treatment resistance is 
extremely complex; however, advances will need to be made in order to improve 
patient response and survival.  Methylation of the MGMT promotor is one factor 
known to be beneficial for GBM patient survival as these tumours are sensitive to 
temozolomide chemotherapy.   
Methylation downregulates MGMT expression meaning tumours with MGMT 
promoter methylation are more responsive to temozolomide treatment as O-6-
methylguanine bases are left unrepaired, leading to futile MMR cycles and 
eventually apoptosis of the GBM tumour cells (figure 1.5) (Xie et al., 2016).  This 
induction of apoptosis by temozolomide relies on a proficient MMR pathway 
(Hickman and Samson, 2004).      
As MGMT is able to directly repair the toxic lesions caused by temozolomide, 
inhibitors of this enzyme have been tested in GBM clinical trials as potentiators of 
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temozolomide cytotoxicity. O-6-benzylguanine (O6-BG) irreversibly inhibits MGMT 
repair activity via the transfer of a benzyl group to the active site of MGMT (Konduri 
et al., 2009). In a phase I trial combining O6-BG with temozolomide, haematological 
toxicity, particularly myelosuppression, was a major limitation. The dose of O6-BG 
to inhibit MGMT activity for 48 hours and the maximum tolerated dose (MTD) of 
temozolomide in combination with O6-BG was established.  The regime established 
from the phase I trial was as follows: 1 hour IV infusion of 120mg/m2 O6-BG 
followed immediately by a 30mg/m2 O6-BG infusion for 48 hours. Oral 
temozolomide, at a maximum tolerated dose of 472mg/m2, was given within 60 
minutes of completing the initial O6-BG infusion (Quinn et al., 2005).  This regime 
was tested in a phase II clinical trial in patients with GBM and anaplastic gliomas 
(anaplastic astrocytoma and anaplastic oligodendrogliomas). Combination 
treatment was able to re-sensitise anaplastic gliomas to temozolomide, however, 
this was not seen in GBM cases. As haematological toxicity was an issue with the 
combination treatment, the temozolomide dose was reduced by 50% which may 
partially explain this lack of sensitivity observed in this trial (Quinn et al., 2009), 
however, even this reduced dose is above the 100-200mg/m2 recommended as part 
of standardised care.    
High grade brain tumours can also become resistant to temozolomide treatment 
very quickly, and almost 90% of patients with recurrent GBM have tumours that 
have a complete lack of response to a second cycle of temozolomide (Oliva et al., 
2010).  This is not due to a change in MGMT promotor methylation status, as when 
patients who are initially sensitive to temozolomide treatment (methylated MGMT 
promoter) become resistant; their methylation status remains unchanged (Felsberg 
et al., 2011, Maxwell et al., 2008).  The  constantly mutating and evolving tumour 
genome results in massive intratumoural heterogeneity (ITH) and consequently 
treatment failure and disease recurrence (Qazi et al., 2017). 
Patients with mutations in the MMR pathways within their tumours have an 
increased resistance to temozolomide treatment.  Their ineffective repair pathway 
and lack of MRR induced apoptosis means they have a tolerance for mismatched 
base pairs and lesions in DNA.  This causes an increase in mutagenic properties 
resulting in many changes, including resistance to chemotherapy.  Loss of MLH1 has 
been shown to confer temozolomide resistance in GBM cell lines and loss of MSH6 
protein has been shown to be a driver in the development of GBM (Forsström et al., 
2017, Stritzelberger et al., 2018).  However, mutations in MMR pathway are not 
believed to be important in resistance to temozolomide treatment in GBM due to 
the minimal detection of microsatellite instability (MSI), a marker of MMR 
deficiency (Maxwell et al., 2008).   
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Cells can overcome depletion of MSH6 (a key MMR protein) by forming a dimerised 
MSH2-MSH3 complex (MUTSβ), enabling the MMR pathway to re-establish its 
repair activity (Maxwell et al., 2008).  As MSH3 expression is less than that of MSH6, 
the formation of MUTSβ complexes reaches a saturation point resulting in limited 
MMR repair which may be insufficient to repair multiple mismatched bases, 
generating an increase in the number of somatic mutations (Marsischky et al., 1996, 
Maxwell et al., 2008).  Interestingly, an increase in mRNA expression of MMR genes 
MSH6, MSH3, MSH6 and PMS1 was detected in GBM patients following treatment 
with temozolomide.  The only patient who did not have a significant increase in 
MSH6 mRNA post temozolomide treatment survived the longest, suggesting an 
increase in MMR gene expression may play a role in temozolomide resistance (Sun 
et al., 2018).  In addition to gliomas, high MSH6 expression has been correlated 
with worse survival in melanoma and osteosarcoma (Alvino et al., 2014, Jentzsch et 
al., 2014, Liang et al., 2017). This dysregulation of MMR proteins could possibly 
result in defective interaction between MMR proteins resulting in an incompetent 
DNA repair pathway, a tolerance for mismatched base pairs and lesions in DNA and 












































Figure 1.5: O-6-methylguanine Repair: MGMT and Mismatch Repair  
O-6-methylguanine damage (red circle) is directly repaired by MGMT, which accepts the 
methyl group and is then ubiquitinated and degraded leaving the DNA repaired (A).  This 
enzyme is inactivated and degraded in a similar mechanism by accepting a benzyl group from 
O-6-benzylguanine (O6-BG) or PaTrin-2.  However, if the level of methylation exceeds the level 
of MGMT enzyme, unrepaired O-6-methylguainine will be incorrectly paired with thymine 
(blue circle).  This incorrect base pairing is detected by the mismatch repair (MMR) pathway 
which recognises the damage.  This pathway begins with the dimerization of both MSH2 and 
MSH6 (MUTSα complex) and MLH1 and PMS2 (MUTLα complex) which recognise the 
mismatched pairing and go on to recruit the exonuclease EXO1 to remove the newly paired 
thymine on the daughter strand of DNA.  The methylated base is then re-paired with thymine 
by DNA polymerase and Ligase I.  This results in a futile cycle of MMR causing single strand 
gaps or breaks in DNA.  In the subsequent cycle of replication, replication fork collapse can 
causing double strand DNA breaks (DSB) and eventually cell death (Liu and Gerson, 2006, 
Friedman et al., 2000).  In order for a cell to undergo apoptosis as a result of O-6-
methylguanine induced futile MMR cycling, the MUTSα complex must be present (Hickman 
and Samson, 2004).    
 
Figure adapted with permission from (Liu and Gerson, 2006). 
License number: 4465320276281  
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1.7.2 APNG and Base Excision Repair 
 
Higher MGMT expression positively correlates with resistance to temozolomide 
chemotherapy; however, alkylpurine–DNA–N-glycosylase (APNG) has also been 
shown to play a role in in resistance to temozolomide in GBM patients, with high 
expression conferring poorer overall survival (Agnihotri et al., 2012).   
APNG is a DNA repair protein which is part of the Base Excision Repair (BER) 
pathway which easily repairs the majority of lesions caused by temozolomide: N-3-
methyladenine and N-7-methylguanine (Lee, 2016).  shRNA depletion of APNG is 
able to sensitise previously resistant primary orthotopic xenograft GBM cells (which 
are heterogonous and express MGMT)  to  temozolomide.  Temozolomide resistant 
T98G cells are also sensitised following APNG silencing by siRNA, with both 
depleted primary and immortalised GBM cells exhibiting  reduced cell viability, 
increased DNA damage and apoptosis in response to temozolomide treatment 
(Agnihotri et al., 2012).  
Inhibition of the BER pathway has therefore been targeted in order to attempt to 
sensitise resistant tumour cells to temozolomide.  By using methoxyamine which 
binds to the abasic site inhibiting BER, tumour cells are sensitised to alkylation 
damage caused by temozolomide (Fishel et al., 2007, Taverna et al., 2001). 
Interestingly, when APNG protein expression was investigated in MGMT positive 
GBM tumours from patients who received either radiotherapy or radiotherapy and 
temozolomide, those without detectable APNG protein had significantly improved 
overall survival.  However, when patients who received only radiotherapy were 
selected, there was no difference in survival in relation to APNG expression 
(Agnihotri et al., 2012).  However, a more recent study, which excluded healthy 
cells from the analysis, has shown high expression of APNG confers better survival 
in GBM patients (Fosmark et al., 2017).  It is speculated that high APNG protein 
levels could cause dysregulation of the downstream BER pathway increasing the 
burden on the subsequent repair proteins, particularly on the rate limiting step 
including polymerase β, resulting in cytotoxic levels of 5’dRP and ultimately 



































Figure 1.6: Short Patch Base Excision Repair  
Short patch base excision repair (BER) pathway is the main DNA repair pathway involved in 
repairing lesions more commonly caused by temozolomide resulting in N-3-methyladenine 
and N-7-methylguanine.  DNA glycosylase and AP endonuclease 1 (APE1) process the 
damaged DNA base, removing the lesion and creating a nick in the DNA.  DNA polymerase β 
(polβ) identifies the single nucleotide gap in the DNA acting to remove 5’ sugar phosphate and 
incorporating a single nucleotide into gap to the 3’ end before recruiting XRCC1 and DNA 
ligase IIIα (LigIIIα) for the final ligation.   
 
Figure adapted with permission from (Almeida and Sobol, 2007) 
License number: 4473630988720 
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1.7.3 Associated DSB Repair Pathways: Homologous Recombination 
 
Homologous recombination (HR) is a highly faithful repair mechanism for double 
strand breaks in DNA (DSB).  HR uses the homologous sister chromatid to carry out 
repair of DSB breaks and can therefore only occur when a cell is in S-phase or G2-
phase of the cell cycle (Branzei and Foiani, 2008).  Although not used to directly 
repair lesions caused by temozolomide, HR may be employed to repair the DNA 






















Figure 1.7: Homologous Recombination Repair  
Homologous recombination (HR) pathway is involved in the repair of DNA damage causing 
stalled forked and DSBs.  HR resolves the damage in a way that restores the DNA back to its 
original sequence.   HR repairs damaged in a sequence of steps reliant on a many proteins, 
including tumour suppressors highlighted in bold.  Following a DSB (1), a complex of MRE11-
NBS1-RAD50 detects and binds to the break and recruits ATM, initiating repair (2).  DNA is 
resected on the 5’ ends of both strands, requiring BRCA1 activity (3).  PALB2 recruits BRCA2 to 
the DSB, then BRCA2 sequesters RAD51 to the resected single strand DNA (4).  RAD51 
complexed to DNA invades homologous double strand DNA (red) (5).  New DNA is synthesised 
using the homologous DNA as a guide, DNA polymerases to synthesis the nucleotides and the 
ssDNA as the primer (6).  DNA is ligated and cleaved before the break is completely restored (7 
& 8).  Crossover of DNA into the homologous chromosome is a common occurrence.    
 
Figure adapted from (Lord and Ashworth, 2016) 
License number: 4554770634745 
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1.7.4 Associated DSB Repair Pathways: Non-homologous End Joining 
 
Non-homologous End Joining (NHEJ) acts largely in G1-phase and is also involved in 
the repair of DSBs.  Ku70 and Ku80 dimerise to form the Ku complex which 
recognises the DSB.  NHEJ, although it will resolve the DSB, can result in the loss of 
genetic information and the breaks will be simply be ligated back together (Branzei 
and Foiani, 2008).  Similarly to HR, NHEJ is not used to directly repair lesions caused 
by temozolomide but may be used to repair the DNA DSBs subsequently generated 





















Figure 1.8: Non-homologous End Joining Repair  
Non-homologous end joining (NHEJ) is another pathway involved in the repair of DSBs.  NHEJ 
is much less faithful in its repair mechanism, simply ligating broken ends of DNA together 
which can result in loss of genetic material and translocations.  The Ku complex of Ku70 and 
Ku80 recognises the DSB and recruits other NHEJ proteins.  DNA-PKcs are recruited to the Ku 
heterodimer bound to DNA forming the DNA-PK complex.  Active DNA-PK recruits NHEJ 
proteins such as ARTEMIS, DNA polymerase, XRCC4, XLF and DNA Ligase IV, as well as ɣH2AX 
a well-established marker of DSBs which also recruits further DSB repair proteins.  Several 
cycles of additions and deletions of nucleotides can occur before NHEJ is complete. 
 
Figure adapted with permission from (Brochier and Langley, 2013) 
License number: 4466611036385 
 
45                                                                                                                   Natasha Carmell 
 
1.7.5 Heterogeneity, Tumour Microenvironment and Glioma Stem Cells 
 
As previously mentioned, GBM tumours have been classified into 4 subtypes based 
on gene expression and mutations (figure 1.4); however prognosis for 3 subtypes is 
similar with recurrence after 8-9 months of treatment and an average survival of 15 
months (Verhaak et al., 2010). Only mutant IDH tumours classified as proneural 
GBMs have a better prognosis (Verhaak et al., 2010).  Although GBM tumours have 
now been subtyped, this may be an oversimplification of this extremely complex 
disease, as even within individual tumours there is massive morphological and 
phenotypical heterogeneity, including changes in gene expression, cell metabolism, 
proliferation, angiogenesis, immunogenicity, motility and metastasis, as well as 
evidence supporting heterogeneous glioma stem cell and tumour propagating 
populations (Patel et al., 2014, Piccirillo et al., 2009, Piccirillo et al., 2015, Sottoriva 
et al., 2013, Qazi et al., 2017).  Intratumoural heterogeneity (ITH) is most likely 
driven by a combination of factors including genetic instability, tumour 
microenvironment (TME) and heterogenic cancer stem cells (CSCs) (Marusyk and 
Polyak, 2010).  As such, this  constantly mutating and evolving tumour can become 
resistant to multi-modal treatment resulting in disease recurrence and subsequent 
death of the patient (Qazi et al., 2017).   
The TME has roles in initiation, propagation and metastasis of cancer and includes 
the vasculature, immune cells, fibroblasts, signalling molecules and extracellular 
matrix which surround the tumour (Wang et al., 2018b).  Tumour cells are able to 
change their phenotype in response to signals from their microenvironment, for 
example, injecting teratocarcinoma into mice blastocysts resulted in the 
development of healthy mice with cells from different lineages derived from the 
injected tumour cells (Mintz and Illmensee, 1975).  As the TME is not 
homogeneous, the tumour will have differences in vasculature and immunity and 
will be surrounded by ECM of varying compositions, all of which will result in 
altered signalling throughout the TME and consequently phenotypic heterogeneity 
throughout the tumour (Marusyk and Polyak, 2010).     
Similarly to the TME, CSCs are also implicated in ITH and were first isolated in 1997 
from patients with acute myeloid leukaemia (AML), whereby CD34+ and CD38- cells 
were able to induce AML in non-obese diabetic and severe combined 
immunodeficiency disease (NOD/SCID) mice across multiple transplantations (Dick, 
1997).  CD34 is a transmembrane phosphoglycoprotein which binds to l-Selectin, a 
cell adhesion molecule on leukocytes and binds to Crkl, a protein which also 
regulates cell adhesion, however, little is known about the function of CD34 (Sidney 
et al., 2014).  CD38 is also a transmembrane glycoprotein which is usually found on 
the surface of immune cells; however, loss of this marker is associated with 
haematopoietic precursors identified from embryonic stem cells (Lu et al., 2004).  
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Cell surface markers CD44 (positive) and CD24 (negative) were then used to identify 
CSCs from the first solid tumour (breast cancer) in 2003 (Al-Hajj et al., 2003).  CD24 
and CD44 both have roles in cell adhesion, CD44 is a hyaluronic acid receptor and 
CD24 is a heat stable antigen and both are expressed in many tumour cells 
(Agnihotri et al., 2012).  However, it is unclear whether CD44+/CD24- cells are true 
CSCs due to conflicting reports (Abraham et al., 2005, Jang et al., 2016). 
Glioma cancer stem-like cells (GCSc) have also been identified and have the 
following properties:  ‘self-renew in culture, propagate phenotypically similar 
tumours upon in vivo secondary transplantation and give rise to neurons and glia-
like differentiated progenies both in vivo and in vitro’ (Ahmed et al., 2013).  
Prominin 1, also called CD133, is a transmembrane glycoprotein which is normally 
located on embryonic stem cells or localised to plasma membrane protrusions such 
as microvilli (Li, 2013b).  CD133 was used as a marker to isolate high grade primary 
medulloblastoma cells which could differentiate in vitro into phenotypically similar 
cells to those seen in the primary tumour.  These cells were termed brain tumour 
stem cells (BTSCs) (Singh et al., 2003).  CD133 positive cells, purified from both GBM 
patient samples and GBM patient derived xenograft tissues, recover from ionising 
radiation induced DNA damaged significantly more quickly than CD133 negative 
cells (Bao et al., 2006). This is achieved through increasing the activation of DNA 
damage checkpoint genes, CHK1 and CHK2,  and an enhanced ability to repair DNA 
damage leading to a greater survival in response to DNA damage (Ahmed et al., 
2015, Bao et al., 2006).  Cells isolated from primary cultured GBM cells which are 
CD133 positive and upregulate other CSC markers (nestin, CD44, CXCR4) are more 
resistant to temozolomide and also over-express MGMT (Liu et al., 2006). 
Furthermore, recurrent GBM tumours also have higher CD133 expression 
compared to the primary GBM tumour.  Additionally grade III glioma patients with 
>1% CD133+ cells have a significantly reduced survival and an increased chance of 
tumour recurrence (Liu et al., 2006, Zeppernick et al., 2008).  However, it has been 
shown that CD133- cells are also able to initiate tumour formation in 
immunocompromised mice (Beier et al., 2007, Ogden et al., 2008).  A combination 
of CD133 positive cells and other neural stem cell markers  are now used to identify 
GSC populations more accurately (Ahmed et al., 2015).  Examples of such markers 
include nestin and OLIG2 (Ahmed et al., 2013).  Nestin is upregulated during CNS 
development and is involved nerve cell mitosis, however, expression is usually 
downregulated as cells differentiate into glial- or neuronal-derived cells (Suzuki et 
al., 2010).  OLIG2 is a transcription factor which is predominantly expressed in the 
CNS and is also important in the development of motor neurons and 
oligodendrocytes (Tsigelny et al., 2016).   
As GSCs are quiescent, they have an increased resistance to both radio- and 
chemotherapy which selectively target highly proliferative cells (Rich and Bao, 
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2007).  Once proliferative tumour cells have been killed, remission of disease is 
achieved and then treatment stops which enables previously quiescent GSCs to re-
initiate tumour regrowth.  As GSCs have increased MGMT expression; recurrent 
tumours are more likely to be resistant to temozolomide chemotherapy, however, 
some GBM tumours have MGMT negative GSCs which are still resistant to 
temozolomide chemotherapy (Ahmed et al., 2013, Liu et al., 2006).  There is still a 
lot to learn about GSCs, importantly whether the heterogeneous GSCs are derived 
as a consequence of intratumoural heterogeneity or whether they are the drivers of 
this complex microenvironment.   
 
1.8 Novel Therapies and Current Targets in Clinical Trials 
 
Out of 36 completed phase III or IV trials listed on a clinical trials database 
(https://clinicaltrials.gov/), 10 trials (28%) currently have published results.  Of 
these, only 3 were investigating targeted therapy in combination with the standard 
treatment of radiotherapy and temozolomide, one trial was investigating pain 
management and another was investigating neurological side effects of 
radiotherapy (confusion, tiredness etc.), therefore 8 trials are included in table 1.1.  
 
Table 1.1: Completed Phase III and IV GBM clinical trials 
Trial Number Therapeutic IR Chemotherapy Diagnosis Phase 
Improved 
OS 
689221 Cilengitide Yes TMZ New III No 
777153 Cediranib No CCNU Recurrent III No 
943826 Bevacizumab Yes TMZ New III No 
686725 TMZ Yes Early post-surgery TMZ New IV Yes 
154375 Imatinib No HU Recurrent III No 
884741 Bevacizumab Yes TMZ New III No 
00482677 TMZ Yes TMZ in Elderly (65 yrs) New III Yes 
304031 TMZ Yes Increased Adjuvant TMZ New III No 
 
Table 1.1 - There were no improvements in overall survival with the addition of novel therapeutics to 
the treatment regime.  Early-post surgery temozolomide and temozolomide treatment for the elderly 
did improve overall survival. 
 
Two trials of the three trials combined standard treatment with bevacizumab, a 
monoclonal antibody which binds to and inhibits VEGF-A – an important pro-
angiogenic protein overexpressed in GBM (Chinot et al., 2014, Gilbert et al., 2014, 
Stupp et al., 2014).  The remaining trial combined cilengitide, an αvβ3 and αvβ5 
integrin inhibitor, with standard temozolomide chemo-radiotherapy treatment.  
Integrins are found on the cell surface enabling binding to the extracellular matrix, 
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they are abundant in GBM tumours and tumour vasculature (Bello et al., 2001).  In 
a phase II trial, cilengitide had more effective anti-cancer activity as a mono- and 
combined therapy in patients with MGMT promoter methylation (Stupp et al., 
2014).  Neither bevacizumab nor cilengitade was able to improve overall survival; 
however, progression free survival did increase by 3-4 months in both bevacizumab 
trials (Chinot et al., 2014, Gilbert et al., 2014).  Since the addition of the 
chemotherapeutic temozolomide, treatment for GBM has remained unchanged for 
around a decade, highlighting a lack of translation from research findings to clinical 
trials through to patients.  Aside from a selection of various chemotherapeutics 
(temozolomide, carmustine/BiCNU, lomustine/CCNU and everolimus) bevacizumab 
is the only other FDA approved treatment for brain tumours, however, it is not 
endorsed by NICE for the treatment of patients with newly diagnosed GBM 
(NationalCancerInstitute, 2018, NICE, 2018b). 
Asunercept is a fusion protein combining the Fc domain from an IgG fused to the 
cell surface receptor CD95 (CD95-Fc) (Wick et al., 2014).  Asunercept inhibits the 
CD95 ligand binding to its receptor CD95, reducing migration and invasion of GBM 
tumour cells and in a phase II trial showed an improved 6 month progression free 
survival in combination with radiotherapy when compared to radiotherapy alone 
(20.7% v 3.8%) (Kleber et al., 2008, Wick et al., 2014).  Asunercept has been 
undergoing NICE technology appraisal for the treatment of GBM since August 2017 
in order to determine the cost benefit of the drug to the NHS (NICE, 2017a). 
Depatuxizumab mafodotin (ABT-414) has also been undergoing NICE technology 
appraisal since March 2017 as a potential treatment for patients newly diagnosed 
with GBM that have EGFR amplifications.  However, investigation into the use of 
this treatment by the NHS for recurrent EGFR amplified GBM has been suspended 
as of January 2018 (NICE, 2017b).  ABT-414 is an EGFR monoclonal antibody 
conjugated to the antimitotic drug monomethyl auristatin F.  ABT-414 is able to 
target both amplified EGFR and mutant EGFRvIII and is currently being investigated 
in a phase III clinical trial in combination with temozolomide chemo-radiotherapy 
treatment in newly diagnosed patients (ADCReview, ClinicalTrials.gov, 2018). 
Nivolumab is a monoclonal antibody which binds to PD-1 receptors on the surface 
of T-cells thereby activating an immune response. However, as a phase III trial 
comparing nivolumab alone to bevacizumab alone in patients with recurrent GBM 
showed no survival benefit, nivolumab was withdrawn from NICE technology 
appraisal (NICE, 2016b).  Nivolumab is currently in phase III in clinical trials for 
patients with newly diagnosed GBM, however, patients with a methylated MGMT 
promoter will receive nivolumab in addition to temozolomide and radiotherapy 
(checkmate-548) and those with an un-methylated and active MGMT promoter will 
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receive either nivolumab and radiotherapy or temozolomide and radiotherapy  
(checkmate-498) (ClinicalTrials.gov, 2018). 
DCVax®-L is a cell based immunotherapy which uses lysates from the patient’s GBM 
tumour and immature dendritic cells taken from the patient’s blood to activate the 
dendritic cells to raise an immune response targeting the tumour.  Both phase I and 
phase II trials which combined DCVax®-L with temozolomide chemo-radiotherapy 
showed promising results in newly diagnosed patients, with a median survival of 3 
years and a 10 year survival achieved by 2 patients.  A phase III trial is currently 
underway in 348 newly diagnosed GBM patients (NorthwestBiotherapeutics, 2018).  
DCVax®-L was undergoing NICE technology appraisal, however, this was suspended 
as of September 2018 due to lack of evidence from the company (NICE, 2016a).    
 
1.9 Hypothesis and Project Aims  
 
siRNA screens have been used previously to identify novel targets to improve 
treatment for patients with GBM.  For example, an siRNA screen identified SGK1 as 
an important gene in maintaining GSCs,  a genome-wide siRNA screen identified 
genes important for tumour migration and chemo-resistance and a kinome-wide 
siRNA screen which showed depletion of PLK1 radio-sensitises GBM cells (Kulkarni 
et al., 2018, Tandle et al., 2013, Yang et al., 2013a).  
The hypothesis for this project was ‘inhibition of yet to be identified targets or 
pathways will enhance the cytotoxic effect of temozolomide in GBM’. 
The aim of this project was to identify and validate novel molecular targets and/or 
druggable pathways that confer an increase in sensitivity to the NICE approved and 
extensively used GBM chemotherapeutic agent temozolomide.  Targets identified 
from these proof-of-concept data could then be developed into future adjuvant 
therapies to improve the outcome for GBM patient survival. 
The objectives were to: 
1. Carry out a kinome wide siRNA and small molecule drug re-purposing 
screens in the temozolomide resistant immortalised GBM cell line T98G. 
2. Validate and refine primary hits from the siRNA screen using an alternative 
pooled siRNA library and siRNA pool deconvolution into individual siRNA. 
Determine whether targets confer an increase in temozolomide sensitivity 
in a panel of GBM cell lines. 
3. Validate any targets by determining their expression (mRNA and protein) in 
brain tumours compared to healthy brain tissue. 
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4. Validate and refine primary hits from small molecule drug screens by dose-
response curves in a panel of GBM cell lines. 
5. Investigate mechanism(s) by which GBM cells are sensitised to 
temozolomide using functional assays investigating DNA damage, 
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Chapter 2 – Materials and Methods 
2.1 Materials 
2.1.1 General Laboratory Equipment, Plastics and Consumables 
 
Table 2.1: General Laboratory Equipment, Plastics and Consumables.   
Airstream ESCO Class II Biological Safety Cabinet  
Agar Granulated, Melford 
Applied Biosystems 7900 Real-Time PCR 
BD FACSCalibur™ 
BD Plastipak™ 10ml Syringe  
BD FACSCalibur™ 
Bio-Rad mini-PROTEAN Tetra Cell 
Bio-Rad S1000 Thermal Cycler 
Bio-Rad PowerPac™ Basic Power Supply 
Biosphere® Filter Tips 0.1-10l, 2-20 l, 2-100 l, 100-1000 l 
BioTek Elx405 Select CW Plate Washer 
Cellstar ® Cell Culture Dishes 100x20mm 
Corning 50ml Reagent Reservoir 
Costar 96 Well Tissue Culture Treated Plates  
CytoOne Multiwell Plate, 6 well 
Eppendorf Centrifuge 5430 
Eppendorf Centrifuge 5810 R 
Eppendorf Centrifuge S415 R 
Epson Expression 1680 Pro Scanner 
Fisher Scientific FB15-12 TopMix 
Fisher Scientific MH-214 Analytical Balance 
Fisher Scientific SG-607 Analytical Balance 
FisherBrand™ 5 ml, 10 ml and 25 ml Disposable Serological Pipettes 
Fisherbrand™ Electric Pipet Controller 
Fujifilm Fuji Medical X-ray Film Super RX 
GE NanoVue Plus 
Gilson P10, P20, P200 Multichannel Pipettes 
Gilson P2, P10, P20, P200 and P1000 Pipettes 
Grant JB Aqua 18 Plus 
Hawksley AC1000 Improved Neubauer Haemocytometer 
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Jenway 3510 pH Meter 
Konica Mibolta SRX101A Film Processor 
Life Technologies Countess II 
Microplate 384 well PP PCR with skirt, Greiner Bio-one 
Millex-GP Syringe Filter Unit, 0.22 µm, polyethersulfone, 33 mm, gamma sterilized 
Molecular Devices ImageXpress Micro High Content Microscope 
Nanodrop ND 1000 Spectrophotometer 
Nikon Eclipse TE200 Fluorescent Microscope 
PlateLoc Velocity 11 
Sanyo MCO-19AIC (UV) 
Sarstedt Cell Scraper 25 cm 
Sarstedt CryoPure 1.8 ml White 
Sarstedt P200, P1000 Pipette Tips 
SLS 15ml/50ml polypropylene tubes 
Star Lab 8-strip PCR Tubes, 0.2 ml & Caps 
Sterilin Universal Tubes  
Stuart® Mini Gyro-rocker 
Techne Dri-Block® DB-2D 
Thermo Fischer Immu-Mount 
Thermo Megafuge 40  
Thermo Multidrop 384 
Thermo Multiskan FC 
Thermo Nunc™ EasYFlask™ 25 cm2 Nunclon™ Delta Surface 
Thermo Nunc™ EasYFlask™ 75 cm2 Nunclon™ Delta Surface 
Thermo Scientific Multidrop Combi 
Walker Safety Cabinet Class II MSC (Model TDA-2G) 
Welch 2515C-75 REV A  




Table 2.2: Reagents 
1,4-dithiothreitol (DTT): Sigma DTT-RO 
30% acrylamide mix: Geneflow 
Acetic Acid, Glacial: Fisher Scientific, A38-212 
Ammonium Persuphate (APS), Fisher 
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Benzonase Nuclease: Novagen, 70664-3 
Biotinylated Goat Anti-Mouse IgG Antibody: Vector Laboratories, BA9200 
BioRad Protein Assay Dye Reagent Concentrate: BioRad, 500-0006 
Bovine Serum Albumin (BSA): Sigma, A2153 
Calcium Chloride: Sigma 499609 
DAB Peroxidase (HRP) Substrate Kit: Vector Laboratories SK-4100 
Dako Target Retrieval Solution, Citrate pH 6 (x 10): Agilent, S2369 
DharmaFECT 1: GE Healthcare,   T-2001-01 
Dimethyl Sulfoxide (DMSO): Fisher Chemical, D/4120/PB08 
DPX Mountant: Sigma 06552 
Dulbecco’s Modified Eagle Medium (DMEM): Lonza, BE12-604F 
Ethylenediaminetetraacetic Acid (EDTA): Sigma, 1233508 
Ethanol: Fisher Scientific, AC615090010 
Foetal Calf Serum:  Lonza, BE12-60F4 
Goat Serum Blocking Solution: Vector Laboratories, S-1000 
Glycerol: Sigma, G5516 
Hoechst 33342 Trihydrochloride, Trihydrate: Life Technologies, H3570 
Hydrochloric Acid (HCL) 37%: Fisher Sceintific A144-500LB 
Hydrogen Peroxide: Sigma, 95321 
Isopropanol: Fisher Scientific, A416-4 
Lipo 2000: ThermoFisher,11668019 
Lipofectamine RNAiMAX Transfection Reagent: Life Technologies, 13778030 
Magnesium Chloride: Sigma, M8266 
Marvel Milk Powder 
Methanol: Fisher Scientific, A452SK-4 
Methylene Blue: Sigma Aldrich, M9140 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide): Sigma, M2128 
NuPAGE® LDS Sample Buffer (4X): ThermoFisher, NP007 
NuPAGE® MOPS SDS Running Buffer (20X): ThermoFisher, NP001 
NuPAGE® Transfer Buffer (20X): ThermoFisher NP0006 
NuPAGE™ 4-12% Bis-Tris Protein Gels, 1.5 mm, 10 well: ThermoFisher, NP0335BOX 
NuPAGE™ 4-12% Bis-Tris Protein Gels, 1. 5mm, 15 well: ThermoFisher, NP0336BOX 
Oxoid PBS tablet: Thermo Scientific, Cat. No. BR0014 
Paraformaldehyde (PFA) solution 4% in PBS: Sanat Cruz, SC-281692 
Phosphatase Inhibitor: Sigma, P5726 
PIB: Sigma, P2714 
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Pierce ECL Western Blotting Substrate: Thermo Scientific, 32106 
Potassium Chloride: Sigma, P9333 
Protran Nitrocellulose Membrane: VWR, 732-4016 
Propidium Iodide, Sigma P4864 
QAIshredder (50): Qiagen, 79654 
Qiagen Rneasy Mini Kit: Qiagen 74104 
RNase A: Sigma 
SeeBluePlus2 Prestained Standard: ThermoFisher, LC5925 
5X siRNA Buffer: Dharmacon, B-002000-UB-100 
Sodium Chloride: Sigma, S7653 
Sodium Citrate: Sigma, 1613859 
Sodium Dodecyl Sulphate (SDS): Sigma, L3771-500G 
Sodium Hydroxide (NaOH) Pellets: Sigma, 1.06462 EMD 
Sucrose: Sigma, S7903 
SYBR® Gold Nucleic Acid Gel Stain: Thermo Scientific, S11494 
TaqMan™ Reverse Transcription Reagents: Applied Biosystems, N8080234 
TaqMan™ Universal PCR Master Mix No AmpErase UNG: Applied Biosystems, 
4324018 
Tris Base: Sigma, TRIS-RO 
Tris Hydrochloride: Sigma 10812846001 
Triton™ X-100: Sigma, X100 SIGMA-ALDRICH 
Trypsin (0.5g/l trypsin, 0.2g/l versene (EDTA)): Lonza, 17-161E 
TWEEN® 20: Sigma, P1379 
VECTASTAIN® ABC Kit: Vector Laboratories, PK-4000 
Visualiser™ Western Blot Detection Kit: Fisher Scientific, 10553414 
Xylene: Sigma, 247642 
-Mercaptoethanol: Fisher, M/P200/05 
 
2.1.3 Inhibitors and Cytotoxic Agents 
 
Table 2.3: Cytotoxic Agents 
Item Mechanism of Action Solvent Company 
BIX 02189 MEK5 inhibitor Ethanol Selleckchem (S1531) 
BLU554 FGFR4 inhibitor DMSO Selleckchem (S8503) 
Butamben Anaesthetic DMSO Selleckchem (S4583) 
ERK5-IN-1 Inhibits EGFR-induced 
ERK5 auto-
phosphorylation 
DMSO Tocris (5393) 





Water Simga (P4875) 
Nocodazole Anti-mitotic agent DMSO Sigma (M4104) 
O6-Benzylguanine AGT inhibitor Methanol Sigma (B2292) 
Pyrvinium Pamoate Androgen receptor 
inhibitor 
DMSO Sigma (P0027) 
Roscovitine Cyclin-dependent 
kinase inhibitor 
DMSO Sigma (R7772) 
Temozolomide Methylation of DNA DMSO Sigma (T2577) 








Glassware was washed in RBS detergent and rinsed in cold water followed by 
ddH2O before being dried in a hot air oven at 80 °C.  Glassware was then autoclaved 





Table 2.4: Primary Antibodies 
Primary Antibody Raised In Company Protein 
Size (kDa) 
Dilution 
Anti-53BP1 Rabbit Abcam 
(ab368823) 
214 1:500 
Anti-β-Actin Mouse Abcam 
(ab8226) 
42 1:2000 








Anti-ERK5 Mouse Santa Cruz 
(sc-398015) 
89 1:1000 
Anti-FANCD2 Mouse Abcam (ab12450) 166 1:1000 
Anti-FGFR4 Rabbit Cell Signalling 
(2894) 
89 1:500 
Anti-MGMT Mouse Abcam 
(ab39253) 
22 1:1000 















2.1.6 siRNA Sequences 
 
Table 2.6: siRNA Sequences 
Library Gene Sequence 
ON-TARGET plus MGMT siRNA # 1 GGUUGUGAAAUUCGGAGAA 
ON-TARGET plus MGMT siRNA #2 GAUGGAUGUUUGAGCGACA 
ON-TARGET plus MGMT siRNA #3 AAAUAAAGCUCCUGGGCAA 
ON-TARGET plus MGMT siRNA #4 UGGCCGAAACUGAGUAUGU 
siGENOME MGMT siRNA # 1 GAAAUUCGGAGAAGUGAUU 
siGENOME MGMT siRNA # 2 CCAGACAGGUGUUAUGGAA 
siGENOME MGMT siRNA # 3 CAAGGAUUGUGAAAUGAAA 
siGENOME MGMT siRNA # 4 GCCCGAGGCUAUCGAAGAG 
ON-TARGET plus PARP-1 siRNA # 1 GAUUUCAUCUGGUGUGAUA 
ON-TARGET plus PARP-1 siRNA # 2 GAAAACAGGUAUUGGAUAU 
ON-TARGET plus PARP-1 siRNA # 3 GUUCUUAGCGCACAUCUUG 
ON-TARGET plus PARP-1 siRNA # 4 CCAAUAGGCUUAAUCCUGU 
ON-TARGET plus TDP-1 siRNA # 1 CCACAAAUCUGGAGAGUCG 
ON-TARGET plus TDP-1 siRNA # 2 GACCAUAUCUAGUAGUGAU 
ON-TARGET plus TDP-1 siRNA # 3 GGACCAGUUUAGAAGGAUA 
ON-TARGET plus TDP-1 siRNA # 4 GUGAUAAGCGAGAGGCUAA 
siGENOME FANCD2 siRNA # 1 GGUCAGAGCUGUAUUAUUC 
siGENOME FANCD2 siRNA # 2 GAUAAGUUGUCGUCUAUUA 
Table 2.5: Secondary Antibodies 
Secondary  Antibody Company Dilution 
Alexa Fluor ® 488 Goat Anti-Mouse Life Technologies 
(A-11304) 
1:1000 
Alexa Fluor ® 488 Goat Anti-Rabbit Life Technologies 
(A-11034) 
1:1000 
Alexa Fluor ®594 Goat Anti-Rabbit Life Technologies 
(A-11012) 
1:1000 
Polyclonal Goat Anti-Mouse IgG, HRP-Linked Dako 
(P0447) 
1:1000 
Polyclonal Swine Anti-Rabbit IgG, HRP Linked Dako 
(P0399) 
1:1000 
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siGENOME FANCD2 siRNA # 3 GAUCAACUCUCCUAAAGAU 
siGENOME FANCD2 siRNA # 4 GAACAAAGGAAGCCGGAAU 
siGENOME GRK6 siRNA # 1 GAGCUUGGCCUACGCCUAU 
siGENOME GRK6 siRNA # 2 CGAACACGGUGCUACUCAA 
siGENOME GRK6 siRNA # 3 UGGUGAAGAAUGAACGGUA 
siGENOME GRK6 siRNA # 4 UGGCGGUGGAAAUCGCAAA 
siGENOME PI4KA siRNA # 1 GUGAAGCGAUGUGGAGUUA 
siGENOME PI4KA siRNA # 2 CCACAGGCCUCUCCUACUU 
siGENOME PI4KA siRNA # 3 GCAGAAAUUUGGCCUGUUU 
siGENOME PI4KA siRNA # 4 CCAACAUGACUGAGCGCGA 
siGENOME CAMK2B siRNA # 1 GGACGAGGACCAGCACAAG 
siGENOME CAMK2B siRNA # 2 GGACACCGUCACUCCUGAA 
siGENOME CAMK2B siRNA # 3 GCAAGCCUGUGGACAUCUG 
siGENOME CAMK2B siRNA # 4 CGGCCUAGCUAUCGAGGUG 
siGENOME DYRK1A siRNA # 1 UAAGGAUGCUUGAUUAUGA 
siGENOME DYRK1A siRNA # 2 GCUAAUACCUUGGACUUUG 
siGENOME DYRK1A siRNA # 3 AAACUCGAAUUCAACCUUA 
siGENOME DYRK1A siRNA # 4 CUUUGAACCUAACACGAAA 
siGENOME PNCK siRNA # 1 AGAAACACACGGAGGACAU 
siGENOME PNCK siRNA # 2 GCAGUGCUCCGUAGGAUCA 
siGENOME PNCK siRNA # 3 AAGAAACACACGGAGGACA 
siGENOME PNCK siRNA # 4 GAUUUGAGGGUGUGGCGCA 
siGENOME SCYL3 siRNA # 1 GAACAUUGGUGGAAAGUUU 
siGENOME SCYL3 siRNA # 2 GAGCUGAACUGGGAAGAUA 
siGENOME SCYL3 siRNA # 3 UUAAAGAGCUAUACACUGA 
siGENOME SCYL3 siRNA # 4 CAACAGACCUUGCACUCAA 
siGENOME DGKG siRNA # 1 GAAUAUUCCUCCAAGAAGA 
siGENOME DGKG siRNA # 2 CAGCGCAGAUACUAAUAUA 
siGENOME DGKG siRNA # 3 CACAUGAGCCGAUUAGCUA 
siGENOME DGKG siRNA # 4 GCAGCCAUGUUGCACGAUU 
siGENOME PIK3C2B siRNA # 1 GCCGGAAGCUUCUGGGUUU 
siGENOME PIK3C2B siRNA # 2 CAAGAGCUCUGGCCGAAUC 
siGENOME PIK3C2B siRNA # 3 GCUGAGACCCUGCGUAAGA 
siGENOME PIK3C2B siRNA # 4 GCUACCAGCUAUGAAGAUU 
siGENOME PRKAR1A siRNA # 1 CGAGACAGCUAUAGAAGAA 
siGENOME PRKAR1A siRNA # 2 GAUAAUGAGAGAAGUGAUA 
siGENOME PRKAR1A siRNA # 3 UACGGUAGCUGAUGCAUUG 
siGENOME PRKAR1A siRNA # 4 GUGGGAACGUCUUACGGUA 
siGENOME STK16 siRNA # 1 GAGGUACGCUGUGGAAUGA 
siGENOME STK16 siRNA # 2 CGACAUGCAUCGCCUCUUC 
siGENOME STK16 siRNA # 3 GGUACGCUGUGGAAUGAGA 
siGENOME STK16 siRNA # 4 UGAAGCGAAUCCUGUGUCA 
siGENOME DMPK siRNA # 1 GCACUUCGCCUUCCAGGAU 
siGENOME DMPK siRNA # 2 GCGGAGACCUAUGGCAAGA 
siGENOME DMPK siRNA # 3 UGAAGAUCAUGAACAAGUG 
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siGENOME DMPK siRNA # 4 GCUUGAGCCACACGUGCAA 
siGENOME PDGFRB siRNA # 1 GAAAGGAGACGUCAAAUAU 
siGENOME PDGFRB siRNA # 2 GGAAUGAGGUGGUCAACUU 
siGENOME PDGFRB siRNA # 3 CAACGAGUCUCCAGUGCUA 
siGENOME PDGFRB siRNA # 4 UGACAACGACUAUAUCAUC 
siGENOME PRKDC siRNA # 1 GCAAAGAGGUGGCAGUUAA 
siGENOME PRKDC siRNA # 2 GAGCAUCACUUGCCUUUAA 
siGENOME PRKDC siRNA # 3 GAUGAGAAGUCCUUAGGUA 
siGENOME PRKDC siRNA # 4 GCAGGACCGUGCAAGGUUA 
siGENOME ALPK3 siRNA # 1 UAGAUUCCCUGAAGAACUA 
siGENOME ALPK3 siRNA # 2 CCAAAGACCUGCUGAAAGC 
siGENOME ALPK3 siRNA # 3 GCAAGCCCCUGGAGUCUUA 
siGENOME ALPK3 siRNA # 4 GAACAUGAGUCGGGAGUAC 
siGENOME FGFR4 siRNA # 1 GCACUGGAGUCUCGUGAUG 
siGENOME FGFR4 siRNA # 2 CCUCGAAUAGGCACAGUUA 
siGENOME FGFR4 siRNA # 3 AUAACUACCUGCUAGAUGU 
siGENOME FGFR4 siRNA # 4 GCAUUCGGCUGCGCCAUCA 
siGENOME PRKAG1 siRNA # 1 GGACAUCUACUCCAAGUUU 
siGENOME PRKAG1 siRNA # 2 GAUGCUGUCUCUUCAUUAA 
siGENOME PRKAG1 siRNA # 3 CAACAUCGAUCACAUUACU 
siGENOME PRKAG1 siRNA # 4 AAGCAGAGGUUCACCGACU 
siGENOME MAP3K3 siRNA # 1 GAUAGAAGCUCAAGCAUGA 
siGENOME MAP3K3 siRNA # 2 AAACUCAGCUUUAUGACAA 
siGENOME MAP3K3 siRNA # 3 CCAAGCAGGUCCAAUUUGA 
siGENOME MAP3K3 siRNA # 4 GCAAACGCCUGCAGACGAU 
siGENOME IPPK siRNA # 1 GCAAGAUCGUCAACUAUUA 
siGENOME IPPK siRNA # 2 UAACGAAGGUGCAGCAGUA 
siGENOME IPPK siRNA # 3 CGUCAACUAUUAUUCAAAG 
siGENOME IPPK siRNA # 4 AGAUGGGCCUUAUGAUGAA 
siGENOME CALM3 siRNA # 1 GGGAGAAGCUGACCGAUGA 
siGENOME CALM3 siRNA # 2 GGAUGGAGAUGGCACUAUC 
siGENOME CALM3 siRNA # 3 GGACAGAACCCCACUGAAG 
siGENOME CALM3 siRNA # 4 GAGAUGGCCAGGUCAAUUA 
siGENOME STK3 siRNA # 1 GCCCAUAUGUUGUAAAGUA 
siGENOME STK3 siRNA # 2 ACAAGUACCUGUUGAAUCA 
siGENOME STK3 siRNA # 3 CCACAAGCACGAUGAGUGA 
siGENOME STK3 siRNA # 4 CGGUCAAGUUGUCGCAAUU 
siGENOME PRKAR2B siRNA # 1 GAACAUCGCUACCUAUGAA 
siGENOME PRKAR2B siRNA # 2 GAACGAACAUGGAUAUUGU 
siGENOME PRKAR2B siRNA # 3 GUUCAAUGCUCCAGUAAUA 
siGENOME PRKAR2B siRNA # 4 GAAAGUAGUAGAUGUGAUA 
siGENOME PGK1 siRNA # 1 CAAAAUUGAUGAUCCAUUA 
siGENOME PGK1 siRNA # 2 UUGAUGAUCCAUUAAGUAA 
siGENOME PGK1 siRNA # 3 GCACAGCAUCUCAGCUCAU 
siGENOME PGK1 siRNA # 4 GAAGCGGGUCGUUAUGAGA 
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siGENOME FES siRNA # 1 CGAGGAUCCUGAAGCAGUA 
siGENOME FES siRNA # 2 AGGAAUACCUGGAGAUUAG 
siGENOME FES siRNA # 3 CAACAGGAGCUCCGGAAUG 
siGENOME FES siRNA # 4 GGUGUUGGGUGAGCAGAUU 
siGENOME NEK4 siRNA # 1 GAACAAACAUCAUCAAAGU 
siGENOME NEK4 siRNA # 2 GGAGGUAUAUGCAGUAUUU 
siGENOME NEK4 siRNA # 3 GAAGAAAGGCCGUCUGUGA 
siGENOME NEK4 siRNA # 4 AAACAGGACUUGAGCAAUA 
siGENOME PRKCZ siRNA # 1 GAACGAGGACGCCGACCUU 
siGENOME PRKCZ siRNA # 2 GACCAAAUUUACGCCAUGA 
siGENOME PRKCZ siRNA # 3 GGUUGUUCCUGGUCAUUGA 
siGENOME PRKCZ siRNA # 4 CGUCAAAGCCUCCCAUGUU 
siGENOME CDKL3 siRNA # 1 GUAUAGAGCUCCCGAAUUA 
siGENOME CDKL3 siRNA # 2 GAACAGUCAUGAAAUGUAA 
siGENOME CDKL3 siRNA # 3 UGUAAUGGCUUGAAAGAAA 
siGENOME CDKL3 siRNA # 4 GAUAGUGGCCAUUAAGAUA 
siGENOME ALPK2 siRNA # 1 GCAACAAGCUGAAGAUUAU 
siGENOME ALPK2 siRNA # 2 CAACAUACCUGACAAUUUC 
siGENOME ALPK2 siRNA # 3 GGACAAAGCAGAAUUGAUU 
siGENOME ALPK2 siRNA # 4 GACCUUCAUUGAUCAGUUU 
siGENOME PRKCSH siRNA # 1 UGAAGAAGAUCCUUAUUGA 
siGENOME PRKCSH siRNA # 2 GGUCAACGAUGGUGUUUGU 
siGENOME PRKCSH siRNA # 3 GGAGUUUGCUUACCUGUAC 
siGENOME PRKCSH siRNA # 4 UCACCAAUCAUCACUUCUA 
ON-TARGET plus PNCK siRNA # 1 GCAGUGCUCCGUAGGAUCA 
ON-TARGET plus PNCK siRNA # 2 AGAAACACACGGAGGACAU 
ON-TARGET plus PNCK siRNA # 3 CAUCGUCGCUCUGGAGGAU 
ON-TARGET plus PNCK siRNA # 4 CAGCAGCGUCUACGAGAUC 
ON-TARGET plus DMPK siRNA # 1 GUACGUGGCCGACUUCUUG 
ON-TARGET plus DMPK siRNA # 2 GGGACGACUUCGAGAUUCU 
ON-TARGET plus DMPK siRNA # 3 GAAAUGUUCUAUGGGCAGA 
ON-TARGET plus DMPK siRNA # 4 GAACUUCGCCAGUCAACUA 
ON-TARGET plus FGFR4 siRNA # 1 CCUCGAAUAGGCACAGUUA 
ON-TARGET plus FGFR4 siRNA # 2 AUAACUACCUGCUAGAUGU 
ON-TARGET plus FGFR4 siRNA # 3 GCACGAGGCUCCAUGAUCG 
ON-TARGET plus FGFR4 siRNA # 4 GAUUACAGGUGACUCCUUG 
ON-TARGET plus MAP3K3 siRNA # 1 GAGCACAAAUGGCGAGAAC 
ON-TARGET plus MAP3K3 siRNA # 2 GAUCUACAUUACAUGAACA 
ON-TARGET plus MAP3K3 siRNA # 3 GAACCGACGUCACCGGAUG 
ON-TARGET plus MAP3K3 siRNA # 4 GAUAGAAGCUCAAGCAUGA 
ON-TARGET plus FES siRNA # 1 CGAGGAUCCUGAAGCAGUA 
ON-TARGET plus FES siRNA # 2 GGUGUUGGGUGAGCAGAUU 
ON-TARGET plus FES siRNA # 3 GAAGAGUGGUGUUGUCCUG 
ON-TARGET plus FES siRNA # 4 GAAAGUGGAUGGCCCAGCG 
ON-TARGET plus PRKCSH siRNA # 1 GGUCAACGAUGGUGUUUGU 
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ON-TARGET plus PRKCSH siRNA # 2 GCUACGAGCUCACCACCAA 
ON-TARGET plus PRKCSH siRNA # 3 GAGAAGGGCCGUAAGGAGA 
ON-TARGET plus PRKCSH siRNA # 4 GCGAGUACCUCAUGGAGCU 
ON-TARGET plus TWF2 siRNA # 1 CCAUUGAGCUGGUGCACAC 
ON-TARGET plus TWF2 siRNA # 2 UUAACGAGGUGAAGACAGA 
ON-TARGET plus TWF2 siRNA # 3 GGGUACAAGUGCAGCAUCA 
ON-TARGET plus TWF2 siRNA # 4 GAGCAGGACUUCCAUCUGG 
 
Table 2.7: siTOOLS™ siRNA Sequences 
Gene Sequence 
ERK5 siRNA#1 TCAAAGACTTGAGCAGGGC 
ERK5 siRNA#2 ATCCTGGAACTAGGTCTAC 
ERK5 siRNA#3 AGACTGGTTTAAGAATTCC 
ERK5 siRNA#4 TCTACTGTGGCAGCAAGGC 
ERK5 siRNA#5 TTGGTACAGGAAGTAGCGC 
ERK5 siRNA#6 AACATCTGGACAGCCAGGC 
ERK5 siRNA#7 ATGCCATGGCCTTCGAGCC 
ERK5 siRNA#8 AATCACGGCTGGTGATGGG 
ERK5 siRNA#9 TATCGGCAGGGTTCATGCC 
ERK5 siRNA#10 AGTCAGCAAGCAGGGAGGC 
ERK5 siRNA#11 TAAGGCTGAAAGGTGGGTC 
ERK5 siRNA#12 TTTGAGAATGCTCCCATGG 
ERK5 siRNA#13 AATTTCAGCCACAATGGCC 
ERK5 siRNA#14 TATAGGCCCGCACCCTCTC 
ERK5 siRNA#15 TACTGATGTTCAGCGGGCG 
ERK5 siRNA#16 ATTCCTCCAGGTCAAAGCC 
ERK5 siRNA#17 TGAGGAGTGGATGATCTGG 
ERK5 siRNA#18 TGACATGGAAGACTGAGGG 
ERK5 siRNA#19 AAAGTCACCAATCTTGAGC 
ERK5 siRNA#20 AATGGTGTCAGGTGCAGGG 
ERK5 siRNA#21 ACTGGTAGGTTGGACTGGG 
ERK5 siRNA#22 AAAGGCAAAGTCAAAGGGC 
ERK5 siRNA#23 ATACTCAGTCATGAAGTAC 
ERK5 siRNA#24 AATGGCCTCCTTAATGCGC 
ERK5 siRNA#25 TAGAGCCCGCAGATTGTGG 
ERK5 siRNA#26 TTGGCTCGTTCTTGCCGCC 
ERK5 siRNA#27 TGTGCCTGAGAACACAGGG 
ERK5 siRNA#28 TGAACCTGCAGAATAATCC 
ERK5 siRNA#29 ATCTCTGAGCCGGCTCCTC 
ERK5 siRNA#30 TCAGGATCATGGTACTTGG 
FGFR4 siRNA #1 TTGACTTGCCGGAAGAGCC 
FGFR4 siRNA #2 TAGGGTCCGAAGGTCAGGC 
FGFR4 siRNA #3 TCATCATCGTTGCTGGAGG 
FGFR4 siRNA #4 ATGACGATGTGCTTCAGCC 
FGFR4 siRNA #5 AACCTCCTGCTGGTATTGG 
61                                                                                                                   Natasha Carmell 
 
FGFR4 siRNA #6 ATGCCAAAGGCCTCTGCAC 
FGFR4 siRNA #7 TAGTCAATGTGGTGGACGC 
FGFR4 siRNA #8 ATAGCAGCTCTCCAGCCAG 
FGFR4 siRNA #9 TCAAGCTCCACTTCCTCAG 
FGFR4 siRNA #10 AAACCGTCGGCTCCGAAGC 
FGFR4 siRNA #11 TTAGGACTTGCACATAGGG 
FGFR4 siRNA #12 TACACTTCCGGGACTCCAG 
FGFR4 siRNA #13 TGACATTTGGGCCATCAGG 
FGFR4 siRNA #14 AAGCTGGCAATCTCTAGGC 
FGFR4 siRNA #15 TACAGGACCTCCACCTCTG 
FGFR4 siRNA #16 AATGCTCCCGTCAAGACGC 
FGFR4 siRNA #17 ACGCATCAGCCCGTACAGC 
FGFR4 siRNA #18 AGGACTGGGAAGGAGAGCG 
FGFR4 siRNA #19 TCTAGCAGGTAGTTATAGC 
FGFR4 siRNA #20 TATAGCGGATGCTGCCCAC 
FGFR4 siRNA #21 TCTGAGCTATTGATGTCTG 
FGFR4 siRNA #22 ACACGTTCCGCAGGTACAG 
FGFR4 siRNA #23 ATTCTGCAGGACGATCATG 
FGFR4 siRNA #24 ATTTGCTCCTGTTTTCGGC 
FGFR4 siRNA #25 AGACTGGTAGGAGAGGCCG 
FGFR4 siRNA #26 TAACTGTGCCTATTCGAGG 
FGFR4 siRNA #27 AGGCTCAGCCAAACCCGGG 
FGFR4 siRNA #28 TAATCAAGGTGAGATTCTG 
FGFR4 siRNA #29 AGAGACGGCCAGCAGGACC 
FGFR4 siRNA #30 TCATGGAGCCTCGTGCCAG 
 
2.1.7 TaqMan™ Gene Expression Probes for Quantitative PCR 
 
Table 2.8: TaqMan™ Gene Expression Probes 
Gene Assay ID Company Fluorescent 
Reporter Dye 
DMPK Hs0104329_m1 ThermoFisher FAM 
FES Hs01120751_m1 ThermoFisher FAM 
FGFR4 Hs01106910_g1 ThermoFisher FAM 
GAPDH Hs02758991_g1 ThermoFisher FAM 
MAP3K3 Hs00176747_m1 ThermoFisher FAM 
MGMT Hs01037698_m1 ThermoFisher FAM 
PNCK Hs00736137_m1 ThermoFisher FAM 
PRKCSH Hs00160457_g1 ThermoFisher FAM 
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2.1.8 Standard Solutions 
 
Alkaline Unwinding Solution 4g NaOH pellets and 2.5ml 20mM EDTA (included in 
comet assay kit) made up to 500ml with ddH2O 
Comet Electrophoresis Buffer 8g NaOH pellets and 2ml 500mM EDTA made up to 
1000ml with ddH2O 
10% APS 1g APS dissolved in 10ml ddH2O 
5% BSA 25g BSA dissolved in 500ml PBS 
1M DTT 1.54g DTT dissolved in 10ml ddH2O 
500mM EDTA 146.12g EDTA dissolved in 1000ml ddH2O 
70% Ethanol 700ml ethanol and 300ml ddH2O 
5% Marvel Milk 10g Marvel milk powder dissolved in 200ml PBS-T 
70% Methanol 700ml methanol and 300ml ddH2O 
Methylene Blue (0.4%) 2g methylene blue dissolved in 500ml 70% or 100% 
methanol 
5M NaCl 146g NaCl dissolved in 500ml ddH2O 
NuPAge MOPS SDS Running Buffer 25ml NuPage MOPS SDS Running Buffer (20X) in 
475ml ddH2O 
NuPage Transfer Buffer 50ml NuPage Transfer Buffer (20X), 750ml ddH2O and 
200ml methanol 
PBS 1 Oxoid PBS tablet dissolved in 100ml ddH2O and sterilised by autoclaving 
PBST 500µl TWEEN 20 dissolved in 500ml PBS 
10% SDS 50g SDS dissolved in 500ml ddH2O 
10X TBS 24.2g Tris-Base and 80g NaCl dissolved in 300ml ddH2O.  HCl was added 
until pH 7.6 was reached and ddH2O made the solution up to 1000ml 
TBST 500µl TWEEN 20 dissolved in 500ml TBS 
1.0M Tris pH 8.0 131.14 g tris base dissolved in 600ml ddH2O.  HCl was added until 
pH 8.0 was reached.  ddH2O made the solution up to 1000ml. 
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2.2 Methods 
2.2.1 Mammalian Cell Culture  
 
Passaging Cells 
T98G cells, U-87 cells and LN-18 cells were purchased from American Type Culture 
Collection (ATCC) and U-138 cells were taken from lab stocks originally purchased 
from ATCC.  U-251 cells were a gift from Professor Susan Short (Leeds Institute of 
Cancer and Pathology).  All mammalian cell lines were cultured in T75 flasks in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% foetal calf 
serum (FCS).  Cells were incubated at 37°C with 5% CO2.  .   
For general maintenance, cells were passaged as follows upon reaching 80-90% 
confluence.  Media was removed and cells were washed twice in 10ml PBS.  1ml of 
trypsin was added to the flask which was incubated at 37°C with 5% CO2 until the 
cells had detached.  Cells were pelleted at 1200 RPM for 3 minutes.  Supernatant 
was removed and the pellet was re-suspended in 10ml 10% FCS in DMEM.  A 
fraction of this suspension was used to re-seed a new flask containing 10% FCS 
DMEM, typically 1:10 for all cell lines.  
All cell lines were routinely tested for mycoplasma infection and were only 
passaged 20 times in order to avoid phenotypic drift. 
 
Table 2.9: GBM Cell Line Derivation 
Cell Line Source MGMT 
Status 
Other Reference 
LN-18 65 year old 
male 
Positive Mutant & 
WT TP53 
(Diserens et al., 1981) 





U-87 male Negative WT TP53 (Ponten and Macintyre, 
1968) 
U-138 47 year old 
male 
Positive FA deficient 
WT TP53 
(Beckman et al., 1971) 




(Ponten and Macintyre, 
1968) 
 
Table 2.9 - Immortalised GBM cell lines used throughout the studies.  Cell lines have various genetic 




After trypsinising and centrifuging cells at 1200 RPM for 3 minutes, the pellet was 
re-suspended in 10% FCS DMEM with 10% DMSO.  An 80% confluent flask was re-
suspended in 2700µl of 10% FCS DMEM and 300µl of DMSO was added slowly.  1ml 
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aliquots were placed in cryovials, stored at -80 °C for 24 hours and then transferred 
to liquid nitrogen. 
 
Thawing Cells 
Cells were rapidly thawed in a 37°C water bath, transferred to a falcon tube and 
9ml of 10% FCS DMEM was added.  After spinning at 1200 RPM for 3 minutes, the 
supernatant was removed and the pellet re-suspended in 10ml 10% FCS DMEM.  
The cells were transferred to a T25 flask and incubated at 37°C with 5% CO2. 
 
2.2.2 Reverse siRNA transfection 
 
siRNA stocks 
ON-TARGET plus and siGENOME siRNAs, all purchased from Dharmacon, were 
diluted in RNase free water and 5X siRNA buffer to make a stock of 20mM.  
6 well plate transfections 
3µl of 20µM siRNA was added to 250µl of DMEM and 4µl of RNAiMAX was added to 
250µl of DMEM.  These were left to incubate for 5 minutes at room temperature.  
RNAiMAX-DMEM mix was added to the siRNA-DMEM mix and these were left to 
complex for 30 minutes at room temperature.  This complex was pipetted to the 
bottom of the well before adding cells.  200,000 cells were seeded in 1ml of 10% 
FCS DMEM and a further 500µl of 10% FCS DMEM added.  The total well volume 
was 2ml.  The final siRNA concentration was 30nM in each well.  The plate was left 
to incubate for 24/48/72 hours at 37°C with 5% CO2, before harvesting for a 
western blot. 
96 well plate transfections 
For each column on a 96 well plate, 1.9 µl of 20µM siRNA was added to 125µl of 
serum free SFM and 3µl of RNAiMAX was added to 125µl of SFM.  These were left 
to incubate for 5 minutes at room temperature.  RNAiMAX-SFM mix was added to 
the siRNA-SFM mix and these were left to complex for 30 minutes at room 
temperature.  25µl of this complex was pipetted to the bottom of the well.  Cells 
were seeded in 100µl of 10% FCS DMEM.  The final siRNA concentration was 
30nM/well.  The plate was left to incubate for 48 hours at 37°C with 5% CO2, before 
the addition of various drugs as specified in results.  Cytotoxicity was then analysed 
using 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) and an 
average was taken across 6 inner wells in a column. 
384 well plate transfections 
1.25µl of 20µM siRNA was diluted in 8.75µl of RNase free water, giving a 
concentration of 2.5µM.  9µl of 2.5µM siRNA was added to 141µl of RNase free 
water to give a siRNA concentration of 150nM.  5µl of 150nM siRNA was added to 
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each well of a 384 well plate, followed by 0.06µl of RNAiMAX in 5 µl of SFM.  This 
mix was left to complex for 30 minutes at room temperature.  400 T98G cells in 
15µl of 10% FCS DMEM were seeded in each well of the plate which was then  left 
at room temperature for 60 minutes in order to reduce edge effects .  The plate 
was incubated for 48 hours at 37°C with 5% CO2.  25µl of 10% FCS DMEM was 
added to each well to dilute out the siRNA and 50µM temozolomide was added 
where necessary.  Cells were then incubated for a further 5 days, before fixing and 
staining ready for imaging. 
 
2.2.3 siRNA and Drug Screen Timings 
 
Both the siRNA and small molecule drug screens were 7 day assays conducted in 
384 well plates as outlined in figure 2.1.  Following a 48 hour transfection or drug 
treatments, cells were then incubated with temozolomide for 5 days (Patil et al., 



























Figure 2.1: siRNA and Drug Screening procedure 
Cells were reverse transfected with siRNA and plated on day 0.  Following a 48 hour knock 
down, RNAi was diluted and TMZ was added for 5 days. Cells were then fixed in 4% PFA with 
5µg Hoescht/ml, imaged and analysed (A). 
Cells were plated on day 0.  24 hours later, cells were then treated with various compounds 
using a LabCyte Echo 500 machine.  24 hours after the first treatment TMZ was then added 
using a LabCyte Echo 500 machine for 5 days.  Cells were fixed in 4% PFA with 5µg 
Hoescht/ml, imaged and analysed (B). 
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2.2.4 384 Well Plate Fixing, Staining and Imaging 
 
384 well plates were washed 3 times in 50µl of PBS/well using a ELx405 Select Deep 
Well Washer.  Cells were fixed and stained in 5µg of Hoescht/ml in 4% PFA for 20 
minutes in the dark at room temperature.  Plates were washed 3 times in 50µl of 
PBS/well, with the final 50µl remaining in the well.  Plates were then sealed using a 
PlateLov Velocity 11 and imaged on a Molecular Devices ImageXpress Micro high 
content microsope at a 2X objective.  One image was taken per well and a Multi 
Wavelength Cell Scoring application on MetaXpress was used to analyse the 
images.  
 
2.2.5 RNA Studies 
 
RNA Extraction 
Qiagen RNeasy Mini Kit was used to extract RNA from cultured cells.  Media was 
removed and cells were washed in PBS before 350µl of RLT Buffer was added to 
each well of a 6 well plate.  The cells were scraped off the well and placed into a 
QIAshredder before being centrifuged for 2 minutes.  350µl of 70% ethanol was 
added to the supernatant which was then transferred to an RNeasy minispin 
column and centrifuged for 15 seconds.  700µl of RWI buffer was added to the 
column which was centrifuged for a further 15 seconds.   This was repeated twice 
with 500µl of RPE buffer with the final centrifugation step being 2 minutes.  Finally 
the RNA was eluted with 50µl RNase free water.  Total RNA levels in each sample 
were quantified using the Nanodrop ND 1000 Spectrophotometer. 
 
Reverse Transcription 
RNA samples were reverse transcribed using the TaqMan™ Reverse Transcription 
Reagents (table 2.10) ready for qPCR.  Each sample was made up to 25µl with 
200ng of RNA and ddH2O.  These samples were then amplified on a PCR machine, 
making cDNA from the extracted RNA (table 2.11).   
 




Random Hexamers 1.25µl 
RNase Inhibitor 0.5µl 
Multiscribe RTase 0.625µl 
10X Buffer 2.5µl 




RT-qPCR - Relative mRNA Expression 
cDNA samples generated from extracted RNA were run in triplicate on a 384 well 
PCR plate.  Each reaction was made up of: 2µl of cDNA, 5µl of TaqMan™ Universal 
PCR Mastermix, 2.5µl of ddH2O and 0.5µl of probe (table 2.7).  GAPDH was run as a 
control for each sample.  After sealing, the plate was run on a 7900 Real Time-PCR 
machine with FAM filter and 40 repeats settings.  Double delta Ct (2-ΔΔCT) analysis 
was used to determine gene expression and calculate siRNA knockdown using an 
average Ct value from the triplicate runs.  
Example: 
ΔΔCT = ΔCT (Target Probe target siRNA transfected – GAPDH Probe target siRNA transfected) – ΔCT 
(Target Probe non-targeting siRNA transfected – GAPDH Probe non-targeting siRNA transfected) 
Fold change = 2- ΔΔCT    
% Knockdown = (1-(2- ΔΔCT) *100     
 
2.2.6 Western Blotting  
 
Protein Extraction and Quantification  
Cells previously transfected and seeded in a 6 well plate were washed twice in PBS 
and 100µl of lysis buffer (table 2.12) was added to each well.  Cells were harvested 
from the plate using a cell scraper and transferred to an eppendorf, vortexed and 
then left to lyse for 30 minutes on ice.  The cells were centrifuged at 15,000G for 15 
minutes at 4°C and the supernatant was then transferred into fresh eppendorfs.  4X 
NuPage LDS Loading Buffer and 5mM DTT were added to the lysates which were 




Table 2.11: RT-PCR Programme for cDNA 
Step Temperature (°C) Minutes 
1 25 5 
2 48 60 
3 95 5 
4 4 - 
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39µl of ddH2O and 1µl of protein lysate were added to a well of a 96 well, in 
triplicate.  200µl of Protein Assay Dye Reagent Concentrate (BioRad), diluted 1:5, 
was then added to the wells.  Optical Density (OD) was read at 595nm on a 
Multiskan FC, Thermo Scientific spectrophotometer.  The protein standard curves, 
which were made using bovine serum albumin (BSA), were used to quantify protein 
concentration by solving the linear quadratic equation y = mx + c, where m is the 


























Table 2.12: Lysis Buffer 
Reagent Stock Amount for 5ml 
50mM Tris pH 8.0 1M 250 μl 
200mM NaCl 5M 200 μl 
1% Triton X-100 100% 50 μl 
1mM DTT 1M 5 μl 
1mM EDTA 500mM 10 μl 
Benzonase 25U/ml 10 μl 
PIB 10x 500 μl 
Phos. Inhibitors 100x 50 μl 

































Figure 2.2: BSA titration standard curve 
The standard curve created from BSA standards was used to calculate protein concentration.  
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SDS-PAGE and Western Blotting 
 
10 or 15 well NuPAGE 4-12% Bis-Tris gels were used for western blotting.  50µg of 
protein and 4X NuPage LDS Loading Buffer were loaded on to the gels.  5µl of 1X 
SeeBluePlus2 Prestained Standard was also loaded beside the protein samples as a 
molecular weight reference.  Any empty wells were loaded with 5µl of 4X NuPage 
LDS Loading Buffer.  The samples were electrophoresed in Mini PROTEAN Tetra 
Cells, using 1X NuPage Running Buffer, at 150V for 90-120 minutes.  Protein from 
the gels was transferred to nitrocellulose membranes at 100V for 120 minutes in 
Mini PROTEAN Tetra Cells, using 1X NuPAGE transfer buffer.  Membranes were 
blocked for 60 minutes in 5% milk dissolved in PBS-T.  Membranes were incubated 
with primary antibodies overnight at 4°C.  After 3 washes in PBS-T, membranes 
were incubated with secondary antibodies conjugated to HRP at a concentration of 
1:1000.  Membranes were again washed 3 times in PBS-T and then visualised using 
Pierce ECL western blotting substrate.  The membrane were developed using 
medical x-ray film and a Konica SRX 101A Processor. 
 
2.2.7 Clonogenic Survival Assay 
 
Cells were seeded at various densities in 10cm plates in 10ml of 10% FCS DMEM.  
After a 24 hour incubation period which enabled the cells to adhere, each plate was 
either drug or DMSO treated in triplicate, as specified in the results. 
The cells were grown for 21 days before the media was removed and methylene 
blue (0.4%) was used to stain the colonies.  Following 30 minutes incubation, 
methylene blue was removed and any excess was washed from the plates in warm 
water.  The colonies were counted and the plating efficiency (PE) was calculated by 
the average number of colonies counted on the DMSO treated control plates 
divided by the number of cells plated.  The survival fraction (SF) was then calculated 
by the number of colonies counted/ number of colonies plated multiplied by the PE.   
 
2.2.8 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Cytotoxicity 
Assay 
 
If un-transfected, cells were plated in 100µl of 10% FCS DMEM per well of a 96 well 
plate or in 125µl of 10% FCS DMEM per well of a 96 well plate if siRNA transfected.  
The seeding densities had previously been optimised to yield a linear relationship 
between OD540 and cell number. Cells were incubated for 24 hours or 48 hours prior 
to the addition of various drugs at different concentrations (6 wells/concentration), 
as specified in results.  6 or 7 days after plating (as specified in results), 50µl of 
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3mg/ml MTT diluted in PBS, was added to the cells.  Following a 3 hour incubation 
period, media was removed using a pipette and the purple formazan precipitate 
dissolved in 200µl of DMSO.  OD values were read at 540nm on a Multiskan FC 
plate reader.  The survival fraction was calculated from an average taken from 6 
replicates compared to DMSO treated or DMSO treated and non-targeting siRNA 
transfected controls.   
 
2.2.9 Flow Cytometry 
 
Annexin V and Propidium Iodide (PI) 
Annexin V and PI are used as a dual stain to determine whether cells are apoptotic, 
necrotic or healthy.  Healthy cells have an intact membrane and do not take up 
either dye.  Annexin V has a high affinity for phosphatidylserine which is relocated 
to the outer membrane of a cell during early apoptosis.  If annexin V is conjugated 
to a fluorescent marker such as FITC (fluorescein isothiocyanate) then apoptotic 
cells can be detected using fluorescent activated cell sorting (FACS).  PI is naturally 
fluorescent and intercalates in between base pairs of double strand DNA.  If a cell is 
necrotic it does not have an intact membrane and therefore PI is able to access the 
DNA where it can bind.  This can also be detected using FACS 
(ThermoFisherScientific, 2018).  After cells were plated in 10cm dishes and drug 
treated in triplicate, they were collected at various time points specified in results.  
Media was removed and cells were washed twice in PBS before 2ml of trypsin was 
added.  Both media and PBS washes were retained.  Following detachment, cells 
were collected in 5ml of PBS which was added to the media and PBS washes.  This 
was then centrifuged at 1,200 rpm for 3 minutes.  Following removal of the 
supernatant, the cell pellet was washed in 10ml of PBS.  Cells were re-suspended in 
100µl of 1x annexin V binding buffer before 5µl of both annexin V and PI were 
added.  Cells were left to incubate for 15 minutes.  400µl of 1x DNA binding buffer 
was added to each sample before being analysed on the FACSCalibur.  FITC Annexin 
V apoptosis detection kit (BD Biosciences, 556547) was used.  FlowJo was used to 
analyse the results.    
 
2.2.10 Immunofluorescence  
 
Immunofluorescence (IF) was used to detect DNA damage within the cells via 
markers such as: 53BP1, DNA-PKcs (s2056) and RAD51.  Cells were seeded (20,000 
in 500µl of 10% FCS DMEM) on glass coverslips in 24 well plates in triplicate.  
Following 24 hours for the cells to adhere, they were treated with various drugs as 
specified in the results. Following drug treatment, cells were permeablised in 
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Triton-X100 for 1-3 minutes before being fixed in 4% PFA for 10 minutes.  Cells were 
then blocked in 10% FCS for 1-2 hours. Primary antibodies diluted in 2% FCS were 
added to each well and left over-night at 4°C.  The following day, cells were washed 
thoroughly with PBS before the secondary Alexa-Fluor antibodies (made in 2% FCS) 
were added for 1-2 hours at room temperature in the dark.  The cells were washed 
in PBS alone, washed in DAPI made up in PBS (1µg/ml) and washed again in PBS 
alone.  Cells were then washed in ddH2O before being mounted using immu-mount 
(Thermo).  Slides were imaged on a Nikon Eclipse TE200 Fluorescent Microscope.  
Images were scored by counting the foci of around 100 nuclei for each condition in 
an experimental repeat or as a percentage of total cells visible in each field of view 
over multiple fields across each slide.  
IF was also used to detect methylation of guanine at O6 using O-6-methyl-2‘-
deoxyguanosine antibody.  Following seeding and drug treatment, cells were 
washed in PBS before being fixed in 4% PFA for 10 minutes.  Cells were washed and 
then 2.5M HCl was used to denature the DNA for 30 minutes.  Cells were washed 
and then permeablised in 0.5% Triton-X100 in PBS for 15 before being blocked in 
3% BSA made in PBS for 1-2 hours.  Cells were incubated with primary antibody 
(1:100) over-night at 4 °C.  Day 2 followed the same protocol as the standard IF 
above.  
     
2.2.11 Alkaline Comet Assay 
Alkaline comet assays are used to detect single strand DNA breaks.  Following lysis 
which leaves DNA unharmed, a current is applied to the DNA suspended in agarose.  
The more breaks in the DNA, the further it will migrate through the agarose 
(negatively charged DNA migrates to positive cathode).  Once a nucleotide stain is 
applied, the DNA ‘tails’ can be visualised using fluorescent microscopy (Ostling and 
Johanson, 1984). A Trevigen comet assay kit was used and instructions were 
followed.  Cells were suspended in agarose, lysed in lysis buffer provided (triton-
X100 and 2.5M NaCl) for an hour at 4°C.  The lysis buffer enables the DNA to form 
supercoiled loops which appeared as the heads of the comets.  The DNA nucleoids 
were then exposed to alkaline unwinding buffer before the gels were run at 21V for 
30 minutes in an electrophoresis buffer.  Slides were dipped in 70% ethanol before 
being dipped in ddH2O and left to dry.  SYBR Gold (1:30000) nucleotide stain was 
used to stain the DNA.  50 cells in each condition were imaged using FITC channel 
and 20x lens on a Nikon Eclipse TE200 Fluorescent Microscope.  Tail moment, 
calculated by TriTek Comet Score software, was used as a measure of DNA damage 
severity, combining tail length and intensity of DNA within the tail 
(AMSBiotechnology, 2010). 
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2.2.11 Immunohistochemistry  
 
Fixing and Embedding cell pellets 
To prepare a cell line pellet for immunohistochemistry (IHC), cells were reverse 
transfected as before (2.2.2 Reverse siRNA transfection) however, transfections 
were scaled up into a T75 flask.  Control or ERK5 siRNA from siTOOLS™ was used 
over a 48 hour transfection, and each flask had a final concentration of 10nM 
siRNA.  Following transfection, cells were washed with PBS, detached using 2ml of 
trypsin EDTA, re-suspended in PBS and pelleted at 1200 RPM for 2 minutes in a 
50ml falcon tube. Cells were then washed twice with 10ml of PBS before being 
pelleted again. 1ml of 4% PFA was used to re-suspend and then fix the cells for 10 
minutes at room temperature.  Cells were then pelleted in a 1.5ml eppendorf 
before PFA was removed.  The cell pellet was then encased in molten 2% agarose 
before being stored in 70% ethanol until processing.  The following steps were all 
completed by Maggie Glover (Technician in the Department of Oncology and 
Metabolism within the University of Sheffield). Leica TP 1020 tissue processor was 
used to automatically process the pellets.  An alcohol concentration gradient was 
used to dehydrate the cells, xylene was used to clear the cells and finally molten 
wax under vacuum was used to fill the cells.  Processed cell pellets were then 
embedded in wax using a Leica EG1150 wax embedder before being sectioned at 5 
microns using a Leica RM2245 Microtome.  
IHC staining protocol 
Both cell pellets and commercial tissue microarrays (TMAs) underwent the 
following IHC staining protocol. 
Slides were submerged in xylene for 10 minutes followed by 100% ethanol for 10 
minutes.  Slides were then placed in 95% ethanol for 3 minutes.  30ml hydrogen 
peroxide in 270ml of 100% methanol was then added to the slides for 30 minutes in 
order to exhaust the samples of natural peroxidases.  Slides were then placed in 
Dako Target Retrieval Solution (pH 6) made up 1:10 in ddH2O in a pressure cooker 
for a 20 minute heat cycle, in order to break methylene bonds formed during 
formalin fixing and make the epitopes available again for antibody binding.  Slides 
were then washed in PBS-T before being blocked in 10% goat serum made up in 1% 
BSA Triton-X100 in PBS for an hour.  Primary antibody (anti-ERK5) made up in 2% 
goat serum was added to the slides which were left to incubate over-night at 4°C.  
Slides were washed in PBS-T before the secondary antibody (biotinylated goat anti-
mouse) was added to the slides 1:200 made up in 1% BSA in PBS-T for 1 hour.  
Slides were washed with PBS-T and then Avidin-Biotin Complex (ABC) (Vector 
Laboratories) was added to the slides for 30 minutes.  ABC contains tetravalent 
avidin and biotinylated HRP, which are complexed in equal ratios prior to being 
added to the slides, resulting in 3 HRP molecules bound to 1 avidin molecule at the 
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site of the biotinylated secondary antibody. This is used to intensify the target 
antigen signal.  DAB substrate (3,3'-diaminobenzidine)(Vector Laboratories), along 
with hydrogen peroxide, was added to the slides for 30 seconds.  DAB is oxidized by 
hydrogen peroxide and catalysed by HRP resulting in a brown insoluble precipitate 
at the site of the antibody-HRP complex.  A secondary antibody alone was used as a 
negative control.  Tap water was used to stop the DAB reaction and slides were 
then dehydrated in alcohol before being cleared in xylene and then mounted using 
DPX Mountant (sigma).  
The following human paraffin embedded TMAs were purchased from US Biomax: 
GL481, BS17016b and BS17016c.    
 
2.2.12 Statistical Analysis 
 
Statistical analysis was performed using Microsoft Excel or GraphPad Prism 7, 
however, Dr Stephen Brown, who analysed the results from the siRNA screen, used 
R.  Means and standard deviation were calculated from 3 experimental repeats 
where possible.  Non-parametric tests were used to analyse the data: Mann-
Whitney U Tests (t-test) or Kruskal-Wallis H Tests (one way ANOVA) with Dunn’s 
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In 2004, 291 mutated genes were identified as ‘cancer genes’.  Protein kinases were 
predicted to make up only 2.16% of the oncogenic genes identified, however, they 
were found to make up 9.28%, more than four times the original prediction (Futreal 
et al., 2004).  Not only have protein kinases have been shown to be causal in cancer 
development, they also have enzymatic activity which requires ATP binding to an 
active site in order to function, making them attractive drug targets (Bhullar et al., 
2018).   
Imatinib was the first protein kinase inhibitor to be FDA approved for treating 
cancer in humans.  Imatinib is a tyrosine kinase inhibitor used to treat patients with 
chronic myeloid leukaemia (CML), a blood cancer causing uncontrolled division of 
white blood cells (Roskoski Jr., 2003).  The fusion gene BCR-Abl, which characterises 
CML, is formed when Abelson Leukaemia Virus (ABL) kinase is translocated to 
Breakpoint Cluster Region (BCR) on chromosome 22, generating the shortened 
Philidelphia chromosome (de Klein et al., 1982).  Imatinib is effective at treating 
patients with CML as it inhibits  BCR-Abl kinase activity, a mutation which is present 
in 95% of patients (Roskoski Jr., 2003).  Since this initial approval for Imatinib, 37 
protein kinase inhibitors targeting cancer have been approved by the FDA (Bhullar 
et al., 2018).  It is not only the ‘druggability’ of kinases which makes them attractive 
targets, inhibition of master regulator kinases also unlocks the potential to target 
subsequent downstream signalling pathways which may be fundamental to the 
development and progression of cancer (Manning, 2009).   
Given this previous success and the potential to target complex signalling networks 
combined with the fact GBM patient survival has remained unchanged for decades 
(Manning, 2009, Stupp et al., 2005), a kinome-wide siRNA screen was chosen to 
investigate the hypothesis ‘inhibition of yet to be identified targets/pathways will 
enhance the cytotoxic effects of temozolomide in Glioblastoma Multiforme’.   
Data from a previous siRNA screen conducted in GBM cells was published by 
another research group in 2012, who investigated synthetic lethality in GBM using a 
combination of siRNA and temozolomide, with a focus on resistance to alkylation 
damage (Svilar et al., 2012).  Temozolomide resistant GBM cells, were reverse 
transfected with targets from the Ambion Silencer Druggable Genome siRNA Library 
(Version 1.1) (final conc. 20nM) for 5 hours, incubated for a further 48 hours (in 
fresh media) to allow knock-down of targets and finally treated with 1mM 
temozolomide for 24/48 hours.  Cell viability was assessed by a redox reaction.  
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Bacteria, yeast and human cells were used to try to identify novel targets important 
in resistance to alkylation. A ubiquitin ligase (E3B) and DNA repair protein (UNG) 
showed interesting results, however, some initial findings in yeast did not translate 
into human cells (Svilar et al., 2012).  A previous siRNA screen investigating GBM 
survival genes was also conducted by the same group and published prior to their 
temozolomide screen.  Here they identified 55 genes which also showed a 
particular enrichment in proteasomes and the ubiquitin degradation pathways 
(Thaker et al., 2009). 
Temozolomide causes methylation damage to several DNA bases, however, the 
most toxic O-6-methylguanine lesion accounts for less than 8% of the total lesions 
formed (Kaina et al., 2007).  Methylation of O-6 guanine is either directly repaired 
by MGMT or if unrepaired, the methylated guanine can be incorrectly paired with 
thymine.  Mismatch repair (MMR) recognises this incorrect pairing and removes the 
newly paired base on the complementary strand so O-6-methylguanine remains on 
the parental strand of DNA.  The methylated base is then re-paired with thymine 
and the futile cycle of MMR continues resulting in single strand gaps or breaks in 
DNA eventually causing apoptosis.  Second round synthesis can also result in GC to 
AT transitions when the mispaired T is used as a template (Friedman et al., 2000).  
GBMs rapidly become resistant to temozolomide treatment, reflected by the 
complete lack of response to a second cycle of temozolomide in more than 90% of 
recurrent GBM cases (Oliva et al., 2010).  Resistant cells can have increased MGMT 
expression or may have inactivating mutations in MMR proteins (e.g. mutS 
homolog 6) limiting MMR induced apoptosis (Cahill et al., 2007, Sarkaria et al., 
2008).  However, a trial inhibiting MGMT activity did not show promising results in 
a Phase II trial; failing to increase sensitivity to temozolomide and causing 
haematological toxicities (Quinn et al., 2009). 
Therefore, to provide novel, relevant and potentially druggable hits, an siRNA 
screen was carried out in the temozolomide resistant T98G cell line using the 
Dharmacon™ On-TARGETplus (OTP) Protein Kinase SMARTpool siRNA Library. 
 
3.2 RNAi Screen Optimisation 
3.2.1 Temozolomide Sensitivity in GBM Cells 
 
T98G cells are a GBM cell line resistant to temozolomide treatment.  These cells 
have an un-methylated MGMT promoter (MGMT +ve), resulting in an increase in 
levels of the enzyme MGMT which facilitates efficient repair of toxic lesions caused 
by temozolomide.  Patient tumours with an un-methylated MGMT promoter are 
also temozolomide resistant and account for up to 45% of malignant glioma cases 
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(Thon et al., 2013).  The initial siRNA screen was conducted in T98G cells, however, 
pan-GBM clinical applicability of candidate genes was ensured by additional 
validation studies in the temozolomide sensitive GBM cell lines U-87 (MGMT –ve) 
and U-251 (MGMT –ve) and TP53 mutant GBM cell line LN-18 (MGMT +ve) (figure 
3.1A).   
To determine a non-toxic dose of temozolomide to be used in the siRNA screen, 
T98G cells were treated with increasing doses and cell viability was assessed by 
MTT cytotoxicity assays 5 days after the addition of temozolomide (figure 3.1B).  
Combining both a non-toxic dose of temozolomide (50µM) and non-toxic siRNA 
would ideally enable us to detect any potential hits more easily as the cells treated 
with temozolomide or siRNA alone would have cell viability comparable to control 























To transfect T98G cells within the Collis Lab, the transfection reagent RNAiMAX is 
used, however, the Sheffield RNAi Screening Facility (SRSF) recommends the use of 
Dharmafect 1 (DF1) for all cell lines.  In order to determine which of these reagents 
was most efficient, FANCD2 was depleted over 24 and 48 hours using previously 
validated siRNA complexed with either transfection reagent.  Inhibiting the Fanconi 
Anaemia (FA) pathway has previously been shown to increase the sensitivity of 
Figure 3.1: MGMT status of cell lines and cytotoxicity curves in TMZ treated T98G cells  
Cells were plated and allowed to adhere for 24 hours. Untreated cells were collected for 
western blotting (A). Western blotting showed T98G, LN-18, U-138 and HeLa cells express 
varying amounts of MGMT. β-actin was used as a loading control.  Following plating, T98G 
cells were treated with a range of doses of TMZ (0-400µM) prior to incubation for 5 days 
before an MTT assay was performed (B).   
Data shown is the average surviving fraction (normalised to DMSO treated control) +/- 
standard deviation derived from three independent biological repeat experiments. 
  
Western blot was completed by Connor McGarrity-Cottrell, 2nd Year Undergraduate Student 
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GBM in vitro to treatment with temozolomide, with over-expression of FANCD2 






























From the western blots (figure 3.2A) both RNAiMAX and DF1 equally depleted cells 
of FANCD2 protein, with a 48 hour transfection generating a more effective knock 
down.  Images taken from a 384-well plate (figure 3.2B) of T98G cells transfected 
with non-targeting siRNA showed an increased in cytotoxicity when DF1 was used 
and therefore RNAiMAX was determined to be the best transfection reagent for 
T98G cells and was selected for use in the siRNA screen. 
 
3.2.3 Positive and Negative Controls 
 
Experimental controls are needed to ensure that the results generated are due to 
the variable being tested.  A negative control, in this case the non-targeting siRNA, 






































24 hour KD  48 hour KD  
RNAiMAX DF1 
Figure 3.2: FANCD2 depletion and cell viability using DF1 and RNAiMAX 
Effective knock-down of FANCD2 protein in T98G cells can be seen using both RNAiMAX and 
DF1 as transfection reagents over 24 and 48 hours via western blot.  β-actin was used as a 
loading control (A).  T98G cells were reverse transfected with control siRNA in a 384 well 
plate.  48 hours later, cells were fixed in PFA and stained with Hoechst and wells were imaged 
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other results could be compared to.  Dharmacon™ recommends the use of On-
TARGETplus (OTP) siRNA over siGENOME (Dharmacon™, 2018).  OTP non-targeting 
negative control siRNAs have been shown to have reduced off target effects 
compared to ‘scrambled’ control siRNA following microarray analysis 24 hours post-
transfection, which is thought to be due to seed-region optimisation and dual 
strand modifications (Dharmacon™, 2018).  SRSF also recommends completing the 
first siRNA screen using OTP as it is less toxic in the majority of cell lines when 
compared to siGENOME, therefore giving the best chance of identifying potential 
hits.   
The non-targeting negative control siRNA is made up of a pool of 4 different 
combinations of siRNA and occasionally one of these ‘non-targeting’ siRNAs can 
have an off target cytotoxic effect.  To test the effect of these siRNAs on T98G cells, 
the pool was deconvolved so any potential cytotoxic effects would be highlighted.  
As there was no significant difference in the number of cells counted for the control 
pool when compared to each individual siRNA (figure 3.3), the pool of non-targeting 
negative control siRNA was chosen for use in the siRNA screen. 
 












































Figure 3.3: Effect of 4 individual non-targeting negative control siRNAs and non-targeting 
negative control pool siRNA 
T98G cells were reverse transfected with non-targeting negative control siRNA for 48 hours in 
a 384-well plate.  Following dilution of the siRNA, the cells were then incubated for a further 5 
days.  Cells underwent staining, fixing and imaging and wells were analysed using a Multi 
Wavelength Cell Scoring application on MetaXpress which counted cells based on minimum 
and maximum microns and intensity above background. 
 
There was no significant difference in the number of cells counted for each individual non-
targeting negative control siRNAs compared to each individual control siRNA and the pool 
(Kruskal-Wallis H Test).  
 
Data shown is the average surviving fraction +/- standard deviation derived from three 
independent biological repeat experiments. 
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A positive control shows a positive result can be generated using the experimental 
method, and any negative results are not due to the experimental procedure, but 
other factors.  
In order to identify a suitable positive control, potential targets were selected based 
on previously published data (Alagoz et al., 2013, Liu et al., 2008, Newlands et al., 
1997, Patil et al., 2014).  Depleting cells of PARP-1, TDP-1 and FANCD2 significantly 
sensitised T98G cells to treatment with 50µM temozolomide (figure 3.4).  MGMT, 
however, when used in combination with temozolomide caused a much more 
























Figure 3.4: Identification of a positive control for the TMZ sensitisation screen in T98G cells  
T98G cells were reverse transfected with non-targeting negative control siRNA or a potential 
positive control siRNA for 48 hours in a 384-well plate (PARP-1, TDP-1, FANCD2, MGMT).  
Following dilution of the siRNA, half of the wells were then treated with 50µM TMZ or DMSO 
for 5 days.  Cells underwent staining, fixing and imaging and wells were analysed using a 
Multi Wavelength Cell Scoring application on MetaXpress which counted cells based on 
minimum and maximum microns and intensity above background. 
 
PARP-1, TDP-1 and FAND2 sensitised T98G cells to treatment with 50µM TMZ, however, 
MGMT caused a significant increase in cell death and was therefore chosen as the positive 
control.   
 
Data shown is the average surviving fraction (normalised to control siRNA) +/- standard 
deviation derived from three independent biological repeat experiments. 
**=P<0.005 using a Mann-Whitney U Test.  
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The use of PARP-1 inhibitors in combination with temozolomide are currently being 
investigated in clinical trials for patients with both newly diagnosed and recurrent 
GBM (ClinicalTrials.gov, 2018), therefore PARP-1 siRNA was a rational positive 
control target.  However, as PARP-1 inhibitors are most effective at killing cells 
when they are able to trap PARP-1 and not just inhibit the enzyme activity (Murai et 
al., 2014), the limited cell death induced by PARP-1 siRNA in combination with 
temozolomide was not too surprising.  There is also evidence to support 
redundancy between PARP-1 and PARP-2, which also may have contributed to the 
limited death induced by PARP-1 siRNA in combination with temozolomide (Ronson 
et al., 2018).  
Inhibiting the FA pathway has previously been shown to increase the sensitivity of 
GBM in vitro to treatment with temozolomide, with over-expression of FANCD2 
protein seen in HGGs  (Patil et al., 2014).  Depleting cells of FANCD2 did show a 
trend towards sensitisation, however, not to the extent needed for a positive 
control.  This discrepancy may be due to pan-FA inhibitors being used previously 
which most likely have unidentified off target effects. 
In T98G cells, knocking- down TDP-1 using siRNA has proved effective at increasing 
the sensitivity of the cells to treatment with temozolomide (Alagoz et al., 2013), 
however, the increase in cell death was not large enough to be used as a positive 
control for the siRNA screen. 
MGMT encodes for the enzyme O-6-methylguanine-DNA methyltransferase which 
repairs the DNA damage induced by temozolomide (Agarwala and Kirkwood, 2000, 
Newlands et al., 1997).  Depleting cells of MGMT caused the largest decrease in the 
number of cells per well and therefore the biggest increase in cell death, hence its 
selection as the positive control siRNA for the screen.  A western blot, (figure 3.5) 







Figure 3.5: Western Blot of 24 and 48 hour knock-down of MGMT using siRNA 
T98G cells were reverse transfected and plated in a 6-well plate.  Cells were harvested and 
lysed 24 and 48 hours later.  Following western blotting, effective knock-down of MGMT 
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The z-prime calculation was then used to determine the robustness of the assay 
using MGMT as the positive control and non-targeting siRNA as the negative 
control.  A z-prime value of greater than 0.5 reflects excellent robustness and 
reproducibility of the assay.  A z-prime score of 0 – 0.5 reflects an acceptable assay 
and a score of less than 0 is a poor assay, likely to generate many false positive 
results (Bray and Carpenter, 2017).   A z-prime of greater than 0.5 was achieved 
consistently after automation of cell plating and a general improvement of cell 














Figure 3.6: Z-prime scores  
T98G cells were reverse transfected with non-targeting negative control siRNA or MGMT 
siRNA for 48 hours in a 384-well plate.  Following dilution of the siRNA, all of the cells were 
then treated with 50µM TMZ for 5 days.  Cells underwent staining, fixing and imaging and 
wells were analysed using a Multi Wavelength Cell Scoring application on MetaXpress which 
counted cells based on minimum and maximum microns and intensity above background. 
 
Hand-plating cells caused a larger SD between control cells, resulting in a poor z-prime.  As 
plating moved towards automation, the z-prime improved, eventually reaching 0.51. 
 
The z-prime was calculated as 1 – 3(SD control siRNA values * SD MGMT siRNA values) 
                                                                mean control siRNA values – mean MGMT siRNA values 
 

















hand plated automated automated automated automated automated
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3.3 On-TARGETplus Kinome Screen 
 
OTP pooled siRNA was used for the kinome screen which was repeated 3 times in 
T98G cells transfected with either siRNA alone (to determine any inherent siRNA-
mediated cytotoxicity) or siRNA with 50µM temozolomide.  The z-prime was 
calculated for each plate that was treated with temozolomide and all were ≥0.5 




























Z-scores were generated, by Dr Stephen Brown from the SRSF using R software, for 
every siRNA target both with and without temozolomide.  Wells were each 
normalised to the appropriate controls on the same plate and then median values 
were used to generate the z-scores, eliminating the effects any outliers would have 
if the mean values were used.  Z-scores are directly related to standard deviation 
(SD) and if data are normally distributed, 95.45% will have a z-score of -2 to +2 
(Bray and Carpenter, 2017).  This enabled us to identify potential hits which were 
relatively non-toxic alone but when combined with temozolomide the number of 















Figure 3.7: Z-prime scores for the TMZ treated plated in the Kinome Screen 
A z-prime value of ≥ 0.5 was achieved in all 3 plates when MGMT siRNA was used the positive 
control for T98G cells treated with TMZ across the 3 repeats (n=3).  
 
The z-prime was calculated as:  1 – 3(SD control siRNA values * SD MGMT siRNA values) 
             (mean control siRNA values – mean MGMT siRNA values) 
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more stringent with the results, a cut off of <-2.2 was therefore used when the 














3.4 Hit Validation 
3.4.1 Hit Validation – siGENOME Pooled siRNA  
 
siGENOME siRNA was used to validate potential hits that sensitised T98G cells to 
temozolomide using OTP pooled siRNA.  siGENOME siRNA is synthesised differently 
to OTP siRNA and consists of different target regions within the mRNA, therefore 
any targets that had the ability to sensitise cells to temozolomide using both siRNAs 
would have an increased chance of being a ‘real’ hit and would then be validated 












































































































Figure 3.8: Z scores for hits identified in the Kinome Screen 
The graph shows the median z-score for the negative and positive controls and potential hits 
when T98G cells were reverse transfected with siRNA and then treated with 50µM TMZ 48 
hours later.  Cells underwent staining and fixing following 5 days incubation before wells were 
imaged and analysed using a Multi Wavelength Cell Scoring application on MetaXpress.  This 
application counted cells based on minimum and maximum microns and intensity above 
background. 
 
The MGMT positive control generated a z-score of -5.25 (red diamond), which was a lower z-
score than all but one of the potential hits.  Potential hits were selected based on a z-score of 
<-2.2 when treated with siRNA and TMZ and >-2 when treated with siRNA alone. 
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OTP MGMT siRNA was used in this mini-screen as siGENOME MGMT siRNA was 
unable to generate a z-prime of >0.5 and could only be used as a weak positive 
control (figure 3.9).  siGENOME MGMT siRNA combined with temozolomide did 
show a trend towards increased cell death but this did not reach significance 
(p=0.07).  Unfortunately, all of the hits treated with a combination of temozolomide 
and siGENOME siRNA did not cause a significant increase in cell death when 
compared to the DMSO treated controls; however, several targets did show a trend 

























































































































































Figure 3.9: Survival Fraction of T98G cells treated with siGENOME siRNA +/- TMZ 
T98G cells were reverse transfected with siRNA and then treated with 50µM TMZ 48 hours 
later.  Cells underwent staining and fixing following 5 days incubation.  Wells were imaged 
and analysed using a Multi Wavelength Cell Scoring application on MetaXpress.  This 
application counted cells based on minimum and maximum microns and intensity above 
background.  OTP MGMT siRNA was the only siRNA which caused a significant reduction in 
the survival fraction (p=0.009).  Survival fractions of <90%, shown in the grey bars, were taken 
forward as positive results. 
 
Data shown is the average surviving fraction (normalised to control siRNA) +/- standard 
deviation derived from three independent biological repeat experiments. 
**=p<0.01 using a Mann-Whitney U Test. 
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3.4.2 Hit Validation – OTP siRNA 
 
When combined with siGENOME siRNA and temozolomide, targets which were able 
to achieve less than 90% survival were taken forward as potential hits for further 
validation.  These were PNCK, DMPK, FGFR4, MAP3K3, FES and PRKCSH.   
PRKDC siRNA did reduce survival by more than 10% when combined with 
temozolomide; however it was not taken forward as a potential hit.  PRKDC is the 
gene that encodes for DNA-PKcs.  It has previously been shown that inhibition of 
this target using a small molecule inhibitor (KU0060648) is able to sensitise GBM 
cells to temozolomide (Lan et al., 2016) and it was therefore discarded from further 
analyses.  
Initially, further validation of the targets was to be investigated using 4 individual 
OTP siRNAs to each target.  However, to show that comparable temozolomide 
sensitisation could be seen with the original OTP siRNAs, the 4 individual siRNAs 
were pooled together and used in combination with temozolomide.  The only target 
to show any sensitisation in combination with temozolomide was MAP3K3 
(Mitogen-Activated Protein Kinase Kinase Kinase 3, also known as MEKK3), which 















Figure 3.10: Survival Fraction of T98G cells treated with Pooled OTP siRNA +/- TMZ 
T98G cells were reverse transfected with siRNA and then treated with 50µM TMZ 48 hours 
later.  Cells underwent staining and fixing following 5 days incubation.  Wells were imaged 
and analysed using a Multi Wavelength Cell Scoring application on MetaXpress.  This 
application counted cells based on minimum and maximum microns and intensity above 
background. 
 
Data shown is the average surviving fraction +/- standard deviation derived from three 
independent biological repeat experiments. 
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As this result was unexpected, reverse transcription polymerase chain reaction (RT-
PCR), also known as quantitative PCR (qPCR), was used to determine the gene 
expression of each gene following 48 hour knock down using OTP pooled siRNA 
(figure 3.11).  Both OTP and siGENOME MGMT siRNA caused greater than 80% 
reduction in the expression of their target gene.  More than 80% reduction in gene 
expression was only seen only in MAP3K3 and PRKCSH pooled OTP siRNA samples.  
This may explain why MAP3K3 was able to show a trend towards increased cell 
death when combined with temozolomide (figure 3.11).  PRKCSH gene expression 
was effectively depleted by siRNA; however, it did not result in a decreased survival 
fraction so is likely to be a false positive result. The use of another housekeeping 
gene, such as 18S, would further improve confidence in this qRT-PCR data, as off 
target effects of siRNA could have altered GAPDH expression, subsequently 
affecting ΔΔCT calculations and generating incorrect values which could account for 












Figure 3.11: Gene Expression of T98G cells treated with Pooled OTP for 48 hours 
T98G cells were reverse transfected with siRNA and cells were harvested for RNA extraction 48 
hours later.  Following RNA extraction, cDNA was made and qRT-PCR was performed.   
 
Green bars represent a knock down of >80%.  MGMT, MAP3K3 and PRKCSH siRNA were all 
able to generate sufficient knock down of their targets.  GAPDH was used as a house keeping 
gene to normalise samples. 
 
Fold change was calculated by 2- ΔΔCT 
 
% Knockdown was calculated by (1-2- ΔΔCT) *100     
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As MAP3K3 (MEKK3) pooled siRNA had shown optimum knock-down of gene 
expression (figure 3.11), qRT-PCR was used to determine gene knock-down using 
the individual siRNAs, and again the use of another housekeeping gene, such as 
















siRNAs 1, 2, and 4 were able to sufficiently  deplete T98G cells of MAP3K3 
expression (figure 3.12).  siRNA 3, however, did not show sufficient knock-down.  
These results from the qRT-PCR are reflected in clonogenic survival data from LN-18 
cells (figure 3.13).  Following a 48 hour reverse transfection, LN-18 cells were re-
plated into 10cm dishes, allowed to adhere for 24 hours and then treated with a 
Figure 3.12: Gene Expression in T98G cells treated with Individual MAP3K3 OTP siRNA for 
48 hours 
T98G cells were reverse transfected with siRNA and cells were harvested for RNA extraction 48 
hours later.  Following RNA extraction, cDNA was made and qRT-PCR was performed.   
 
siRNA sequence 1, 2, 4, and pooled siRNA were all able to generate sufficient knock down of 
their targets (>75%).  GAPDH was used as a house keeping gene to normalise samples. 
 
Fold change was calculated by 2- ΔΔCT 
 
% Knockdown was calculated by (1-2- ΔΔCT) *100     
 
















Individual MAP3K3  siRNA
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range of temozolomide doses, 0 - 400µM.  After 12 days incubation, a clonogenic 
survival assay showed a modest increase in sensitivity to temozolomide could be 
achieved using 3 out of 4 siRNAs when compared to OTP Control siRNA also treated 
with temozolomide (figure 3.13).  siRNA 3 which was shown to be ineffective at 
depleting cells of MAP3K3 expression (figure 3.12) was unable to sensitise LN-18 
cells to temozolomide in the clonogenic survival assay (figure 3.13). 























3.5 Small Molecule Inhibitors – MAP3K3 and FGFR4 
 
As siRNA cannot be used in patients, the next step was to identify any inhibitors for 
the 6 potential hits as this would increase the likelihood of potential clinical 
translation of these findings, and these inhibitors could be used to further validate 
the initial siRNA hits.  There can, however, be phenotypic differences between 
Figure 3.13: Cytotoxicity curves of GBM cells treated with MAP3K3 siRNA and TMZ 
LN-18 cells were reverse transfected with the indicated siRNA for 48 hours.  Cells were re-
plated into 10cm dishes and left to adhere for 24 hours.  They were treated with a range of 
TMZ doses (0 - 400µM) and left to incubate for a further 12 days, allowing colonies to form.  
Cell colonies were fixed in 0.04% methylene blue in 100% ethanol for 30 minutes at room 
temperature.  >50 cells were counted as a colony.  siRNAs 1, 2, and 4 were able to sensitise 
cells to temozolomide.   
 
Survival fraction (A) shows LN-18 cells treated with a maximum dose of 200µM TMZ. 
Survival fraction (B) shows LN-18 cells treated with a maximum dose of 400µM TMZ. 
A and B show the same data plotted against a different x-axis. 
 
Data shown is the average surviving fraction (normalised to control, 1, 2, 3 or 4 siRNA treated 
cells) +/- standard deviation derived from two independent biological repeat experiments. 
 
B A 
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siRNA depletion and catalytic inhibition of kinases, most likely due to differences in 
protein-protein interactions. siRNA reduces protein expression by targeting mRNA 
for degradation, however, catalytic inhibition will not affect protein expression, 
allowing protein-protein interactions and any biologically important scaffold roles 
of the protein to continue (Weiss et al., 2007).   
In 2015, BLU9931, created by Blueprint Medicines, was published as the first 
selective fibroblast growth factor receptor 4 (FGFR4) inhibitor.  This inhibitor is 
designed to inhibit active FGFR4 pathways in hepatocellular carcinoma  (Hagel et 
al., 2015).  This inhibitor is commercially available, however, during the course of 
this study, another inhibitor (BLU554) made by the same company was launched 
into clinical trials and was also commercially available.  BLU554 was therefore 
purchased from Selleckchem (Catalogue Number S8503).  
There are, however, currently no selective inhibitors that are commercially 
available for any of the other hits; however, mitogen-activated protein 
kinase kinase kinase 3 (MAP3K3/ MEKK3) pathway has inhibitors available to 
downstream targets.  Mitogen-activated protein kinase kinase 5 (MAP2K5/MEK5) 
and extracellular signal-related kinase 5 (ERK5) are found downstream of MAP3K3 
and can be inhibited using a commercially available inhibitors, BIX 02189 and ERK5-
in-1.  These inhibitors were also purchased from Selleckchem (Catalogue Numbers 
S1531 and S7334).  ERK5 generated a z-prime of -1.92 from siRNA screen results 
(cut off was -2.2), however, MEK5 generated a z-prime close to 0.  Therefore, both 
the MAP3K3 and FGFR4 pathways were taken forward into further validation 




It was hypothesised that inhibition of yet to be identified kinase(s)/signalling 
pathways would enhance the cytotoxic effects of temozolomide in GBM.  To 
investigate this hypothesis, a kinome-wide siRNA screen was completed both with 
and without temozolomide. 
MGMT depletion was successfully used as a positive control for the kinome-wide 
siRNA screen, generating the second highest z-score.  MGMT depletion using O-6-
benzylguanine has been explored in phase I and II clinical trials in patients with 
recurrent GBM, however, it was poorly tolerated resulting in haematological 
toxicity, a subsequent reduction in temozolomide treatment and no improvement 
to overall patient survival (Quinn et al., 2005, Quinn et al., 2009).  MGMT is the 
enzyme responsible for repairing DNA base adducts which occur following 
methylation, catalysing the removal of methyl groups from DNA to itself.  This 
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enzyme is important for both protection against mutagenesis and defence against 
the cytotoxicity of alkylating agents (Konduri et al., 2009), therefore, it may not be 
too surprising that the depletion of this enzyme following O-6-benzylguanie 
treatment was poorly tolerated in patients.  However, almost a third of newly 
diagnosed GBM patients and almost a quarter of recurrent GBM patients who have 
failed temozolomide therapy do not express high levels of MGMT and 97% of these 
patients have tumours with proficient MMR pathways, indicating alternative 
temozolomide resistance pathways independent of MGMT and MMR proteins 
(Maxwell et al., 2008).  These findings therefore highlight both the heterogeneity of 
GBM tumours and the need for novel and well-tolerated targets to improve the 
potency of existing treatment regimes such as temozolomide. 
There are, however, limitations to using siRNA including the variability of mRNA 
depletion and off-target effects resulting in downregulation of other mRNAs.  One 
example is a screen which was investigating ABT-737 sensitivity, an anti-cancer drug 
which inhibits a selection of anti-apoptotic proteins in the BCL-2 family (BCL-2, BCL-
xl and BCL-w) without inhibiting other family members (MCL-1, BCL-B, BFL-1).  The 3 
best hits involved in ABT-737 sensitivity were all a result of off target effects acting 
on MCL-1 as opposed to their intended target (Lin et al., 2007).  However, 
Dharmacon™ recommends the use of OTP siRNA as it has a ‘dual strand 
modifications pattern to reduce off-target effects by 90%’ (Dharmacon™, 2018).    
One problem that arose during validation of potential hits from the initial OTP 
screen was the loss of reproducibility when the siRNA pools were deconvoluted.  
This could be due to a number of factors including ineffective transfection, poor 
siRNA quality, incorrect dilution of lyophilised siRNA, transfection into non-
replicating cells and many more; all would result in ineffective knock-down of the 
intended target.  The positive control siRNA MGMT was purchased as 4 
deconvoluted sequences alongside the other siRNAs identified as potential hits.  
Deconvoluted MGMT siRNA was reconstituted, transfected, stored identically to all 
other deconvoluted siRNAs yet it was effective at depleting cells of the intended 
target, sensitising GBM cells to temozolomide.  This would suggest the lack of 
reproducibility was not due to the reconstitution, dilution, transfection processes.  
The ineffective depletion of target mRNA caused a problem in the progression of 
the project and disappointingly Dharmacon only guarantee a knock-down of more 
than 75% in 3 out of 4 siRNA sequences if a final concentration of 100nM is used.  
Therefore it was decided that the targets which had available inhibitors would be 
taken forward and validated using either effective individual OTP siRNA (MAP3K3) 
or using alternative siRNA from siTOOLs (ERK5 and FGFR4) (chapter 4.4 and chapter 
5.3). 
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Another criterion to take hits forward to further validation studies was evidence of 
pathway dysregulation in human cancers.  Both MAP3K3/ERK5 and FGFR4 pathways 
have previously been shown to be dysregulated in cancer.   
MAP3K3 is over-expressed in almost two thirds of ovarian carcinomas (where 
expression is correlated with both grade and response to chemotherapy), and has 
also been shown to be amplified in up to 20% of breast cancers, with shRNA 
depletion increasing sensitivity to both doxorubicin and 5-FU (Fan et al., 2014, Jia et 
al., 2016).  Overexpression of MAP3K3 in GBM cell lines enhances NF-κB activation, 
increasing cell survival and resistance to both doxorubicin and camptothecin 
(Samanta et al., 2004).  Although the inhibition of MAP3K3 would subsequently 
inhibit a whole pathway of downstream targets and signalling pathways, there 
currently no successful specific inhibitors reported.  Examples of downstream 
targets of MAP3K3 include MEK5/ERK5 (chapter 4), ERK1/2, JNK, p38 and NF-κB 
(Johnson and Lapadat, 2002, Yang et al., 2001).  Interestingly, temozolomide has 
been shown to activate both JNK and p38 signalling in GBM cells, and following 
pharmacological inhibition of JNK, GBM cells become sensitised to temozolomide 
(Vo et al., 2014).  The same trend is seen with p38 inhibition, however, to a lesser 
extent than following JNK inhibition (Vo et al., 2014).  ERK1/2 activation, a 
downstream target of MAP3K3, has also been shown to be both positively and 
negatively regulated in GBM cells following temozolomide treatment (Wang et al., 
2016, Xu et al., 2018a).  
Once ERK5, downstream of MAP3K3, is activated, it has many roles within normal 
cells including survival, proliferation, differentiation and migration, as well as anti-
apoptotic functions (Drew et al., 2012, Wang and Tournier, 2006).  An siRNA screen 
has identified the MEK5-ERK5 pathway to be involved in the EMT of breast cancer 
cells, driven by MEF2B and TGFβ activation by ERK5 (Pavan et al., 2018).  
Hepatocellular carcinoma (HCC) and osteosarcoma have also been shown to have 
ERK5 gene amplification and over-expression which correlates with worse prognosis 
due to increased disease aggression and metastasis (Rovida et al., 2015, Tesser-
Gamba et al., 2012).  More recently, ERK5 has been shown to be activated in the 
development of lung cancer, activating CHK1 and the subsequent DNA damage 
response pathways in response to radiation (Jiang et al., 2019).  Additionally, ERK5 
together with a member of the H2A histone family (H2AFJ), has also been linked in 
chemo- radio-resistance in colorectal cancer through a gene set enrichment 
analysis (Wang et al., 2018c).  
FGFs and FGFRs are thought to play a role in oncogenesis as dysregulation of the 
associated pathways (proliferation, survival, angiogenesis, epithelial-mesenchymal 
transition and migration) is associated with increased tumorigenicity.  For example, 
driver mutations in the FGF and FGFR signalling pathways are present in over 90% 
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of  melanoma cases (Flippot et al., 2015).  FGFR4 is a target for patients with HCC as 
FGF19, which binds to FGFR4 in normal physiological conditions, is both amplified 
and over-expressed in these tumours (Sawey et al., 2011, Wu et al., 2011). 
Of the remaining 26 kinases identified, 3 targets were shown to be linked to either 
calcium or calmodulin signalling.  These were Calmodulin 3 (CALM3), 
Calcium/Calmodulin Dependent Protein Kinase II Beta (CAMK2B), 
Calcium/Calmodulin-Dependent Protein Kinase Type 1B (PNCK).  Calcium 
Modulated Protein or calmodulin has previously been shown to be important for 
the growth of rat glioblastoma cells (C6 cells), with increasing inhibition of 
calmodulin correlating with reduced tumour cell growth and is discussed further in 
chapter 6.6 (Lee and Hait, 1985).  However, when an anti-psychotic and calmodulin 
inhibitor (trifluoperazine) was combined with chemotherapy (bleomycin) in 17 GBM 
patients in a Phase II trial, there was unfortunately no improvement with the 
combination.  Although trifluoperazine is lipophilic and readily crosses the blood 
brain barrier, bleomycin is amphipathic and therefore potentially ineffective at 
treating GBM; possibly explaining why there was no sensitisation observed (Hait et 
al., 1990, Kristiansen et al., 1981).  More recently, data has been published showing 
that trifluoperazine decreases tumour growth and metastasis in both flank and 
orthotopic xenograft models of GBM specifically through reactivation of the calcium 
channel IP3R (Kang et al., 2017).  By identifying the associated mechanism of action, 
this could be developed as a novel target to enhance the cytotoxicity of 
temozolomide in order to potentially improve GBM patient survival.     
G-Protein Coupled Receptor Kinase 6 (GRK6) generated the highest z-score from the 
OTP screen with a value of -5.49, lower than that of MGMT.  Overexpression is 
associated with worse overall survival for patients with colorectal cancer and 
hepatocellular carcinoma (HCC) and better overall survival for patients with lung 
adenocarcinomas (Li, 2013a, Tao et al., 2018, Yao et al., 2016).  Increased GRK6 
mRNA expression is also correlated with higher glioma grades and increased 
proliferation in vitro, furthermore when U-251 cells which highly express GRK6 
were depleted of GRK6 using siRNA, their temozolomide sensitivity was increased 
(Xu et al., 2017).  These data therefore provide a good positive control for the 
screen, furthermore, dysregulation of GRK6 has recently been shown to be a 
therapeutic target in several cancer types, increasing the likelihood of inhibitors 
being developed and investigated in clinical trials (Che et al., 2018, Li, 2013a, Tao et 
al., 2018, Xu et al., 2017). 
Other targets have also been previously linked to gliomas, for example Dual 
Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A), a kinase 
involved in both cell proliferation and neuronal development, as well as an array of 
signalling pathways (Neumann et al., 2018).  Inhibition of DYRK1A decreases 
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primary glioma cell survival and proliferation, particularly in cells which over-
express Epidermal Growth Factor Receptor (EGFR) and more recently, this target 
has been identified as a positive regulator of angiogenesis in endothelial cells (Pozo 
et al., 2013, Rozen et al., 2018).  DYRK1A, located on chromosome 21, is 
overexpressed in patients with trisomy 21/Down syndrome and is also dysregulated 
in Alzheimer’s disease (Neumann et al., 2018).  Developing a successful inhibitor 
with the ability to cross the BBB could therefore benefit a huge population of 
patients beyond oncology.  Interestingly, epigallocatechin gallate, an inhibitor of 
DYRK1A, is currently being investigated in clinical trials for Down syndrome 
(ClinicalTrials.gov, 2018).   
Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta (PIK3C2B) 
is a member of the phosphoinositide 3-kinase (PI3K) family.  PI3K signalling has 
many roles including cell proliferation and survival, as well as oncogenic potential.  
However, in non-small cell lung cancer (NSCLC) where PI3K signalling dysregulation 
is frequent, mutations targeting the kinase domain of PIK3C2B have been shown to 
have no overall effect on PI3K signalling and therefore it is believed PIK3C2B has 
little involvement in tumorigenesis (Kind et al., 2017).  Contrastingly, PIK2C2B over-
expression is correlated with breast cancer grade, with depletion using shRNA 
targeting PIK3C2B leading to reduced cell proliferation in 3D tumour models as well 
as reducing tumour growths by 55% in vivo when shRNA silenced PIK3C2B cells 
were injected into mammary fat pads of nude mice. However, this difference was 
not significant in vivo, possibly due to a large range in tumour size (Chikh et al., 
2016).  In GBM patients, increased PIK3C2B expression, detected by cDNA 
microarrays, has been identified as a potential cause of resistance to the EFGR 
inhibitor erlotinib, however, EGFR inhibitors are yet to gain NICE approval for 
treating patients with GBM (Loew et al., 2008, NICE, 2018a).  
Platelet Derived Growth Factor Receptor β (PDGFRβ) is important in development 
in utero but also for cell proliferation, survival, migration and many more.  PDGFRβ 
shRNA depletion inhibited xenograft growth and cell proliferation in vitro, 
sensitising rat C6 GBM cells to radiotherapy (Hong et al., 2017).  Unfortunately, a 
PDGFRβ inhibitor tandutinib was unsuccessful in a phase II trial in GBM patients 
failing to improve overall survival but this treatment was not combined with 
temozolomide or radiotherapy and was not enriched for PDGFRβ over-expression 
which may account for the trial failure (Batchelor et al., 2017).  An alternative 
PDGFR inhibitor, AG1295, has also been shown to reduce both proliferation and 
migration of rat C6 GBM cells in vitro, however, this compound has not yet reached 
clinical trials (Singh et al., 2018).  ERK1/2, downstream targets of PDGFR, may play a 
role in temozolomide resistance in GBM which could provide rationale for PDGFR 
inhibitors being trialled in combination with standard GBM chemo-radiotherapy 
regimes (Singh et al., 2018, Wang et al., 2016, Xu et al., 2018a).  However, when 
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sorafenib, an inhibitor of tyrosine kinases PDGFR and VEGFR and an inhibitor the 
RAF/MEF/ERK pathway, was trialled in combination with adjuvant temozolomide in 
GBM patients, there was no improvement to either progression free or overall 
survival (Hainsworth et al., 2010), possibly indicating limited potential for PDGFR 
inhibitors in treating patients with GBM.     
Serine/Threonine Kinase 3 (STK3) is a pro-apoptotic kinase which acts to restrict 
proliferation and is also part of the Hippo signalling pathway, which has been 
shown to be involved in both tumour development and maintenance (Moroishi et 
al., 2015).  High levels of STK3 mRNA (taken from TGCA database) in GBM patients 
have shown a reduced overall median survival to 12.4 months compared to 14.7 
months for patients with low mRNA expression (Varghese et al., 2016).  
Furthermore, STK3 has also been identified as a potential therapeutic target for a 
subset of AMLs as both shRNA depletion and small molecule inhibition of STK3 
leads to decreased proliferation in a some but not all immortalised and patient 
derived AML cell lines (Camgoz et al., 2018).  This finding reinforces the 
heterogeneity of cancer and the need for disease sub-typing in order to drive the 
personalisation of medicine and reduce the reliance on generalised treatment 
regimes.    
Phosphoglycerate Kinase 1 (PGK1) phosphorylation is dysregulated and over-
expressed in in many cancers, increasing proliferation and tumorigenesis of cells, 
and has been shown to increase resistance to radiotherapy in astrocytomas (Yan et 
al., 2012).  Furthermore, phosphorylation of PGK1 at threonine 243, regulated by 
M2 macrophages secreting IL-6, has been shown to correlate with prognosis in 
GBM.  When stratified into low and high PGK1 phosphorylation, patients with high 
levels of phosphorylation had a 7.5 month reduction in survival time (13.5 months 
high v 20 months low), highlighting the importance of macrophages in driving 
changes in gene expression effecting response to treatment and ultimately survival 
(Zhang et al., 2018c).   
Other targets have also been previously linked to cancer, for example Protein 
Kinase cAMP-Dependent Type I Regulatory Subunit Alpha (PRKAR1A) and Protein 
Kinase CAMP-Dependent Type II Regulatory Subunit Beta (PRKAR2B) which 
normally act to regulate cAMP dependent protein kinase (PKA).  Mutations in 
PRKAR1A protein can cause Carney Complex (CNC) which results in pigmentation of 
the skin as well as benign and cancerous tumours (Iliopoulos et al., 2009).  PRKAR1A 
is dysregulated in many cancers with increased protein expression resulting in a 
poorer response to radiotherapy in patients with prostate cancer and depletion 
using siRNA has been shown to reduce cholangiocarcinoma (bile duct cancer) cell 
proliferation (Loilome et al., 2011, Pollack et al., 2009).  PRKAR2B has also been 
linked to prostate cancer, with over-expression resulting in increased EMT and 
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tumour metastasis in vivo (Sha et al., 2018).  Data from an shRNA screen 
investigating temozolomide sensitivity in GBM cells has also identified PRKAR1B as 
a potential target, however, this was not further investigated as hits were selected  
based on currently available small molecule inhibitors (Johannessen et al., 2018).  
However, this could indicate a potential role for cAMP and PKA signalling in 
temozolomide sensitivity.  This is particularly interesting as ion channels are 
frequently mutated in GBM with more than 90% of GBM patients exhibiting 
mutations in genes related to ion transport (Joshi et al., 2011).   
Little is known about Serine/Threonine Kinase 16 (STK16) in comparison to other 
identified targets; however, it is known to be involved in secretory pathways and 
regulation of VEGF.  A selective STK16 inhibitor has been developed; however, it 
was only able to reduce proliferation in one cell line tested (MCF-7) but increasing 
doses of the inhibitor did induce apoptosis in both MCF-7 cells and He-La cells, also 
enhancing the potency of chemotherapeutic doxorubicin, indicating a possible 
target to enhance the potency of other DNA damaging chemotherapeutics  (Liu et 
al., 2016). 
Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 1 (PRKAG1) is a 
regulatory subunit of AMP-activated protein kinase (AMPK) which is activated in 
response to metabolic stress.  Depleting colon cancer cells (HCT-116) of PRKAG1 
using siRNA has been able to reduce cell viability and increase apoptosis (Fisher et 
al., 2015).  Interestingly, when AMPK was depleted using siRNA or inhibited using a 
small molecule, GBM cells became more resistant to temozolomide treatment, 
which may indicate AMPK activity is required for temozolomide-induced cell death 
(Zhang et al., 2010).  
Cyclin Dependent Kinase Like 3 (CDKL3) is part of a family of proteins which are 
important for cell cycle progression, Cyclin Dependent Kinases (CDK).  Curcumol 
which has both anti-proliferative and anti-inflammatory properties has been shown 
to deplete cells of CDKL3 at both mRNA and protein level.  Both shRNA and 
curcumol were able to decrease growth and migration of cholangiocarcinoma cells 
potentially via G1 arrest and subsequent apoptosis (Zhang et al., 2018b).   
Protein Kinase C Zeta (PRKCZ) is a known tumour suppressor in CRC and when lost 
causes microRNA 200 dysregulation.  This depletion of microRNA 200 causes 
increased EMT leading to liver metastases in around 70% of CRC patients (Shelton 
et al., 2018).  However, in a model of breast cancer stem cells, over-expression of 
PRKCZ and MAPK3, both acting upstream of STAT3, are believed to confer 
resistance to chemotherapeutic doxorubicin and PRKCZ has been shown to be 
upregulated (2-fold) in GBM cells compared to normal brain tissue, and to promote 
increased proliferation (Moreira et al., 2018, Seto and Andrulis, 2015).  
Interestingly, STAT3 dysregulation has also been linked to both MEK-ERK5 and 
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FGFR4 signalling pathways, both targets which have been selected for further 
investigation.  MEK5 has been shown to be upregulated (22-fold) in benign cells 
following transformation by expression of a constitutively active oncogene STAT3 
(Song et al., 2004) and activating mutations within FGFR4 in rhabdomyosarcoma 
has been shown to increase in both total and phosphorylated STAT3 (Taylor VI et 
al., 2009).  Potentially the inhibition of PRKCZ could therefore lead to the 
dysregulation of various signalling pathways which activate STAT3.    
siRNA depletion of Never In Mitosis Gene A (NIMA)-Related Kinase 4 (NEK4) is able 
to reduce migration of lung cancer cells, with in vivo studies showing reduced 
metastases in mice treated with NEK4 depleted cells (Ding et al., 2018).  NEK4 has 
also been implicated in the DDR, as NEK4 siRNA depleted cells have an impaired 
NHEJ response to double strand DNA damage mediated by DNA-PKcs, potentially 
highlighting a mechanism by which temozolomide potency could be enhanced.  
Furthermore, shRNA depletion of NEK4 resulted in increased cell proliferation, 
which could also potentiate the cytotoxic effects of temozolomide when combined 
with defective DNA damage pathways (Nguyen et al., 2012).  However, targeted 
therapy which enhances the proliferation rate of cancer cells would be far from 
ideal, particularly in cancer as aggressive and mutational as GBM.  
In summary, 28 targets were identified from the OTP siRNA screen and 7 of these 
were also able to sensitise resistant GBM cells to temozolomide using siGENOME 
siRNA.  From the targets which could be validated using siRNA or from previously 
published data (MAP3K3, FGFR4, PRKDC, GRK6, PRKCSH), only one (PRKCSH) failed 
to sensitise GBM cells to temozolomide treatment.  MAP3K3/ERK5 and FGFR4 were 
taken forward for future studies as small molecule inhibitors were available, 
however, several of the other targets which could not be validated post OTP 
screening would also make interesting targets for further investigation.  
Furthermore, as many of the targets identified by the siRNA screen have been 
linked to cancer or GBM previously and siGENOME siRNA targeting MGMT was not 
able to significantly sensitise cells to temozolomide treatment (p=0.07), if funding 
and time were no object, it may have been prudent to re-test all initial hits using a 
different pooled siRNA (e.g. siTOOLs™).  An example of this is GRK6, which was 
initially identified as a target from the OTP screen and was subsequently not 
identified by the siGENOME validation.  However, GRK6 has recently been validated 
by a publication which showed depleting GRK6 in cells expressing high levels 
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Chapter 4 – Validating Extracellular Signal-Related Kinase 5 as a novel 
Temozolomide sensitising factor. 
4.1 Mitogen-Activated Protein Kinase (MAPK) Signalling  
 
Mitogen-activated protein kinases (MAPKs) are a diverse range of conserved 
proteins which enable a cell to transform extracellular stimuli into signalling 
cascades needed to activate or inhibit various pathways.  These three-tiered 
cascades are involved in pathways ranging from cell survival and apoptosis, to cell 
differentiation and migration, and are tightly regulated through phosphorylation 
cascades.  Following the activation of a receptor, the conventional MAPK 
phosphorylation cascade initiates with MAP kinase kinase kinase (MAPKKK) 
phosphorylating a MAP kinase kinase (MAPKK/MEK) which in turn phosphorylates a 
MAP kinase (MAPK), such as ERK5.  Activated MAP kinases continue the signalling 
cascade by phosphorylating serine or threonine and then proline on various targets 
(Dhillon et al., 2007, Goldsmith and Dhanasekaran, 2007) (figure 4.1).   
There are 7 established human MAP kinase pathways, 4 of which are classified as 
conventional: extracellular signal-related kinase 1/2 (ERK1/2), extracellular signal-
related kinase 5 (ERK5), c-Jun N-terminal kinases 1, 2, 3 (JNK1/2/3) and p38α/β/ɣ/δ.  
These kinases are activated by upstream MAPKKs through phosphorylation of both 
threonine and tyrosine in their activation loop.  Between threonine and tyrosine sits 
an amino acid which varies depending on the MAPK family: glutamic acid for ERK, 
proline for JNK and glycine for p38 (Cargnello and Roux, 2011, Nithianandarajah-
Jones et al., 2012).   
Unconventional MAP kinases, extracellular signal-related kinase 3/4 (ERK3/4) and 
Nemo-like kinase (NLK), have either glycine or glutamine in place of tyrosine and 
extracellular signal-related kinase 7 (ERK7), although it does have the threonine and 
tyrosine present in its activation loop, is not considered to be conventional as it is 
activated by auto-phosphorylation as opposed to phosphorylation by a MAPKK.  
The biological role of unconventional MAPKs are yet to be discovered (Cargnello 
and Roux, 2011).   
Dysregulation of MAP kinases occurs in a spectrum of diseases including polycystic 
kidney disease, diabetes and Alzheimer’s.  Dysregulation of MAP kinase signalling 
has also been identified in cancer, with ERK1/2 signalling is estimated to be 
abnormal in 33% of all human cancers (Mebratu and Tesfaigzi, 2009).  The ERK5 
signalling pathway is not as well studied as the ERK1/2 pathway; however it has 
recently been reported to have an important role in cancer development and 
resistance to treatment (Simões et al., 2016); see section 4.3 for further details. 










4.2 Extracellular Signal-Related Kinase 5 Signalling   
 
ERK5 is the newest member of the MAP kinase family and was first identified as Big 
Mitogen-like Kinase 1 (BMK1) in 1995 (Lee et al., 1995).  ERK5, much larger than 
other MAP kinases, has a kinase domain located in its N-terminal which is 
phosphorylated at threonine 218 and tyrosine 220 by MEK5 (figure 4.2).  Inactive 
ERK5 is folded to allow the N- and C-terminals to interact, tethered to in the 
cytoplasm by Hsp90 and cdc37 (Erazo et al., 2013, Honda et al., 2015).  This 
conformational interaction is thought to potentially act as a nuclear export signal 
(NES), inhibiting the nuclear localisation signal (NLS) allowing ERK5 to accumulate in 
the cytoplasm (Nithianandarajah-Jones et al., 2012).   The C-terminal of ERK5 is 
auto-phosphorylated following activation by MEK5 causing dissociation of ERK5-
Figure 4.1: MAPK Signalling 
Growth factors, cytokines and environmental stresses are all activators of the 4 classical 
MAPK signalling pathways: ERK1/2, ERK5, p38 and JNK1/2/3.  Pathway activation causes a 
phosphorylation cascade activating downstream targets.  Active MAP kinase kinase kinases 
(MAPKKK/MEKK) phosphorylate MAP kinase kinases (MAPKK/MEK) which in turn 
phosphorylate MAP kinases (MAPK).  Activated MAPKs continue the signalling cascade, 
effecting survival, proliferation, differentiation and apoptosis. 
 
Legend adapted from (Nithianandarajah-Jones et al., 2012)  
Figure copied with permission from (Nithianandarajah-Jones et al., 2012) 
License number: 4450740151251 
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cdc37 from Hsp90, activating the nuclear localisation signal (NLS) resulting in the 





























Previous work used a yeast two-hybrid screen that identified both MEKK2 and 
MEKK3; MAPKKKs which share 94% sequence homology, as activators of MEK5 
signalling.   Both were able to phosphorylate MEK5 in response to stimulation with 
epidermal growth factor (EGF) and hydrogen peroxide oxidative stress, however, 
MEKK2 bound to and activated MEK5 more strongly than MEKK3 (Chao et al., 1999, 
Sun et al., 2001, Kato et al., 1998).  Alongside oxidative stress and EGF, there are 
several other known activators of the ERK5 pathway including: vascular endothelial 
growth factor (VEGF), fibroblast growth factor 2 (FGF2), platelet-derived growth 
factor (PDGF), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) 
and several cytokines an example of which is interleukin 6 (IL-6) (Carvajal-Vergara 
et al., 2005, Cavanaugh et al., 2001, Finegan et al., 2009, Nithianandarajah-Jones et 
al., 2012).   
ERK5 is also known to be activated by substrates other than MEK5.  ERK1/2 has 
been shown to phosphorylate threonine 732 in the C-terminal of ERK5, 
translocating ERK5 to the nucleus without the dual phosphorylation of the 
threonine and tyrosine bases in its kinase domain (Honda et al., 2015).  Another 
MEK5 independent activation of ERK5 occurs during mitosis, when ERK5 is 
Figure 4.2: ERK5 Diagram 
ERK5 comprises of 816 amino acids and is highly homologous to ERK1/2 (66% homology).  The 
N-terminal contains the kinase domain with MEK5 binding and phosphorylation sites, a 
common docking (CD) domain and cytoplasmic localisation domain.  The C-terminal contains 
the nuclear localisation signal (NLS) between two proline-rich (PR1/2) domains, a MEF2-
interacting domain and auto-phosphorylation sites. 
 
Legend adapted from (Simões et al., 2016) 
Figure copied with  permission from (Simões et al., 2016) 
License number: 4323220889024 
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responsible for ensuring an appropriate G2-M phase transition.  Here, ERK5 is 
activated by cyclin-dependent kinases (CDKs) phosphorylating its C-terminal 
(Iñesta-Vaquera et al., 2010).  
Once ERK5 is activated it has many roles within normal cells including survival, 
proliferation, differentiation and migration, as well as anti-apoptotic functions 
(Drew et al., 2012, Wang and Tournier, 2006).  To affect these pathways, ERK5 
interacts with and enhances transcription of many targets including: MEF2, c-MYC, 
SAP-1, cFOS (English et al., 1998, Yang et al., 1998, Kamakura et al., 1999).  ERK5 
activates its substrates via phosphorylation of serine or threonine next to proline 
(Nimesh et al., 2003).  ERK5 has also been shown to act upstream of PKB/AKT via 
FGFR2, PDGFβ, FLT3 (Lennartsson et al., 2010, Razumovskaya et al., 2011, Roberts 
















Figure 4.3: ERK5 Signalling  
ERK5 has many downstream targets such as SAP1, c-Myc and MEF2 which are phosphorylated 
as a result of ERK5 activation, influencing survival, apoptosis and proliferation.  ERK5 also 
phosphorylates kinases and cytokines such as SGK and IL-6.  However, ERK5 can also auto-
phosphorylate its C-terminus which results in translocation from the cytoplasm to the nucleus 
where it may act as a transcription factor.   
 
Legend adapted from (Drew et al., 2012) 
Figure copied with  permission from (Hoang et al., 2017) 
License number: 4450910077831 
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As well as the roles previously described, ERK5 is also physiologically vital during the 
course of development. In embryos, the role of ERK5 signalling has been shown to 
be essential for cardiovascular development, with knock out mice dying at around 
9-11 days in utero due to complications in heart development, poor development of 
vasculature in both the embryo and placenta, as well as increased endothelial cell 
death (Regan et al., 2002, Sohn et al., 2002, Yan et al., 2003).  Adult mice with an 
inducible ERK5 knock out also died 2-4 weeks after ERK5 depletion due to increased 
endothelial cell death which caused their vasculature to become ‘leaky’ resulting in 
massive haemorrhage (Hayashi et al., 2004).  The importance of ERK5 in 
maintaining vasculature integrity potentially highlights problems developers might 
face if ERK5 inhibitors are trialled in humans.   
 
4.3 MEK5 and ERK5 in Cancer 
 
The MEK5/ERK5 pathway has been shown to be increasingly important in both 
cancer development and disease progression.  Over-expression of ERK5 in breast 
cancer is associated with reduced disease free survival time (Montero et al., 2009).  
Furthermore, an RNAi screen has identified this pathway in epithelial-mesenchymal 
transition (EMT) of breast cancer cells, driven by MEF2B and TGFβ activation by 
ERK5.  It was noted that both constitutively active MEK5 and over-expression of 
ERK5 was not able to induce EMT alone, however, depletion of MEK5 or ERK5 
reduced the growth of metastatic lung tumours in orthotopic breast cancer mice 
models (Pavan et al., 2018).  Not only is the MEK5-ERK5 pathway important in EMT, 
MEK5 has been shown to be upregulated (22 fold increase) in response to benign 
cells being transformed by constitutively active oncogene STAT3, potentially 
implicating the MEK5-ERK5 signalling pathway in oncogenesis when combined with 
aberrant STAT3 signalling (Song et al., 2004).  
Both constitutively active MEK5 and ERK5 over-expression have been identified in 
prostate cancer, conferring a more progressive and metastatic disease (Mehta et 
al., 2003, Simões et al., 2015).  Downregulation of miRNA-143, which acts to 
downregulate ERK5 mRNA expression, has also been identified in prostate cancers 
and is associated with increased tumorigenicity (Akao et al., 2006).  Furthermore, 
inhibition of ERK5 using the small molecule inhibitor XMD8-92 increased the 
sensitivity of colon cancer cells to the chemotherapeutic fluorouracil (5-FU), a 
thymidine synthesis inhibitor, reducing xenograft growth  by 70% (Pereira et al., 
2016). 
Hepatocellular carcinoma (HCC) and osteosarcoma have also been shown to exhibit 
ERK5 gene amplification and over-expression, both correlating with worse 
prognosis due to increased disease aggression and metastasis (Rovida et al., 2015, 
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Tesser-Gamba et al., 2012).  Additionally, there are several other cancers in which 
ERK5 is dysregulated and this also confers worse prognosis.  These diseases include 
pancreatic cancer, lung cancer, malignant mesothelioma, neuroblastoma, 
leukaemia, bladder cancer and squamous cell carcinoma (Simões et al., 2016). 
Based on the results from the siRNA kinome screen (chapter 3), this chapter focuses 
on validation of ERK5 as a novel target in sensitising GBM cell to temozolomide 
treatment. 
 
4.4 Depletion and inhibition of ERK5 increases GBM cell death in response 
to Temozolomide 
 
siRNA was used to deplete GBM cells of MAP3K3 which sensitised them to 
treatment with temozolomide (chapter 3, figure 3.13), however, as there are no 
small molecule inhibitors to MAP3K3, downstream targets were selected for further 
target validation studies.  siTOOLS Biotech have developed siPOOLS™ siRNA which 
comprises a pool of 30 different sequences of siRNA to the target gene.  As the 
concentration of each of the siPOOLS™ siRNA sequences are used at picomolar, 
compared to nanomolar concentrations when using standard pooled (4 sequences) 
or individual siRNAs, the possibility of any off target effects on other genes is 
reduced, increasing the specificity and reliability (Hannus et al., 2014, 
siTOOLsBiotechGmbH, 2018). 
A range of 1nM to 10nM of siRNA was suggested by siTOOLS™ as the working 
concentrations to initially test for effective depletion of the target using siPOOLS™.  
Western blotting shows a successful knock-down of ERK5 was achieved and 10nM 
depleted GBM cells of ERK5 most effectively (figure 4.4).  A final siRNA 
concentration of 10nM is lower than 30nM as recommended for siRNA screening by 
the SRSF screening facility, and as previously mentioned, Dharmacon will only 
guarantee a knock-down of more than 75% in 3 out of 4 siRNA sequences if a final 
concentration of 100nM is used, highlighting the successful knockdown of ERK5 was 
completed using a relatively low siRNA concentration (Dharmacon™, 2018).  Due to 
the homology between MAPK family members, particularly ERK1/2 and MEK5, it 
would have been good practise to investigate the specificity of the ERK5 siRNA, for 
example, probing for ERK1/2 and MEK5 expression via western blot following siRNA 
knock-down of ERK5. 
   
 
 



















As 10nM siRNA showed the most robust depletion of ERK5, it was selected for 
further experiments.  To validate ERK5 as a target that can sensitise GBM cells to 
temozolomide, multiple MGMT +ve and MGMT -ve GBM cell lines were reverse 
transfected with ERK5 siRNA for 48 hours in 96 well plates.  Cells were treated with 
doses of temozolomide ranging from 0-400µM, and following 5 days incubation, an 
MTT assay was performed. 
 
Depletion of ERK5 increased sensitivity to temozolomide in 4 GBM cell lines (figure 
4.5), which contributes to the validation of the MAP3K3 pathway as a putative drug 
target.  Both MGMT positive (T98G and LN-18) and MGMT negative (U-87 and U-
251) cell lines showed an increased sensitivity which bodes well for pan-GBM 
clinical applicability of ERK5 inhibition as it does not select for one population of 
patients.  However, as ERK5 has been shown to localise in and affect the function of 
mitochondria, it would be important to validate these findings using a non-
metabolic assay, such as crystal violet, which can be used to infer cell viability 
where the staining is proportional to cell number and is independent of 
mitochondrial function (Charni et al., 2010).   
However, as patients cannot be treated with siRNA, small molecule drug-like 
inhibitors of ERK5 were next investigated for further validation (inhibition vs 
mRNA/protein depletion) and to develop proof-of-concept data.  As previsouly 
mentioned, there can be phenotypic differences between siRNA depletion and 
catalytic inhibition of kinases, most likely due to differences in protein-protein 
interactions.  siRNA reduces protein expression by targeting mRNA for degradation, 
however, catalytic inhibition will not affect protein expression, allowing protein-
Figure 4.4: Expression of ERK5 in T98G cells treated with ERK5 siPOOLS siRNA for 48 hours 
T98G cells were reverse transfected with the indicated siRNA at varying concentrations (1-
10nM) before harvesting for protein lysis 48 hours later.  Cells were lysed, protein was 
quantified and samples were run on a western blot.   
siRNA concentration of 10nM generated the best knock down of ERK5 and β-actin was used as 





































104                                                                                                                   Natasha Carmell 
 
protein interactions and any biologically important scaffold roles of the protein to 














There are currently no ERK5 or MEK5 inhibitors in clinical trials; however, there are 
commercially available inhibitors (table 4.1).  ERK5-in-1 was purchased from Selleck 
(S7334) as a selective ERK5 inhibitor, however, a recent paper has shown off-target 
inhibition of BRD4 at IC50 values only slightly higher than those for ERK5 (Deng et al., 
Figure 4.5: Cytotoxicity curves of GBM cells treated with Control or ERK5 siRNA 
Cells were reverse transfected with the indicated siRNA and then treated with a range of TMZ 
(0-400µM) 48 hours later.  Following 5 days incubation an MTT assay was performed.  ERK5 
siRNA alone showed range of toxicities in the different cell lines, being least toxic in LN-18 cells 
and most toxic in U-87 cells.  All cell lines showed a reduced survival fraction when treated 
with TMZ in comparison to control cells, showing a modest increase in sensitivity to TMZ 
irrespective of their MGMT status (T98G and LN-18 are MGMT +ve and U-251 and U-87 are 
MGMT –ve). 
 
Data shown is the average surviving fraction (normalised to DMSO treated control siRNA) +/- 
standard deviation derived from 2 independent biological repeat experiments. 
*=p<0.05 using a Mann-Whitney U Test. 
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2013, Wang et al., 2018a).  There is another ERK5 inhibitor available, XMD8-92, 
which has been historically used to target ERK5, however, this compound also 
targets DCLK1 with similar IC50 values to those for ERK5 and also targets BD4 at 
higher doses (Sureban et al., 2014, Wang et al., 2018a, Yang et al., 2010).  XMD8-92 
was purchased from Sigma Aldrich (SML1382).  There are 2 inhibitors for MEK5, 
BIX02188 and BIX02189, which were purchased from Selleck (S1530 and S1531).  
However, as BIX02188 and BIX02189 were discovered from the same high-
throughput screen and BIX02189 has a lower IC50 value for MEK5 (Tatake et al., 
2008), this was selected over BIX02188 for future work.   
 
 Table 4.1: IC50 of MEK5/ERK5 inhibitors 















Table 4.1 - Commercially available MEK5 and ERK5 inhibitors with a range of IC50 values.  Both 
XMD8-92 and ERK5-in-1 also inhibit bromodomain-containing proteins (BRD4s) (Tatake et al., 2008, 
Wang et al., 2018a, Yang et al., 2010).  
 
 
BIX02189 is a MEK5 inhibitor and at higher concentrations an ERK5 inhibitor (Tatake 
et al., 2008).  As this inhibitor has an IC50 value of 1.5nM for MEK5 and 59nM for 
ERK5, a dose response ranging from 0-1µM in combination with temozolomide 
(50µM) was carried out.  There was, however, no difference in survival (data not 
shown).  The concentration was further increased up to 10µM of BIX02189; 
however, this resulted in more cell death from BIX02189 alone but there was no 
increase in temozolomide sensitivity (50µM) (data not shown).  A clonogenic assay 
was completed at a dose of 1µM in LN-18 cells, again with no increase in 
sensitisation (data not shown).  However, this may not be surprising as several 
published studies use at least 10µM for inhibition of kinase activity in cell lines 
(Belkahla et al., 2018, Su et al., 2014).  As ERK5-in-1 has off-targets effects on BRD4, 
the lack of sensitisation seen when using MEK5 inhibitors could potentially indicate 
that BRD4 inhibition is important in temozolomide sensitivity rather than the loss of 
ERK5 catalytic activity.  Bromodomain inhibition has previously been shown to 
decrease the proliferation of GBM cells, also resulting in additive cell death when 
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cells were treated in combination with temozolomide (Lam et al., 2018, Pastori et 
al., 2014). 
ERK5-in-1 was tested in combination with temozolomide in GBM cells.  Initially a 
western blot was used to detect inhibition of ERK5 activity using a range of doses of 
ERK5-in-1 (ERK5i) (figure 4.6A); however, phosphorylation of ERK5 could only be 
detected following stimulation of the pathway using EGF.  ERK5i was able to 
sensitise T98G cells to temozolomide when both drugs were used in combination 
(figure 4.6B).  0.25µM ERK5i was selected for future experiments as it was able to 
inhibit ERK5 phosphorylation and sensitise T98G cells to temozolomide most 
significantly (p=<0.0001) whilst causing with little cell toxicity when used alone 





















ERK5i was then combined with increasing doses of temozolomide in a panel of GBM 
cell lines and was able to sensitise them irrespective of MGMT status (figure 4.7).  
Combination treatment did not sensitise U-251 cells significantly to temozolomide, 
however, there was a trend in decreased survival.  All other cell lines had a 
significant decrease in survival with at least one concentration of temozolomide 
Figure 4.6: Inhibition of ERK5 activity using ERK5i in GBM cells 
Cells were plated and allowed to adhere for 24 hours. Cells were treated with a range of doses 
of ERK5i (0-500nM) before being treated with EGF or TMZ 1.5 hours later.  Cells were collected 
for western blotting 30 minutes after EGF treatment (A) or were incubated for 5 days with 
TMZ before an MTT assay was performed (B).  ERK5i was able to inhibit ERK5 phosphorylation 
and sensitise T98G cells to TMZ when used in combination.  The most significant decrease in 
survival fraction was using a combination of 250nM ERK5i and 50µM TMZ. 
 
Data shown is the average surviving fraction (normalised to DMSO treated controls) +/- 
standard deviation derived from 5 independent biological repeat experiments. 
**=p<0.005 ***=p<0.001 ****=p<0.0001 using a Mann-Whitney U Test. 
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used, with variability in sensitivity possibly due to differences in ERK5 protein 











Clonogenic survival assays are more sensitive compared to MTT assays, as they are 
a more accurate measure of growth and survival as opposed to metabolism.  
Clonogenic survival assays are not reliant on mitochondrial function therefore the 
results generated cannot be modulated by any possible changes which could be 
caused to mitochondria following ERK5i drug treatment.  To determine the 
Figure 4.7: Cytotoxicity curves of GBM cells treated with ERK5i and TMZ 
Cells were plated before being treated with 0.25µM ERK5i 24 hours later. A range of doses of 
TMZ (0-400µM) were added 90 minutes later.  Following 5 days incubation an MTT assay was 
performed.  ERK5i showed little toxicity alone, however, all cell lines showed a reduced 
survival fraction when treated with the combination of ERK5i and TMZ in comparison to TMZ 
alone. 
 
Data shown is the average surviving fraction (normalised to DMSO treated controls) +/- 
standard deviation derived from 2 independent biological repeat experiments. 
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temozolomide potentiating effects of ERK5i, clonogenic assays were completed in 
LN-18 and U-251 cells in combination with ERK5i and/or temozolomide.  ERK5i was 
able to dramatically sensitise both cell lines to temozolomide at the sub-micro 














A              B 
Figure 4.8: Cytotoxicity curves of GBM cells treated ERK5i and TMZ 
Cells were plated before being treated with ERK5i 24 hours later.  Following a 90 minute 
incubation a range of doses of TMZ were added.  0-400µM TMZ was added to LN-18 cells 
(MGMT +ve) and 0-100µM was added to U-251 cells (MGMT -ve).  Cells were incubated for 12 
days allowing colonies to form.  Cell colonies were fixed in 0.04% methylene blue in 100% 
ethanol for 30 minutes at room temperature.  >50 cells were counted as a colony.  Both cell 
lines were sensitised to TMZ, however, U-251 cells are more sensitive so lower doses were 
used.   
 
Data shown is the average surviving fraction (normalised to DMSO treated controls) +/- 
standard deviation derived from 5 independent biological repeat experiments. 
A x-axis – 0.0001 B x-axis 0.001  
*=p<0.05 **=p<0.005 ***=p<0.001 ****=p<0.0001 using a Mann-Whitney U Test. 
 
U-251 experiments were completed by Connor McGarrity-Cottrell, 2nd Year Undergraduate 
Student from Sheffield Hallam University. 
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Due to the variation in temozolomide sensitivity observed across GBM cell lines 
following ERK5 inhibition (figure 4.7, figure 4.8), total and phosphorylated ERK5 
protein were investigated using western blotting (figure 4.9).  As previously seen 
with T98G cells, other GBM cell lines also express un-phosphorylated ERK5 under 
normal conditions and may therefore be more reliant on total protein levels as 
opposed to catalytic activity.  Although there are small changes in ERK5 expression 
between the cell lines, this does not reflect the variability seen in temozolomide 
sensitivity following treatment with ERK5i, perhaps indicative that off-target BRD4 



















To ensure this was not a drug specific effect, XMD8-92 was also used in 
combination with temozolomide in a clonogenic survival assay.  XMD8-92 was able 
to sensitise GBM cells to temozolomide, however, this effect was less than that of 
ERK5i (figure 4.10).  XMD8-92 was used at a concentration 10 times higher than 
that of ERK5i in order to establish any sensitisation, however, although the IC50 for 
XMD8-92 is double the IC50 for ERK5-in-1, XMD8-92 is an inhibitor of BRD4 at higher 
concentrations  (1-2µM) had to be used in order to generate sensitisation to 
temozolomide (table 4.1).  These data could therefore be a result of off-target 







Figure 4.9: Expression of ERK5 in GBM Cell Lines  
Cells were plated and allowed to adhere for 24 hours before being collected for western 
blotting.  Samples were probed for ERK5 expression and β-actin was used as a loading control 
for the western blot.  There is a small difference in ERK5 expression between GBM cell lines, 
however, ERK5 remains un-phosphorylated under normal conditions.  
 
Western blot was completed by Connor McGarrity-Cottrell, 2nd Year Undergraduate Student 
from Sheffield Hallam University. 










Combination  treatment was also able to sensitise patient derived Glioma Stem 
Cells (GSCs) to temozolomide, however, this was not as large an effect as seen in 
immortalised cell lines (figure 4.11).  It is important to note, however, that in order 
to maintain the stem properties of GSCs; they are cultured in EGF and FGF.  As EGF 
is known to activate the ERK5 pathway at doses as low as 0.1ng/ml, the reduced 
effect in sensitisation may be due to increased pathway activation likely requiring 
re-optimisation and an increase in the concentration of ERK5i used (Kato et al., 
1998).   
ERK5 protein levels were also detected in both primary derived glioma stem cells 
and the corresponding ‘bulk’ cells (figure 4.12).  The ‘bulk’ population do not 
express stem cell markers and are not grown in EGF or FGF; however, no difference 
was observed in either ERK5 phosphorylation or total protein expression between 
the two populations.  There appears to be slightly more ERK5 protein in both GBM2 
Figure 4.10: Cytotoxicity curves of GBM cells treated with XMD8-92 or ERK5i and TMZ 
Cells were plated before being treated with XMD8-92 (A) or ERK5i (B) 24 hours later (data 
taken from figure 4.8A).  Following a 90 minute incubation a range of doses of TMZ were 
added (0-200µM).  Cells were incubated for 12 days allowing colonies to form.  Cell colonies 
were fixed in 0.04% methylene blue in 100% ethanol for 30 minutes at room temperature.  
>50 cells were counted as a colony.  Survival fraction (A) shows LN-18 cells treated with 2.5µM 
of XMD8-92.  This sensitised cells to TMZ, however, ERK5i (0.25µM) was able to sensitise cells 
more effectively to TMZ, shown by the increased reduction in survival fraction (B)  
 
Data shown is the average surviving fraction (normalised to DMSO treated controls) +/- 
standard deviation derived from 3 independent biological repeat experiments. 
 
*=p<0.05 **=p<0.005 ***=p<0.001 ****=p<0.0001 using a Mann-Whitney U Test. 
 
A              B 
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stem and bulk samples but very little difference in sensitivity to temozolomide 
following ERK5 inhibition was observed, however, as this experiment was 
completed once under different conditions compared to the data generated from 
immortalised cells, it is difficult to draw any firm conclusions until repeated 

























Figure 4.11: Cytotoxicity curves of Glioma Stem Cells treated ERK5i and TMZ 
Cells were cultured with 20ng/ml EGF and 10ng/ml FGF to maintain stemness, before being 
plated on matrigel coated plates 24 hours before the addition of ERK5i.  Following a 90 minute 
incubation a range of doses of TMZ were added (0-25µM TMZ).  Cells were incubated for 3 
days before media was replaced.  Cells were incubated for a further 17 days allowing colonies 
to form.  Cell colonies were fixed in 0.04% methylene blue in 100% ethanol for 30 minutes at 
room temperature.  >50 cells were counted as a colony.  The combination of ERK5i and 
temozolomide caused a reduction in survival fraction compared to temozolomide alone in 2 
populations of Glioma Stem Cells.   
 
Data shown is the average surviving fraction (normalised to DMSO treated controls) from 1 
independent biological experiment. 
These experiments were completed by Mr Ola Rominiyi, a clinical PhD student in the Collis 






Figure 4.12: Expression of ERK5 in Patient Derived GBM Cells  
Primary cells taken from GBM tumours during surgery were cultured in standard media 
(‘bulk’) or media supplemented to select for stem-like cells.  After 6 weeks cells were 
harvested and lysed for western blotting.  Samples were probed for ERK5 expression and β-
actin was used as a loading control for the western blot.  There is little difference in ERK5 
expression between both the stem and ‘bulk’ populations, with ERK5 remaining un-
phosphorylated.  
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Of the multiple GBM cell line tested, there was only one cell line (U-138) which was 
not sensitised to temozolomide with either ERK5 siRNA or ERK5i (figure 4.13).  U-
138 cells did express the least total ERK5 protein compared to the other GBM cell 





























Obviously there are numerous genetic and epigenetic differences between all the 
GBM cell lines used in this study.  However, one known difference in U-138 cells, 
also known as HTB-16 cells, is that they are deficient in the Fanconi Anaemia (FA) 
DNA repair pathway, which is known to affect cellular sensitivity to temozolomide 
(Chen et al., 2007).  To investigate further whether the presence of an intact FA 
pathway is required for ERK5i-mediated sensitisation to temozolomide, the FA-
proficient LN-18 cells were depleted of the key FA pathway subunit FANCD2 using 
siRNA and then treated with ERK5i and temozolomide both individually and in 
combination.  Depleting cells of FANCD2 caused varying results; two biological 
repeats showed FANCD2-depleted cells were still sensitised to temozolomide by 
ERK5i, whilst another two biological repeats showed FANCD2-depleted cells were 
less sensitive to temozolomide sensitisation by ERK5i, with no significant difference 
between combination treatment and temozolomide alone (figure 4.14).  
Figure 4.13: Cytotoxicity curves of GBM cells treated with ERK5 siRNA or ERK5i 
Cells were reverse transfected with indicated siRNA and then treated with a range of TMZ (0-
400µM) 48 hours later (A) or cells were plated before being treated with 0.25µM ERK5i 24 
hours later and then range of doses of TMZ (0-400µM) were added 90 minutes later (B).  
Following 5 days incubation an MTT assay was performed.  Both siRNA and ERK5i were unable 
to sensitise U-138 cells to treatment with temozolomide.  However, ERK5 siRNA alone did 
cause a significant decrease in survival fraction compared to control siRNA alone (p=0.03). 
 
Data shown is the average surviving fraction (normalised to DMSO treated controls) +/- 
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Combination treatment was always significantly different to DMSO treated controls 
in all repeats.  This variability meant that no firm conclusions could be drawn and it 

















MTT assays and clonogenic survival assays are used to determine cell growth and 
survival; however, annexin V and PI staining are used to identify dead, apoptotic 
and necrotic cells (ThermoFisherScientific, 2018), and were therefore used to 
investigate the mode of increased cell death observed with ERK5i in combination 
with temozolomide.  Annexin V and PI staining showed a decrease in live cells (no 
stain) and an increase in dead cells (annexin V and PI positive) with the combination 
of ERK5i and temozolomide over a time course in T98G and U-251 cells (figure 
4.15).  Interestingly, the percentage of dead cells and reduction in live cells was 
more than additive in the combination treatment 96 hours and 120 hour post 
treatment in T98G cells and 120 hours post treatment in U-251 cells, suggesting a 
potentially induced lethality/synergistic phenotype.  At 120 hours, the percentage 
of live T98G and U-251 cells treated with the combination of ERK5i and 
temozolomide was significantly different when compared to untreated cells (p-
Figure 4.14: Cytotoxicity curves of GBM cells treated with control or FANCD2 siRNA ERK5i 
and TMZ 
Cells were reverse transfected with the indicated siRNA and then treated with 0.25µM ERK5i 
48 hours later.  Following a 90 minute incubation cells were treated with 50µM TMZ.  
Following 5 days incubation an MTT assay was performed.  For 2 repeats FANCD2 depletion 
did not affect ERK5i sensitisation of GBM cells to TMZ, with combination treatment 
significantly reducing survival compared to TMZ alone (p=0.009) (A).  FANCD2 depletion 
reduced the efficacy of this sensitisation in another 2 repeats, with no significant difference 
between combination treatment and TMZ alone (B).  Control and FANCD2 siRNA combined 
with ERK5i and TMZ resulted in a significant increase in cell death when compared to DMSO 
treated controls in all repeats (p=<0.001).    
 
Data shown is the average surviving fraction (normalised to DMSO treated control or FANCD2 
siRNA) +/- standard deviation derived from 2 independent biological repeat experiments. 
**=p<0.005 using a Kruskal-Wallis H Test. 
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value 0.049).  Dead cell values did not quite reach significance (p-values 0.086); 
however, a trend of increased cell death can be seen with combination treatment.  
In U-138 cells which were not sensitive to the combination of ERK5i and 

























Figure 4.15: Percentage of live and dead GBM cells after treatment   
T98G cells (A & C) or U-251 cells (B & D) were plated in 10cm dishes before being treated with 
ERK5i (0.25µM) 24 hours later.  Following a 90 minute incubation 200µM TMZ was added.  
Cells were collected for FACS at various time points, before being stored at -20°C in 70% 
ethanol prior to processing.  Cells were incubated with annexin V and PI as per the protocol 
and then analysed on the FACSCalibur.  Unstained cells were used to determine the gates for 
annexin V, PI or dual stained cells.  Combination of ERK5i and TMZ caused a significant 
decrease in live cells at 120h post treatment in both cell lines (p=0.009), however, dead cells 
showed an increasing trend almost reaching significance (p=0.086).       
 
Data shown is the average (normalised to DMSO treated controls) from 2 independent 
biological repeat experiments. 
*=p<0.05 using a Mann-Whitney U Test. 
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Collectively, these data confirm ERK5 to be a credible drug target to augment the 
efficacy of temozolomide cytotoxicity effects on GBM cells, and provide compelling 
proof-of-concept data to warrant further investigation into the mechanism behind 
this. 
 
4.5 MGMT and ERK5 levels are unchanged by combination treatment 
 
As previous blots have shown ERK5 to be un-phosphorylated in GBM immortalised 
and primary cells under normal conditions, the effect of temozolomide on ERK5 
activity was investigated at increasing concentrations, however, this showed no 
change, suggesting that ERK5 is not observably activated in cells following 
temozolomide treatment (figure 4.17A). 
MGMT is known to play a critical role in sensitivity to temozolomide (Kaina et al., 
2007); the effect of ERK5i on MGMT levels was therefore investigated at various 
time points using western blotting to ascertain if the temozolomide sensitisation 
conferred by ERK5i was a consequence of altered MGMT levels.  There was no 
detectable change in MGMT levels following treatment with ERK5i (figure 4.17B).   
 
 
Figure 4.16: Percentage of live and dead U-138 cells after treatment   
U-138 cells were plated in 10cm dishes before being treated with ERK5i (0.25µM) 24 hours 
later.  Following a 90 minute incubation 200µM TMZ was added.  Cells were collected for FACS 
at various time points, before being stored at -20°C in 70% ethanol prior to processing.  Cells 
were incubated with annexin V and PI as per the protocol and then analysed on the 
FACSCalibur.  Unstained cells were used to determine the gates for annexin V, PI or dual 
stained cells.  Combination of ERK5i and TMZ did not cause a significant increase in dead cells 
(A) or a significant decrease in live cells (B) at any time points.  
 
Data shown is the average (normalised to DMSO treated controls) from 2 independent 
biological repeat experiments. 
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4.6 Combination treatment causes more DNA damage and Genomic 
Instability 
 
The DNA damage response (DDR) of GBM cells treated in combination with ERK5i 
and temozolomide was next investigated.  Previous experiments have used 50µM 
temozolomide over a 5 day period; however, as these next studies were conducted 
over 24 hours, an increased dose of temozolomide was used (200µM) with the aim 
of enhancing any effects seen. 
Firstly, an increase in DNA damage was investigated using 53BP1.  53BP1 is used as 
a marker of double strand breaks in DNA (Schultz et al., 2000).  The number of foci 
per nucleus were counted in around 100 cells except the positive irradiation (IR) 
control.  The score from each nucleus was combined to give an average number of 
foci for each condition (figure 4.18).  LN-18 cells treated with ERK5i and 
temozolomide in combination (E+T) had a more than additive number of 53BP1 
foci/nucleus when values from ERK5i and temozolomide conditions alone were 
added together.  U-251 cells, however, did not exhibit a comparable phenotype, 






 A              B 
Figure 4.17: Effect of TMZ and ERK5i on ERK5 and MGMT protein expression 
T98G cells were plated before being treated with either 50µM TMZ (A) or ERK5i (B).  Cells were 
harvested, lysed and protein was quantified before being loaded on to a gel.  Membranes 
were probed with ERK5 primary antibody (A) or MGMT primary antibody (B).  β-actin was 
used as a loading control. 




















































Figure 4.18: 53BP1 foci in GBM cells 24 hours after treatment   
U-251 cells (A) or LN-18 cells (B) were plated on coverslips before being treated with ERK5i 
(0.25µM) 24 hours later.  Following a 90 minute incubation 200µM TMZ was added.  24 hours 
later cells were fixed ready for IF processing. Cells were imaged at 20x objective on a Nikon 
Eclipse TE200 Fluorescent Microscope and the numbers of foci were counted and averaged.  
LN-18 cells treated with E+T had a slightly more than additive average compared to the value 
of ERK5i and TMZ drug alone combined (8.00 v 7.28) (D).  U-251 cells treated with the 
combination E+T did not have more than an additive average number of foci (C).  All 
conditions were significantly different from untreated cells and each other.  
 
****p=<0.0001 (n=≥2) using a Kruskal-Wallis H Test. 
         A            B 
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Comet assays are used to measure and visualise breaks in DNA, as opposed to IF 
which uses only markers of DNA damage.  Following lysis which leaves DNA 
unharmed, an electric current is applied to the DNA suspended in agarose.  The 
more breaks in the DNA, the further it will migrate through the agarose (negatively 
charged DNA migrates to positive cathode).  Once a nucleotide stain is applied, the 
DNA ‘tails’ can be visualised using fluorescent microscopy (Ostling and Johanson, 
1984). The alkaline comet assay was used for these studies, enabling all DNA 
damage (both single and double stranded DNA breaks) to be visualised and 
quantified.  Tail moment, calculated by TriTek Comet Score, is used as a measure of 
DNA damage severity, combining tail length and intensity of DNA within the tail 
(AMSBiotechnology, 2010).   
Both T98G and U-251 cells had a significant increase in tail moment in 
temozolomide and combination (E+T) treated cells when compared to untreated 
cells (p=<0.0001).  There was also a significant difference between temozolomide 
treated and combination (E+T) treated cells (p=<0.0001).  Average tail moment for 
T98G cells was 34.29 for temozolomide compared to 57.06 for combination 
treatment (E+T), and in U-251 values were 69.65 compared to 136.78.  In both cell 
lines, the combination treatment resulted more than additive DNA damage (figure 
4.19). 
U-138 cells were not sensitive to the combination of ERK5i and temozolomide 
treatment.  These cells were also investigated via a comet assay.  There was a 
significant increase in tail moment in temozolomide and combination (E+T) treated 
cells when compared to untreated cells, however, there was no significant 





















Figure 4.19: DNA damage in GBM cells 24 hours after treatment   
T98G cells and U-251 cells were plated 24 hours before being treated with ERK5i (0.25µM). 
Following a 90 minute incubation 200µM TMZ was added and a further 24 hours later cells 
were harvested for comet assay. Images are representative of T98G cells (A) and U-251 cells 
(B) visualised on Comet Score after various treatments.  Tail moment was calculated for 
around 50 cells per condition for each repeat.  Cells were imaged at 20x objective on a Nikon 
Eclipse TE200 Fluorescent Microscope after being stained with SYBR Gold.  Combination 
treatment of ERK5i and TMZ caused the largest tail moment with values of 57.06 and 136.78 
for T98G and U-251 respectively (C & D) (p=<0.0001). 
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Figure 4.20: DNA damage in GBM cells 24 hours after treatment   
U-138 cells were plated 24 hours before being treated with ERK5i (0.25µM). Following a 90 
minute incubation 200µM TMZ was added and a further 24 hours later cells were harvested 
for comet assay. Images are representative of U-138 cells (A) visualised on Comet Score after 
various treatments.  Tail moment was calculated for around 50 cells per condition for each 
repeat.  Cells were imaged at 20x objective on a Nikon Eclipse TE200 Fluorescent Microscope 
after being stained with SYBR Gold.  Combination treatment of ERK5i and TMZ caused no 
more damage than TMZ alone (B).  
 
(n=2) 
      A           B  
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As both 53BP1 IF and comet assays showed an increase in DNA damaged caused by 
combination treatment, levels of O-6-methylguanine, NHEJ and HR-related damage 
were then investigated in order to try and ascertain a greater understanding of how 
such damage is being generated and what DNA repair pathways are being activated 
in response.  
O-6-methylguanine lesions are the most toxic damage caused by temozolomide.  
These were first investigated by immunofluorescence (IF). 1mM temozolomide was 
used as a positive control.  Both cells treated with the combination of ERK5i and 
200µM temozolomide and the positive control had a significant increase in 
detectable lesions (p-value <0.0001) compared to untreated cells.  Temozolomide 
alone also had a significant increase in the percentage of positive cells; however, 
this increase was slightly less significant (p-value 0.002).  One unexpected finding 
was that ERK5i alone was responsible for a modest increase in O-6-methylguanine 
lesions, however, this increase was not significant (p-value 0.84) (figure 4.21).  
Unlike the trends in DNA damage visualised by the comet assay, there was no 
significant difference between cell treated with 200µM temozolomide and those 
with combination treatments.  Additionally, the percentage of positive cells in the 
combination treatment are likely due to an additive effect of both ERK5i and 
temozolomide individually, suggesting that O-6-methylguanine lesions are unlikely 
to be the mechanism by which more breaks are being generated in cells following 

























DNA-PKcs is used to detect double strand DNA breaks that will be primarily repaired 
by non-homologous end joining (NHEJ) (Meek et al., 2008).  DNA-PKcs activation 
was investigated using phosphorylation of serine 2056. Unfortunately, the number 
of foci could not be accurately counted in these cell lines as the stain was very 
speckled so as an alternative, the number of DNA-PKcs positive cells were scored.  
Results were generated as a percentage of total cells visible in each field of view 
over multiple fields across each slide within individual experimental repeats (figure 
4.22).  Both MGMT positive and MGMT negative GBM cell lines exhibited more 
DNA-PKcs positive cells when treated with the combination of ERK5i and 
temozolomide.  This percentage was more than additive when compared to the 
value generated by ERK5i and temozolomide alone in both cell lines.  All conditions 
except for ERK5i alone were significantly different to untreated cells in LN-18, 
however, combination treatment and positive IR control generated the most 
Figure 4.21: O-6-methylguanine positive GBM cells 24 hours after treatment   
LN-18 cells were plated on coverslips before being treated with ERK5i (0.25µM) 24 hours later.  
Following a 90 minute incubation 200µM TMZ was added.  24 hours later cells were fixed 
ready for IF processing. Cells were imaged at 20x objective on a Nikon Eclipse TE200 
Fluorescent Microscope.  Images are representative of each condition (A).  The numbers of 
positive cells were counted and averaged (B).  LN-18 cells treated with E+T and the 1mM TMZ 
positive control were the most significantly different to the untreated cells (p<0.0001).  TMZ 
alone was also significantly different to untreated cells but to a lesser extent.  
 
**p=<0.005 ****p=<0.0001 using a Kruskal-Wallis H Test. 
(n=2) 
 A                   B 
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statistically significant results (p<0.0001).  Both combination of ERK5i and 
temozolomide and the positive IR control were significantly different to untreated 























Figure 4.22: phospho-DNA-PKcs (s2056) positive GBM cells 24 hours after treatment   
U-251 cells (A) or LN-18 cells (B) were plated on coverslips before being treated with ERK5i 
(0.25µM) 24 hours later.  Following a 90 minute incubation 200µM TMZ was added.  24 hours 
later cells were fixed ready for IF processing. Cells were imaged at 20x objective on a Nikon 
Eclipse TE200 Fluorescent Microscope and the numbers of positive cells were counted and 
averaged.  Both U-251 cells (C) and LN-18 cells (D) treated with E+T had more than additive 
percentage of positive cells compared to the value of ERK5i and TMZ drug alone combined, 
58.37% v 36.45% for U-251 and 50.98% v 44.69% for LN-18.   
 
**p=<0.005 ****p=<0.0001 using a Kruskal-Wallis H Test. 
(n=≥2) 
 
         C            D 
           A          B 
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RAD51 is also used in repairing double strand breaks in DNA; however, it is 
associated with the homologous repair (HR) pathway, particularly within the S-G2 
phases of the cell cycle (Krejci et al., 2012).  When RAD51 was investigated in LN-18 
cells treated with ERK5i and temozolomide in combination, there was a no 
significant difference in RAD51 positive cells when compared to untreated cells.  
Both temozolomide alone and positive IR control were significantly different to 

















Figure 4.23: RAD51 positive GBM cells 24 hours after treatment   
LN-18 cells (A) were plated on coverslips before being treated with ERK5i (0.25µM) 24 hours 
later.  Following a 90 minute incubation 200µM TMZ was added.  24 hours later cells were 
fixed ready for IF processing. Cells were imaged at 20x objective on a Nikon Eclipse TE200 
Fluorescent Microscope and the numbers of positive cells were counted and averaged.  LN-18 
cells treated with TMZ and IR had the highest percentage of positive cells (51.77% and 50.50% 
respectively) (B).  Both conditions had a p value <0.0001.  Combination treatment was not 
significantly different to untreated cells (33.01%).  
 
****p=<0.0001 using a Kruskal-Wallis H Test. 
(n=2) 
  A             B 
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Micronuclei (MNi) are formed during mitosis (anaphase) when a chromosome or a 
fragment of chromosome is not incorporated into daughter nuclei.  MNi are only 
formed in a dividing population of cells, particularly if there is significant DNA 
damage present as cells enter mitosis, and are therefore used as a marker of 
genetic instability (Fenech, 2000).  Combination of ERK5i and temozolomide caused 
an increase in the percentage of MNi compared to untreated cells in both cell lines 


























































Figure 4.24: Micronuclei in GBM cells 24 hours after treatment   
T98G cells (A) and LN-18 cells (B) were plated on coverslips before being treated with ERK5i 
(0.25µM) 24 hours later.  Following a 90 minute incubation 200µM TMZ was added.  24 hours 
later cells were fixed ready for IF processing. Cells were imaged at 20x objective on a Nikon 
Eclipse TE200 Fluorescent Microscope and the numbers of MNi were counted as a percentage 
of total cells. E+T combination treatment was the only condition significantly different to 
untreated cells (p-value 0.0135 and 0.0136 for T98G and LN-18 cells respectively). 
   
**p=<0.05 using a Mann-Whitney U Test. 
 (n=≥5) 
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4.7 Cell Cycle Arrest - Nocodazole and Roscovitine  
 
Nocodazole is an anti-mitotic agent that inhibits the formation of microtubules by 
binding to β-tubulin, inhibiting microtubule polymerisation.  This inhibition causes 
an accumulation of cells in mitosis as cells are unable to form metaphase spindles 
and cannot divide (Zieve et al., 1980).  Roscovitine is a cyclin-dependent kinase 
(CDK) inhibitor targeting CDK1, 2, 5, 7 and 9 by competing with ATP-binding. Acute 
exposure to roscovitine is an established method to prevent entry of cells into S-
phase of the cell cycle (Cicenas et al., 2015). 
GBM cells were treated with nocodazole in combination with ERK5i and 
temozolomide for 24 hours.  Consistent with previous data the combination 
treatment of ERK5i and temozolomide caused the largest tail moment, significantly 
different to temozolomide alone (64.03 v 43.02).  Interestingly, the addition of 
nocodazole reduced the amount of DNA damage levels to those seen in 
temozolomide + nocodazole (T+N) levels, suggesting that this damage is mainly 
derived during mitotic progression (figure 4.24).  This is consistent with the 






































Figure 4.25: DNA damage in GBM cell treated with Nocodazole 
T98G cells were plated 24 hours before being treated with ERK5i (0.25µM). Following a 90 
minute incubation 200µM TMZ and 1ng/ml nocodazole was added and a further 24 hours 
later, cells were harvested for comet assay. Images are representative of T98G cells visualised 
on Comet Score after various treatments.  Tail moment was calculated for around 50 cells per 
condition for each repeat.  Cells were imaged at 20x objective on a Nikon Eclipse TE200 
Fluorescent Microscope after being stained with SYBR Gold.  E+T caused a significant increase 
in tail moment when compared to TMZ alone (p-value 0.04), however, this was significantly 
reduced with the addition of nocodazole (E+T v + E+T+N p-value 0.03). Nocodazole increased 
tail moment slightly in other drug treatments, however, not significantly.  TMZ and E+T were 
significantly different to untreated cells +/- nocodazole.   
 
*p=<0.05 using a Kruskal-Wallis H Test. 
(n=2) 
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GBM cells were also treated with roscovitine, for 4 hours, following the addition of 
ERK5i and temozolomide.  Unlike nocodazole, the addition of roscovitine caused no 


































Figure 4.26: DNA damage in GBM cell treated with Roscovitine 
T98G cells were plated 24 hours before being treated with ERK5i (0.25µM). Following a 90 
minute incubation 200µM TMZ was added and a further 20 hours later 10µM roscovitine was 
added for 4 hours.  Cells were then harvested for comet assay and images are representative 
of cells visualised on Comet Score after various treatments.  Tail moment was calculated for 
around 50 cells per condition for each repeat.  Cells were imaged at 20x objective on a Nikon 
Eclipse TE200 Fluorescent Microscope after being stained with SYBR Gold.  E+T caused a 
significant increase in tail moment when compared to TMZ alone (p-value <0.0001), 
unchanged by treatment with roscovitine.  
 
****p=<0.0001 using a Kruskal-Wallis H Test. 
(n=2) 































Figure 4.27: 53BP1 foci in GBM cells following Roscovitine treatment   
T98G cells were plated on coverslips before being treated with ERK5i (0.25µM) 24 hours later.  
Following 90 minutes incubation 200µM TMZ was added and a further 20 hours later 10µM 
roscovitine was added for 4 hour.  Cells were fixed ready for IF processing. Cells were imaged 
at 20x objective on a Nikon Eclipse TE200 Fluorescent Microscope and the numbers of foci 
were counted and averaged.  Images are representative of conditions.  T98G cells treated with 
roscovitine had no significant change in the number of foci for the identical drug treatment  
E+T caused the highest average foci/nuclei, significantly different to TMZ alone(p<0.0001 (B).   
 
*p<0.05 ****p=<0.0001 using a Kruskal-Wallis H Test. 
(n=3) 
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Taken together, these findings suggest the combination of ERK5i and temozolomide 
causes an increase in DNA damage which is generated during mitosis and ultimately 
leads to cell crisis/death.  The damage generated primarily activates the NHEJ 
pathway (as the HR pathway may be inhibited by ERK5i), which is particularly active 
in the G1 phase of the cell cycle.  However, it has also been reported by several 
groups that deleterious activity of the NHEJ pathway outside of G1 can lead to DNA 
damage and chromosomal aberrations (Adamo et al., 2010, Pace et al., 2010).  
 
4.8 Validating ERK5 as a target in GBM 
 
As ERK5 inhibition is able to sensitise GBM cells to temozolomide, the expression of 
ERK5 within GBM tumours is vital for the combination to work, particularly if a 
therapeutic window is to offer selectivity of tumour cells over normal brain tissue.  
Even though ERK5 has been implicated in several cancers, there has been little 
investigation into ERK5 as a target for treating patients with GBM.   
Initially, ERK5 mRNA expression in GBM was investigated using publically available 
expression data.  This revealed a significant increase in relative mRNA expression in 









































Figure 4.28: Relative ERK5 mRNA Expression  
Relative mRNA expression of ERK5 was calculated using information from the REpository for 
Molecular BRAin Neoplasia DaTa (REMBRANT).  There was significant increase in relative 
mRNA expression in GBM samples when compared to normal samples.  The expression values 
were 341.07 for normal brain (n=20) and 528.77 for GBM (n=215). 
 
****p-=<0.0001 using a Mann-Whitney U Test. 
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To further validate ERK5 as a target in GBM, ERK5 protein expression was 
investigated using immunohistochemistry (IHC).  The ERK5 antibody chosen for IHC 
was able to detect ERK5 protein expression via western blotting in GBM cells shown 
throughout this chapter and it has also been used to detected ERK5 expression via 
IHC in melanoma tissue microarrays (TMAs) (Tusa et al., 2018b). To establish a 
suitable primary antibody dilution for ERK5 staining of FFPE sections, slides 
containing FFPE cell pellet sections formed from cells treated with either control or 
ERK5 siRNA were used.  These were processed, sectioned and mounted by Maggie 
Glover, a histology technician within the Department of Oncology and Metabolism 
at the University of Sheffield.   
Once an appropriate primary antibody dilution was identified (1:4000) there was a 
clear difference observed in ERK5 staining when ERK5 siRNA treated cells were 
compared to control siRNA treated cells (figure 4.29).  Previously published 
methods investigating ERK5 expression in melanoma by IHC used an antibody 
dilution of 1:100 (Tusa et al., 2018b).  The antibody dilution selected for the staining 
of ERK5 in GBM cores was 40 times less, reducing the chances of non-specific 
antibody binding and false positive results.  However, this was very difficult to 
quantify in cell pellets due to the varied dispersion of cells throughout the pellet 
and was therefore judged qualitatively by two independent people.  A secondary 
antibody alone was used as a negative control and haematoxylin was not used as a 
counter stain as it masked the brown DAB staining making it very difficult to assess 
ERK5 expression. 
Following primary antibody optimisation (see above and figure 4.29), a selection of 
TMAs were stained.  These included 28 normal brain cores, 111 astrocytoma cores 
(grade 1: 16 cores, grade 2: 64 cores, grade 3: 31 cores) and 51 GBM cores (grade 
4). 
Intensity of ERK5 staining observed at 20x objective was quantified for each stained 
core.  As ERK5 is expressed in vasculature, cores which only showed vasculature 
staining were classified as ‘0’ intensity.  All cores were scored with numerical value 
ranging from 0 to 3 (table 4.2) (figure 4.30).  Dr Malee Fernando, a Consultant 
Histopathologist at the Royal Hallamshire Hospital, generously donated her time 



































   
   
   
   
   
   
   
   
   
   






 siRNA:                Dilution: 1:4000 
Figure 4.29: ERK5 antibody optimisation 
T98G cells were reverse transfected with control or ERK5 siRNA in a T75 flask.  Following a 48 
hour incubation cells were harvested for fixing in 4% PFA.  Cells were re-suspended in an 
agarose pellet.  Pellets were processed and sectioned before being mounted on coverslips 
ready for IHC staining.  A range of dilutions of antibody were tested (1:100 to 1:5000), 
however, 1:4000 was selected as it showed the largest difference in DAB staining between 
control and ERK5 siRNA treated cells.  




   
   
   
   
   
   
   
   
   
   






                     Dilution: 
siRNA:             1:1000       1:2000            1:3000 
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Table 4.2: Classification of Staining   
Intensity Definition 
0 Vasculature only 
1 Some but not all cells stained 
2 Low intensity pan stain 
3 High intensity pan stain 
 
Table 4.2 - Intensity scale from 0-3 enabled quantification of ERK5 staining for each TMA 
core.  Each core was scored independently by two people before the results were compared 

















T98G cell pellet sections and TMA cores showed ERK5 localisation to be both 
cytoplasmic and nuclear, and as expected, ERK5 was present in endothelial cells, 
subsequently staining vasculature in normal and astrocytoma cores.  Following 
siRNA depletion of ERK5 and staining with an AB dilution of 1:4000, ERK5 
localisation appeared to become absent from the nucleus in a large number of cells 
(figure 4.29). 
Figure 4.30: Examples of scoring grades  
0, 1, 2 and 3 are representative images of cores. Vasculature was discounted as ERK5 is 
expressed in vessels (grade 0).  Grade 3 has a highly intense pan stain, grade 2 has a pan stain 
of varying intensity and grade 1 has a few cells stained but not all. 
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Following independent scoring of the cores, an average was taken across each 
grade (figure 4.31).  All grades exhibited significantly differential ERK5 expression 
scoring compared to normal brain tissue and the average score increased with 
grade, with grade 4 GBM exhibiting the highest average of 2.70.  However, there 
was no significant difference between grade 1 compared to 2 and grade 3 
compared to 4.  GBM cores had the highest percentage of cores classified as 3 
(79%), followed by grade 3 (61.4%), grade 2 (16.7%) and finally grade 1 (12.5%) and 
normal brain tissue was mostly classified as 0 (82.6%) (figure 4.32).  The increased 
ERK5 expression in GBM tumour cells contributes to the validation of ERK5 as a 
viable target and highlights a potentially exploitable therapeutic window for the use 




















Figure 4.31: Average Intensity of ERK5 staining classified by tumour grade   
All cores were given a value from 0 to 3.  The sum of these values was averaged for each 
grade.  Values for grades 1-4 were significantly different to normal brain, with grade 4 GBM 
having the highest average value.  There was no significant difference between grade 1 and 
grade 2 or between grade 3 and grade 4 but these two groups were significantly different 
from each other.  
*p=<0.05 ***p=<0.0005 ****p=<0.0001 using a Kruskal-Wallis H Test. 
 


















There are currently no MEK5 or ERK5 inhibitors in clinical trials; however, there 
have been 3 successful MEK1/2 inhibitors approved for treating patients with 
metastatic melanoma and non-small cell lung cancer (NSCLC) (table 4.3).   These 
drugs are approved for treating patients with activating BRAF mutations, the 









Table 4.3 - MEK1/2 inhibitors have recently been approved for treatment of both metastatic 
melanoma and NSCLC patients with BRAF mutations.  
  
ERK5 has been identified here as a target which is able to sensitise GBM cells to 
temozolomide treatment when depleted by siRNA and when inhibited by either 
Table 4.3: FDA-approved MEK1/2 inhibitors  









Figure 4.32: Intensity of ERK5 staining classified by tumour grade   
All cores were given a value from 0 to 3 and the percentage of cores in each category is show 
(data shown is the same as in figure 4.29).  Grade 4 (GBM) tumours have the highest 
percentage of cores classified as 3 intensity at 79%, followed by grade 3 with 61.4%, grade 2 
with 16.7% and finally grade 1 with 12.5%.  Normal brain tissue was mostly classified as 0 
intensity (82.6%) with only 17.4% of cores being classified as 1 intensity.   
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ERK5-in-1 or XMD8-92.  This study has also shown significant over-expression of 
ERK5 mRNA and protein in brain tumours when compared to healthy brain tissue, 
further validating and strengthening EKR5 as a credible target in these tumours.  
Furthermore, inhibition of ERK5 using XMD8-92 has been shown to sensitise colon 
cancer cells in a xenograft model to chemotherapy and sensitise triple negative 
breast cancer cells to a combination of chemotherapeutic docetaxel and 
doxorubicin (Al-Ejeh et al., 2014, Pereira et al., 2016).  Additionally, a study 
investigating differentially expressed genes  involved in temozolomide resistance 
found enrichment of MAPK signalling (WNT signalling was also enriched) and 
upregulation of JNK1 (MAPK8) when temozolomide resistant cell lines were 
generated from long term temozolomide exposure (Xu et al., 2018b). 
There were, however, some problems which have arisen during this study of ERK5.  
Firstly the inhibition of MEK5 and ERK5 by BIX02189 did not sensitise GBM cells to 
temozolomide treatment in either MTT or clonogenic survival assays.  In the 
clonogenic assay this may be due to ineffective inhibition of MEK5 and ERK5 at the 
concentration used (1µM), as although decreased when compared to DMSO 
treated HeLa cells, the expression of phospho-ERK5 can clearly be seen by western 
blotting (figure 4.33).  Treatment with BIX02189 also appears to upregulate 
phospho-ERK1/2 activity, an off-target effect which may have influenced sensitivity 
to temozolomide in our studies as it previously been shown that ERK1/2 activity is 
influenced in the presence of temozolomide, which may have been further 
enhanced by the addition of BIX02189, negating any sensitisation usually seen 
following ERK5 inhibition (Wang et al., 2016, Xu et al., 2018a).  Sensitisation may 
therefore have been achieved if an increased dose of BIX02189 was used in 
combination with temozolomide in clonogenic survival assays, although, MTT 
assays which combined up to 10µM BIX02189 with temozolomide (50µM) showed 
no sensitisation.  A higher dose of temozolomide may be needed to see any 
sensitisation; however, as both XMD8-92 and ERK5-in-1 have been developed to 
target ERK5 auto-phosphorylation, this may be the key to sensitisation of GBM cells 
to temozolomide (Deng et al., 2013, Yang et al., 2010).  It would be important in 
future to assess the inhibition of ERK5 activity when using BIX02189, enabling an 
effective inhibitory dose to be selected to complete further studies.  However, ERK5 
inhibitors have been shown to generate different effects when compared to MEK5 
inhibitors in chronic myeloid leukaemia (CML) cells.  When cells were treated with 
either 10µM XMD8-92 or 10µM BIX02189 in hypoxic conditions (mimicking the 
bone marrow stem cell niche) differing results were generated regarding progenitor 
cell potential.  When cells were returned to normal oxygen conditions post 
treatment, XMD8-92 abolished this progenitor potential whereas BIX02189 was 
only able to reduce it (Tusa et al., 2018a).   
 

























Western blotting of primary and immortalised GBM cells showed ERK5 remains un-
phosphorylated under normal conditions, which could indicate it is not inhibition of 
ERK5 phosphorylation and catalytic activity but total ERK5 protein levels which are 
upregulated and important in GBM.  ERK5-in-1 is known to cause off-target 
inhibition of BRD4, a target which has been shown to decrease proliferation of GBM 
cells and also increase sensitivity to temozolomide in an additive manner following 
chemical inhibition (Lam et al., 2018, Pastori et al., 2014).  These findings combined 
with the lack of sensitivity to temozolomide following MEK5 inhibition indicate a 
potential mechanism which is independent of ERK5 phosphorylation.  Furthermore, 
XMD8-92 was only able to elicit an increase in temozolomide sensitivity when 
higher, BRD4 inhibiting, doses were used.  However, as more than additive killing 
and DNA damaging effects were observed following ERK5 inhibition when 
combined with temozolomide, off-target effects on BRD4 do not completely explain 
this increase in temozolomide sensitivity. 
Total ERK5 protein expression is upregulated in GBM tumours compared to normal 
brain, and was shown to be both nuclear and cytoplasmic in both cell lines and TMA 
cores and pan-ERK5 staining across whole cores was visible in those which were 
graded as intensities of 2 and 3.  ERK5 is usually located in the cytoplasm, tethered 
by cdc37 and Hsp90, however, following activation ERK5 it is then shuttled to the 
nucleus where is can act as a transcription factor, independent of MEK5 
phosphorylation and kinase activation (Erazo et al., 2013).  siRNA depletion of ERK5 
Figure 4.33: Inhibition of phospho-ERK5 following treatment with BIX02189  
HeLa cells were treated with BIX02189 at varying concentrations for 90 minutes before 
sorbitol stimulation (0.4M).  Phospho and total ERK5 were probed for along with phospho and 
total ERK1/2.  ERK1/2 phosphorylation was increased as a result of BIX02189 treatment at all 
concentrations; however, total ERK1/2 remained relatively unchanged.  ERK5 activity was 
almost totally abolished at 3µM and totally undetectable using 10µM BIX02189.  Both 1 and 
0.3µM BIX02189 had detectable phospho-ERK5 activity.  Total ERK5 was decreased as a result 
of ≥3µM BIX02089 treatment.  Untreated cells were used as a negative control; however, no 
loading control was shown. 
 
Figure copied with permission from (Tatake et al., 2008) 
Licence number: 4452461116168 
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was able to sensitise GBM cells to temozolomide treatment which could indicate 
ERK5 protein loss, not catalytic activity, is key and therefore MEK5 inhibitors 
targeting ERK5 phosphorylation may never elicit temozolomide sensitisation.  This 
may suggest that all the data generated using ERK5-in-1 to deplete cells of ERK5 
activity is unrelated as effects could be due to BRD4 inhibition.  However, ERK5-in-1 
acts to inhibit ERK5 auto-phosphorylation which occurs in the C-terminus which 
also contains the NLS and the transcriptional activation domain, as well as sites for 
CDK1 phosphorylation important in mitosis (Deng et al., 2013, Simões et al., 2016).  
Targeting of these various motifs following ERK5-in-1 treatment could result in 
dysregulated nuclear localisation and transcription of target genes, as well as 
defective mitotic progression.  As depletion of ERK5 following siRNA treatment 
showed localisation of ERK5 to be mainly cytoplasmic, it would have been 
interesting to investigate localisation following ERK5-in-1 treatment in order to 
determine if a similar loss of nuclear ERK5 occurred, which could be contributing to 
the more than additive increase in  temozolomide sensitivity possibly in 
combination with off-target BRD4 inhibition.   
Pan-ERK5 expression in both the nucleus and cytoplasm could be seen in TMA cores 
with very intense staining, similar to the staining seen in GBM cell line pellet 
sections transfected with control siRNA.  Following ERK5 siRNA depletion, 
expression appeared to become absent from the nucleus.  This loss of nuclear ERK5 
could highlight a potential role for nuclear ERK5 protein in temozolomide 
resistance, as seen by an increase in sensitivity following ERK5 siRNA depletion.  
Pan-ERK5 staining was also observed in cores graded as 2 intensity; however, this 
was very clearly to a lesser degree.  The progression from low to high ERK5 
expression could be a result of tumour microenvironment changes which occur as 
the tumour grows, effecting signalling pathways which could induce ERK5 
expression potentiating temozolomide resistance.  It would have been interesting 
to know whether patients were resistant to temozolomide treatment in order to 
compare this with ERK5 expression levels. 
The importance of FANCD2 in sensitising GBM cells to temozolomide using ERK5 
inhibition is yet to be determined as the results from depletion of FANCD2 in LN-18 
cells were variable.  It is possible that the inconsistency seen in FANCD2 siRNA 
treated cells was due to the efficiency of FANCD2 knockdown, which could be 
investigated further using stable shRNA FANCD2 depleted GBM cells (Patil et al., 
2014).  The Fanconi Anaemia pathway is involved in several DNA damage pathways 
including homologous repair (HR), nucleotide excision repair (NER) and translesion 
synthesis (TLS).  The FA pathway is the main mechanism which repairs DNA 
interstrand crosslinks (ICLs).  The FANCM-FAAP24-MFH complex detects ICLs and 
recruits the core FA complex to these DNA damage lesions.  Here the multi-subunit 
core complex ubiqutinates FANCD2-FANCI.  Once ubiqutinated, the FANCD2-FANCI 
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complex recruits or interacts with other DNA damage proteins including BRCA1 and 
BRCA2 (Kee and D'Andrea, 2010).  Depletion of FANCD1/BRCA2 or FANCD2 is 
known to sensitise GBM cells to temozolomide and FANCD2 has also been shown to 
be activated in response to temozolomide (Chen et al., 2007, Kondo et al., 2011, 
Patil et al., 2014).  However, FANCC and FANCA, both part of the core complex, 
were shown to not have any effect on temozolomide sensitivity (Kondo et al., 
2011).  Furthermore, FANCD2 has been identified as a player in HR, acting in a role 
independent to the core FA complex. FANCD1/BRCA2-FANCD2-FANCG-XRCC 
complex is formed in response to phosphorylation of serine 7 on FANCG, which acts 
to initiate HR.  It has therefore been speculated that both DNA damage proteins 
and FA proteins interact in order to repair temozolomide induced damage through 
pathways such as HR (Wilson et al., 2008).  Importantly, previous work from the 
Collis laboratory has demonstrated that brain tumours re-activate and re-express 
high levels of FANCD2 compared to normal brain tissue (Patil et al., 2014).  
Therefore, although the data generated in U-138 cell is interesting, it is unlikely to 
be relevant or detrimental to the use of ERK5i as a temozolomide potentiating 
agent in GBM within the clinic. 
Interestingly, an increase in the ability of cells to perform HR has been shown to 
confer resistance to temozolomide (del Alcazar et al., 2016).  Methylation of O-6 
guanine is the most toxic lesion caused by temozolomide and is either directly 
repaired by MGMT or if unrepaired, the methylated guanine is incorrectly paired 
with thymine.  Mismatch repair (MMR) recognises this incorrect pairing and 
removes the newly paired base on the complementary strand so O-6-
methylguanine remains on the parental strand of DNA.  The methylated base is 
then re-paired with thymine and the futile cycle of MMR continues resulting in 
single strand gaps or breaks in DNA (Friedman et al., 2000).  In the subsequent cycle 
of replication, replication fork collapse can causing double strand DNA breaks 
(DSBs) and eventually cell death. However, this damage at the replication fork can 
be repaired effectively by HR using sister chromatid exchange (SCE) (Kaina et al., 
2007).  RAD51 is used as a marker of HR and was shown to be unchanged in the 
combination of ERK5i and temozolomide when compared to untreated cells, unlike 
temozolomide alone cells which had a significant increase in RAD51 foci and 
subsequently HR.  This reduction in cells ability to repair temozolomide induced 
damage by HR could a contributing factor to the sensitisation induced by the 
combination treatment.  Furthermore, phosphorylation of CHK1 at serine 345 was 
also decreased in combination treatment when compared to temozolomide alone 
at 24 hours (figure 4.34).  CHK1 is phosphorylated at serine 345 principally by ATR in 
response to DNA damage, and once activated will interact with and phosphorylate 
RAD51 which potentiates HR.  This decrease in phospho-CHK1 further suggests 
reduced HR in cells treated with the combination treatment (Narayanaswamy et al., 
140                                                                                                                   Natasha Carmell 
 
2016, Sørensen et al., 2005).  Hypothetically, this could mean that FANCD2 is 
necessary for the sensitisation of GBM cells to this treatment combination as an 
intact HR response would be required.  Furthermore, this could potentially explain 
why there is more phosphorylated DNA-PKcs, indicative of an increase in NHEJ to 
compensate.  NHEJ in place of HR is known to cause chromosomal aberrations and 











Following treatment with the chemotherapeutic hydroxyurea, BRD4 inhibition has 
also been shown to downregulate CHK1 phosphorylation at both serine 317 and 
serine 345 (Zhang et al., 2018a), in a similar manner to that seen with the 
combination of ERK5i and temozolomide (figure 4.34).  This resulted in a defective 
G2/M checkpoint and aberrant restarting of DNA replication, sensitising the cells to 
hydroxyurea (Zhang et al., 2018a).  These findings highlight a role for BRD4 in the 
DNA damage response pathways which could be involved in temozolomide 
sensitisation; however, BRD4 has previously been shown to act as a repair complex 
adaptor in NHEJ.  Following inhibition of BRD4, 53BP1 did not accumulate at site of 
double strand DNA breaks, subsequently resulting in defective NHEJ repair, an 
effect which was not observed during these studies where either ERK5i alone or in 
combination with temozolomide resulted in an increase in 53BP1 foci (Stanlie et al., 
2014).       
Nocodazole arrests cells in M-phase and was able to reduce DNA damage caused by 
combination treatment.  HR is the main repair mechanism for replication fork DSBs, 
not only occurring in S-phase but also G2-phase of the cell cycle (Krejci et al., 2012).  
When cells are treated with nocodazole they are arrested in M-phase after damage 
is repaired by HR.  This could explain the decrease in damage seen in the 
Figure 4.34: phospho-CHK1 (serine 345) following 24 hours treatment with ERK5i and TMZ 
T98G cells were plated for 24 hours before being treated with ERK5i. Following 90 minutes 
incubation 200µM TMZ was added.  Cells were incubated for 24 hours before harvesting for 
protein lysis 48 hours later.  Cells were lysed, protein was quantified and samples were run on 
a western blot.  Membranes were probed with phospho-CHK1 (serine 345) or total CHK1 
primary antibodies. 
   
50 
50 
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combination treatment combined with nocodazole, as cells are arrested after 
damage is repaired and cannot be re-damaged as they are no longer cycling.  
However, if HR is reduced in the combination treatment and this is the mechanism 
by which cells are becoming sensitised then this hypothesis would not be true as 
the damage would be left unrepaired, suggesting that it is cycling through mitosis 
which is inducing more DNA breaks.  When cells are in interphase, any double 
strand breaks that occur are repaired primarily by NHEJ (G1/S) over HR (G2).  
However, less is known about DNA breaks formed in mitosis as it is believed a full 
DNA repair response is supressed, with only partial activation of some components 
such as ATM, ɣH2AX and MDC1 (Giunta et al., 2010).  ERK5 is an important survival 
factor during mitosis, interacting with pro-apoptotic BIM, where inhibition results in 
BIM-induced caspase activation and cell death (Gírio et al., 2007).  Temozolomide is 
also known to induce BIM as part of the late pro-apoptotic response (Tomicic et al., 
2015).  Combining ERK5-in-1 with temozolomide could result in an increase in BIM 
activity and subsequent cell death, however, as ERK5 is only interacts with BIM in 
mitosis, this effect could be reduced following nocodazole treatment possibly 
explaining the decrease in DNA damage and subsequent cell death. 
O-6-methylguanine damage was shown to be increased as a result of ERK5i and 
temozolomide combination and coupled with the reduction in RAD51 positive cells, 
this increase in damage and decrease in repair could be sensitising the cells to 
temozolomide treatment.  Curiously, ERK5i only also appeared to increase O-6-
methylguanine lesions, however, this was not significantly different to untreated 
control cells but a trend could be seen.  Potentially ERK5i could be having off-target 
effects, somehow inhibiting the repair of these lesions whilst reducing a cell’s ability 
to complete HR and repair the damage.  To investigate whether this is an off-target 
effect of ERK5i, the ability of XMD8-92 to induce O-6-methylguanine could be 
investigated.  However, this is unlikely because the effects of temozolomide and 
ERK5i were only seen after 96 hours or 120 hours post treatment and it is highly 
unlikely ERK5i would remain active exerting its inhibitory effects on repair for such 
a long time period.  Not only this, ERK5i alone did not cause any significant increase 
in damage detected by immunofluorescence (53BP1 foci, DNA-PK or RAD51 positive 
cells) and alkaline comet assays, nor was there an increase in MNi.  Inhibition of 
BRD4 has also been shown to cause aberrant chromosome segregation and 
therefore an increase in the presence of MNi, however, this was not observed 
following ERK5-in-1 treatment alone, only occurring as a result of combination 
treatment (You et al., 2009), indicating that BRD4 inhibition may not be toxic until 
combined with temozolomide or that BRD4 inhibition is not implicated here.   
Not only was an increase in DNA damage visualised by comet assays, but both 
53BP1 foci and DNA-PK phosphorylation, markers of DNA damage, were increased 
when cells were treated with ERK5i and temozolomide in combination.  53BP1 is a 
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promoter of NHEJ and is phosphorylated by CHK1, inhibiting its activity in mitosis 
and DNA-PK is a key regulator of NHEJ (Lieber, 2010, Orthwein et al., 2014). Both an 
increase in 53BP1 foci and DNA-PK phosphorylation suggest that combination 
treatment causes an increase in NHEJ (and a reduction in HR), which is activated as 
a result of an increase in DSBs.  Further evidence of genomic instability is reflected 
by the increase in MNi in the combination treatment.  By investigating co-
expression of cyclin A, a cell cycle regulator which accumulates in S-phase and 
peaks in G2-phase, with DNA-PKcs which is active in G1, the presence of aberrant 
NHEJ could be explored further (Yam et al., 2002).  
Crizotinib, an inhibitor of ALK, c-MET and ROS, has been shown to sensitise GBM 
cells to temozolomide.  However, this increase in the potency of temozolomide was 
only effective in cells with mutant ROS1 fusion proteins (Das et al., 2015).  
Nevertheless, pleotrophin (PTN) is a growth factor which binds to and activates ALK 
and the associated cell proliferation pathways, has been shown to be over-
expressed at both mRNA and protein levels, correlating with higher expression in 
higher grade gliomas (Kalamatianos et al., 2018).  In neuroblastoma, ALK signalling 
has been shown to activate ERK5 via AKT signalling, which potentiates oncogenic 
signalling through activation of N-MYC.  Inhibition of ERK5 using 5µM XMD8-92 
resulted in a reduction of N-MYC protein expression that was almost undetectable 
by western blot (Umapathy et al., 2014).  If ALK is over-expressed in GBM an 
increase in ERK5 signalling could be effecting cell proliferation, survival and 
apoptosis which may be targeted by ERK5i, potentiating the effect of 
temozolomide. 
Further work to unravel the precise mechanism by which this occurs needs to be 
completed, focusing on the DNA damage response, as well as further validation in 
patient derived primary cells, 3D culture and orthotopic animal studies.  However, 
the off-target effects of BRD4 inhibition using ERK5-in-1 and higher doses of XMD8-
92 need to be investigated further.  More selective ERK5 inhibitors, such as 
AX15836, are now available and do not show the anti-inflammatory or anti-
proliferative effects which have previously been identified using earlier compounds 
such as XMD8-92 (Lin et al., 2016).  It is believed that efficacy of the older inhibitors 
is mainly due to off-target BRD4 inhibition and that any phenotypes identified 
following ERK5 depletion or deletion are due to C-terminal function, not catalytic 
activity (Lin et al., 2016).  Combining AX15836 with temozolomide in survival assays 
which are not reliant on metabolism, such as clonogenic survival assays or annexin 
V and PI staining, would clearly determine whether ERK5 inhibition is able to 
sensitise GBM cells to temozolomide.  If confirmatory, use of this inhibitor with the 
various mechanistic studies would be important to further validate the findings 
using ERK5-in-1.  
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ERK5 is dysregulated in a vast array of cancers so once clinical trial testing of ERK5 
inhibitors begins, the identification of a safe and efficacious drug could improve 
cancer treatment for a huge proportion of patients.  However, adult mice with an 
inducible ERK5 knock out also died 2-4 weeks after ERK5 depletion due to increased 
endothelial cell death which caused their vasculature to become ‘leaky’ resulting in 
massive haemorrhage (Hayashi et al., 2004).  The importance of ERK5 in 
maintaining vasculature integrity potentially highlights problems developers might 
face if ERK5 inhibitors are trialled in humans, but as ERK5 is over-expressed in GBM 
tumours there is a potentially exploitable therapeutic window which would allow 
for the selective targeting of tumour cells of the normal cell population.  
Furthermore, ERK5 inhibition did not cause significantly more DNA damage or cell 
death when used as an individual agent, which if combined with temozolomide 
targeted directly to the tumour cells using nanoparticles, combining the treatments 
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Chapter 5 – Fibroblast Growth Factor Receptor 4 is involved in 
Temozolomide resistance in GBM cells. 
5.1 Introduction to Fibroblast Growth Factors and their Receptors 
 
Fibroblast growth factors (FGF) were first identified in 1974 and were found to 
promote proliferation of fibroblasts that were extracted from pituitary tissue.  The 
first FGF was named basic FGF and this is now known as FGF2 (Gospodarowicz, 
1974).  There are 18 secreted FGFs which bind to a family of 4 receptors (FGFR).  
These classic receptors (FGFR1-4) transduce ligand binding via an intracellular 
tyrosine kinase domain and a phosphorylation cascade that results in activation of 
signalling pathways.  FGFs must bind to FGFRs in the presence of heparin sulphate 
or heparin sulphate proteoglycans in order to generate a signal cascade (Ornitz and 
Itoh, 2015).  There is 1 receptor (FGFR5 or FGFRL1) which does not have a tyrosine 
kinase domain or an associated signalling pathway (Ornitz and Itoh, 2015, Sleeman 
et al., 2001).  In addition to the 18 secreted FGFs, there are 4 which do not bind to 
an FGFR but instead act as co-factors for other proteins, such as voltage gated 
sodium channels (NaV) (Ornitz and Itoh, 2015).  Table 5.1, adapted from Ornitz and 
Itoh, 2015, summarises FGFs, their subfamily, receptors and associated co-factors. 
 
Table 5.1 - 18 secreted FGFs bind to a family of 4 receptors (FGFRs).  4 FGFs do not bind to 
FGFRs but instead act as co-factors for other proteins e.g. voltage gated sodium channels. 
Table 5.1: Fibroblast Growth Factors, Receptors and Sub-
families   
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FGFs have important roles in development, with some FGF and FGFR deletions 
leading to embryonic lethality in mice, e.g. FGF4, 8, 9, 10, 15, 18, 23 and FGFR1 and 
2 null mice are not viable and die as early as embryonic day 4 or as late as the day 
of birth due to defects in various tissues (heart, CNS, lungs, limbs etc) (Ornitz and 
Itoh, 2015).  Canonical FGFs (table 5.1) have many roles important in maintaining 
tissue homeostasis: survival, proliferation, differentiation, wound healing and 
angiogenesis.  RAS-MAPK, PI3K-AKT, STAT and PLCγ are the signalling pathways 
which are activated in response to FGFs binding to their receptors  (Ornitz and Itoh, 



















As FGFs and FGFRs are important in both development and homeostasis, 
dysregulation of them is often associated with a variety of diseases, including 
cancer. 
Figure 5.1: Canonical FGF Signalling 
When FGF binds to the FGFR receptor along with heparin sulphate (HS) or heparin sulphate 
proteoglycan (HSPG), phosphorylation of the intracellular tyrosine kinase domains occurs.  
This activation causes various signalling cascades: RAS-MAPK (grey), PI3K-AKT (yellow), STAT 
(light blue) and PLCγ (dark blue).   
RAS-MAPK – phosphorylation of the receptor results in an interaction between FRS2α and 
CRLK.  FRS2α recruits GRB2 which in turn recruits SOS. SOS then activates the RAS/MAPK 
pathway.     
PI3K/AKT – activated GRB2 recruits GAB1 alongside SOS.  GAB1 then goes on to activate 
PI3K/AKT pathway. 
PLCɣ - activated PLCɣ produces IP3 which causes intracellular calcium to be released from 
endoplasmic reticulum stores.  DAG is produced alongside IP3 and activates the PKC pathway. 
STAT – STAT 1,3 and 5 are transcription factors which relocate to the nucleus to control gene 
expression once they are active. 
 
Legend adapted and image taken from (Ornitz and Itoh, 2015) 
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5.2 Fibroblast Growth Factors and Receptors in Cancer 
 
FGFs and FGFRs are thought to play a role in oncogenesis as dysregulation of the 
associated pathways (proliferation, survival, angiogenesis, epithelial-mesenchymal 
transition and migration) is associated with increased tumorigenicity.  For example, 
driver mutations in the FGF and FGFR signalling pathways are present in over 90% 
of  melanoma cases (Flippot et al., 2015).   
In normal brain FGF2 (basic FGF) cannot be detected by immunohistochemistry, 
however, it has been shown that within glioma patients high FGF2 expression is 
associated with higher grade gliomas (IV) and increased malignancy, as well as 
increased vascular structures (Takahashi et al., 1992).  However, it is not just FGFs 
that are dysregulated in cancer; FGFRs are also implicated in oncogenesis causing 
downstream pathways to become hyper activated (Babina and Turner, 2017).  For 
example, gene amplification can result in increased protein expression leading to 
more FGFR receptors and an increase in growth signalling.  Receptors can also 
undergo activation mutations which can result in a constitutively active receptor 
and increased signalling irrespective of ligand binding.  Chromosomal 
rearrangement can occur resulting in fusion genes that result in an increase in the 
activation of receptors and their signalling pathways or an increase in receptor 
transcription via a more active promoter (Babina and Turner, 2017).  FGFs produced 
by tumour cells or stromal cells of the tumour can also hyper-activate their 
respective receptors and this increase in FGF ligands can cause permanent changes 
to the receptor.  FGFs also have a role in angiogenesis and epithelial-mesenchymal 
transition (where epithelial cells gain invasive properties), which can increase as a 
result of tumour secreted FGFs (Babina and Turner, 2017).   
FGFR1 and FGFR2 amplifications have been implicated in breast cancer, FGFR3 
translocation causing activation mutations in multiple myeloma and FGFR4 
activating mutations in rhabdomyosarcoma (Chesi et al., 1997, Jacquemier et al., 
1994, Meyer et al., 2008, Taylor VI et al., 2009).  FGFR4 expression has also been 
shown to correlate with erlotinib resistance in GBM cell lines, potentially indicating 
a substitute role for FGFR4 in EGFR signalling pathways (Halatsch et al., 2009). 
There have been and are currently many clinical trials investigating the inhibition of 
FGFs and FGFRs in cancers.  However, there are no FDA approved FGF or FGFR 
inhibitors.  There are currently four selective FGFR4 inhibitors in phase I and II 
clinical trials (table 5.2).  The trials comprise a majority of hepatocellular carcinoma 
(HCC) patients; however, two trials include several other cancer types.  FGFR4 is a 
target for patients with HCC as FGF19, which binds to FGFR4 in normal physiological 
conditions, is both amplified and over-expressed in these tumours (Sawey et al., 
2011, Wu et al., 2011).  The first inhibitor launched into clinical trials was NVP-
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FGF401, a reversible inhibitor with an IC50 of 1.1nM.  6 months later a clinical trial 
involving BLU554, the FGFR4 inhibitor used in these studies, was opened 
(ClinicalTrials.gov, 2018).  Although FGFR4 inhibition is not being investigated in 
relation to GBM, if future work is able to validate FGFR4 as a target, availability of 
FDA-approved drugs may speed up the process to clinical trials.   
 
Table 5.2: FGFR4 inhibitors in clinical trials  
Drug IC50 (nM) Trial Start Disease Phase 
NVP-FGF401 1.1 Dec 2014 HCC I & II 
BLU554 5 July 2015 HCC I 
H3B-6527 1.2 March 2017 Advanced HCC (& others) I 
INCB062079 Not given May 2017 HCC (& others) I 
 
Table 5.2 – FGFR4 inhibitors are currently in phase I and II clinical trials, mainly targeting 
HCC.  All these inhibitors target cysteine 552, a residue located in the tyrosine kinase 
domain of FGFR4, which is not conserved between the other family members. 
 
5.3 Depletion of FGFR4 using siRNA sensitises GBM cells to Temozolomide 
 
As previously seen, FGFR4 pooled siRNA purchased from OTP did not cause an 
effective knock-down of FGFR4 achieving only a 65.71% depletion (figure 3.11, 
chapter 3).  siPOOLS™ siRNA was used these to validate FGFR4 as a hit from the OTP 
kinase screen. 
A range of 1nM to 10nM of siRNA was suggested by siTOOLS™ as the working 
concentrations to initially test for effective depletion of the target using siPOOLS™.  
From both qRT-PCR and western blotting an effective knock-down of more than 
80% was achieved by 2.5nM or more (figure 5.2).  Expression of FGFR4 was 
relatively low in GBM cell lines, with Ct values for qRT-PCR of around 28-30 when 
compared to 16-17 for GAPDH, therefore the use of another housekeeping gene, 
such as 18S, would further improve confidence in this qRT-PCR data.  Such low 
expression levels resulted in difficulties in detection of FGFR4 protein via western 
blotting.  As such, 30-60 minute exposures were required in order to detect FGFR4 
bands, which also resulted to the appearance of various non-specific bands (figure 




































As a working concentration of 2.5nM, 5nM and 10nM siRNA all gave a similar 
percentage knock-down, 5nM was the concentration selected for future 
experiments.  This was selected in order to attempt to minimise any toxicity to the 
cells caused by siRNA and transfection whilst maximising the efficacy of the knock-
down. 
A                                                                                 B 
Figure 5.2: Expression of FGFR4 in T98G cells treated with FGFR4 siPOOLS siRNA for 48 
hours 
T98G cells were reverse transfected with siRNA at varying concentrations (1-10nM) before 
harvesting for RNA extraction or protein lysis 48 hours later.  Following RNA extraction, cDNA 
was made and qRT-PCR was performed (A) or cells were lysed, protein was quantified and 
samples were run on a western blot (B).   
 
siRNA concentration of 2.5nM or greater was able to generate sufficient knock down of FGFR4 
(>85%).  GAPDH was used as a house keeping gene to normalise samples for qRT-PCR and β-
actin was used as a loading control for the western blot. 
 
Fold change was calculated by 2- ΔΔCT 
 
% Knockdown was calculated by (1-2- ΔΔCT) *100     
 
















Final FGFR4 siRNA Conc 
149                                                                                                                   Natasha Carmell 
 
In order to validate the result seen from the initial pooled siRNA OTP screen 
(chapter 3), the ability of FGFR4 depletion to sensitise GBM cells to temozolomide 
was investigated.  T98G and U-87 cells were both reverse transfected for 48 hours 
in 96 well plates.  Cells were treated with doses of temozolomide ranging from 0-







Depletion of FGFR4 conferred a modest yet significant increase in sensitivity to 
temozolomide in both T98G and U-87 cells (figure 5.3), which further validates 
FGFR4 as a hit from the original kinome screen.  In U-87 cells, FGFR4 siRNA alone 
caused  significant decrease in survival fraction (p=0.01)  As T98G cells are MGMT 
positive and U-87 cells are MGMT negative, this bodes well for pan-GBM clinical 
applicability of FGFR4 inhibition and does not select for one population of patients.  




Figure 5.3: Cytotoxicity curves of GBM cells treated with Control or FGFR4 siRNA and TMZ 
Cells were reverse transfected with siRNA and then treated with a range of TMZ (0-400µM) 48 
hours later.  Following 5 days incubation an MTT assay was performed.  FGFR4 siRNA alone 
was relatively non-toxic in T98G cells, however, it caused around 20% cell death in U-87 cells 
(p=0.01).  Both T98G and U-87 cells depleted of FGFR4 showed a reduced survival fraction 
when treated with TMZ in comparison to control cells, reflecting a modest increase in 
sensitivity to TMZ. 
 
Data shown is the average surviving fraction (normalised to DMSO treated control siRNA) +/- 
standard deviation derived from two independent biological repeat experiments. 
 
*=p<0.05 **=p<0.01 using Mann-Whitney U Test. 
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5.4 Inhibition of FGFR4 using BLU554 sensitised GBM cells to Temozolomide 
 
As previously mentioned, in 2015 data from the first FGFR4 inhibitor was published.  
BLU9931, developed by Blueprint Medicines, is an FGFR4 inhibitor that was used to 
treat HCC patients whose tumours exhibited active FGFR pathways (Hagel et al., 
2015).  As the fibroblast growth factor receptor family has 3 other members which 
are highly homologous, there had been difficulty in developing inhibitors which 
target only one member of the family.  BLU9931, however, was the first selective 
inhibitor developed to target only FGFR4, as it is binds to a cysteine molecule 
(cys552) which is not conserved between the other family members.  BLU9931 
covalently binds to the ATP binding motif of the kinase (Hagel et al., 2015).  
Blueprint Medicines have since developed another FGFR4 inhibitor, BLU554, which 
is currently being investigated in a Phase I trial (ClinicalTrials.gov, 2018).  BLU554 
also covalently binds to FGFR4 to inhibit the kinase activity in the same manner as 
BLU9931; however, BLU554 has higher selectivity for FGFR4 over FGFR 2 and 3 






Table 5.3 – IC50 of FGFR4 inhibitors BLU554 and BLU9931.  BLU554 is currently in a phase I 
clinical trial and is more selective over FGFR2/3 compared to BLU9931. 
 
NVP-FGF401, made by Novartis, is an FGFR4 inhibitor currently in phase I and II 
clinical trials, however, there is little published data about how this inhibitor works 
(Graus Porta et al., 2017).  When the current studies reported here were being 
conducted, BLU554 was the only other selective FGFR4 inhibitor in clinical trials 
(ClinicalTrials.gov, 2018).  As there is more published data regarding the mechanism 
of action and IC50 values of BLU554, this was selected as an appropriate FGFR4 
inhibitor to investigate as part of our studies.   
Firstly, a range of doses of BLU554 were used in combination with two doses of 
temozolomide in two GBM cell lines (figure 5.4).  T98G cells are resistant to 
temozolomide as they are MGMT positive and U-251 cells are sensitive to 
temozolomide as they are MGMT negative.  Increasing doses of BLU554 
significantly sensitised both T98G and U-251 cells to set doses of temozolomide 
(25µM, 50µM or 100µM) when used in combination.  BLU554 did however become 
Table 5.3: IC50 (nM)of BLU inhibitors 
FGF Receptor BLU554 BLU9931 
4 5 3 
1 624 891 
2 1202 552 
3 2203 150 
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slightly toxic to both cell lines when a dose of 5µM was reached.  A set dose of 
BLU554 (0.5µM, 1µM or 5µM) also sensitised T98G cells to a range of 
temozolomide doses when used in combination (figure 5.5).  Collectively, this data 
























Figure 5.4: Cytotoxicity curves of GBM cells treated with FGRR4 inhibitor BLU554 and TMZ 
Cells were plated and allowed to adhere for 24 hours. Cells were treated with a range of doses 
of BLU554 (0-10µM) before being treated with TMZ 2 hours later.  Following 5 days incubation 
an MTT assay was performed.  BLU554 alone caused an increase in toxicity at >5µM in both 
cell lines.  Both T98G and U-251 cells treated with BLU554 showed a reduced survival fraction 
when treated in combination with TMZ as opposed to BLU554 alone. 
 
Data shown is the average surviving fraction (normalised to DMSO treated controls) +/- 
standard deviation derived from three independent biological repeat experiments. 
*=p<0.05 **=p<0.01 using a Mann-Whitney U Test. 
 
These experiments were completed by Connor McGarrity-Cottrell, 2nd Year Undergraduate 
Student from Sheffield Hallam University. 
 



















5.5 FGFR4 is expressed in Primary GBM Patient Cells 
 
As FGFR4 expression is low in GBM cell lines, the expression in primary patient 
material was investigated using western blotting (figure 5.6A). Primary patient-
derived GBM samples expressed FGFR4 and interestingly, lysates generated from 
cells grown in stem media had a higher expression of FGFR4 when compared to 
cells grown in normal media.  Putative stem cell markers, nestin and CD133, were 
detected in primary cells grown in 3D scaffolds in stem-selecting media, validating 
their status as a stem-like population (figure 5.6B) (Singh et al., 2004).  The primary 
cells were cultured and imaged Mr Ola Rominiyi (clinical PhD student in the Collis 
laboratory).   
These preliminary findings validate FGFR4 as a potential target for treating GBM 
patients. 
Figure 5.5: Cytotoxicity curves of GBM cells treated with FGRR4 inhibitor BLU554 and TMZ 
Cells were plated and allowed to adhere for 24 hours. Cells were treated with a set dose of 
BLU554 (0-5µM) before being treated with increasing doses of TMZ (0-400µM) 2 hours later.  
Following 5 days incubation an MTT assay was performed.  Combination treatment caused a 
reduced survival fraction; however, at the maximum dose of TMZ, there was little difference 
between TMZ alone and combinations.  1µM and 5µM BLU554 alone caused a significant 
reduction in survival fraction compared to DMSO treated cells (p=0.008 and 0.005).  
 
Data shown is the average surviving fraction (normalised to DMSO treated controls) +/- 
standard deviation derived from two independent biological repeat experiments. 
 
These experiments were completed by Connor McGarrity-Cottrell, 2nd Year Undergraduate 
Student from Sheffield Hallam University. 

















5.6 Future Work/Discussion 
 
FGFR family members (FGFR1, 2 and 3) are targets in current GBM clinical trials 
(table 5.4) (ClinicalTrials.gov, 2018).  Due to the homologous nature of FGFR1, 2 and 
3, one drug to target all 3 receptors is being tested.   The main focus of these two 
trials is the oncogenic fusion gene, FGFR-TACC (Transforming Acidic Coiled-Coil), 
which generates a constitutively active FGFR by combining the tyrosine kinase 
domain of FGFR with the coil-coil domain of TACC, altering the downstream 
regulation of ERK and STAT3 signalling pathways (Singh et al., 2012).  In GBM 
patients, FGFR-TACC fusion genes are only present in a low proportion (3 out of 97 
cases) and are found alongside wild-type IDH-1, which confers a worse prognosis 
than the mutant IDH-1 (Singh et al., 2012).  This fusion gene has been shown in 
various other cancers, including lower grade glioma (3.5%) (Di Stefano et al., 2015), 
cervical squamous cell carcinoma (3%) (Carneiro et al., 2015) and paediatric low 
grade glioma (6-7%) (Zhang et al., 2013).  However, pan-tyrosine kinase inhibitors, 
such as those used when treating chromic myeloid leukaemia, can have off target 
effects (anaemia, nausea, leukopenia) which cannot be tolerated in patients (Tsai et 





























Figure 5.6: Expression of FGFR4 and stem cell markers in Patient Derived GBM Cells  
Primary cells taken from GBM tumours during surgery were cultured in standard media 
(‘bulk’) or media supplemented to select for stem-like cells.  After 6 weeks cells were 
harvested and lysed for western blotting.  Samples were probed for FGFR4 expression and β-
actin was used as a loading control for the western blot (A).  Stem cells, cultured in 3D 
scaffolds, were identified by immunofluorescence detecting the expression of putative stem 
cell markers nestin and CD133.  These images are courtesy of Mr Ola Rominiyi (B). 
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Table 5.4 – FGFR inhibitors which target the whole family of receptors are currently in 
phase I and II clinical trials in patients with recurrent GBM.  
 
 
Here, FGFR4 was identified as a potential target to sensitise GBM cells to 
temozolomide.  By depleting cells of FGFR4 using siRNA or inhibiting the kinase 
activity using BLU554, GBM cells become more sensitive to temozolomide reflected 
by a decreased survival fraction when compared to temozolomide only treated 
cells.  As two different methods have been shown to sensitise GBM cells to 
temozolomide, the strength of FGFR4 as a potential target has been increased.  
Positively, FGFR4 knock-out mice are viable with no apparent defects (Weinstein et 
al., 1998).  However, future work would include western blotting to detect 
inhibition of FGFR4 activity by BLU554 at the range of doses used, in order to 














 Table 5.4: Pan-FGFR inhibitors in clinical trials for GBM 
Drug Trial Start Disease Phase 
NVP-BGJ398 Dec 2013 
FGFR1/3-TACC1/3 fusion 
and/or FGFR1,2,3 activating mutation II 
AZD4547 Sept 2015 
FGFR1/3-TACC1/3 fusion 
IDH wild type I & II 














In the present study, FGFR4 protein has been detected in both GBM cell lines and 
primary patient GBM cells via western blotting; however, the expression of FGFR4 
in non-cancerous and eloquent brain tissue has not been determined.  An increased 
FGFR4 protein expression in GBM tumours could increase the potential of FGFR4 as 
a valid target.  In order to explore this, immunohistochemistry investigating FGFR4 
protein expression in both non-cancerous brain (normal) and GBM tissue would 
enable us to detect any changes in expression.  Interestingly, FGFR4 mRNA 
expression in a cohort of GBM tumours is significantly less when compared to 
normal samples (figure 5.7) (Betastasis, 2018).  This decrease in mRNA expression, 
also mirrored by a decrease in FGFR2 and FGFR3 mRNA expression in GBM 
tumours, although initially disappointing, needs to be investigated further as gene 
expression and protein function is not always co-dependent.  For example, The 
Human Protein Atlas database does show FGFR4 expression to be low in brain 
tissue, however, IHC protein expression data has been shown to conflict with mRNA 
data (TheHumanProteinAtlas). 
Although the over-expression of receptors is usually a therapeutic target, for 
example HER2 in breast cancer, in relation to mutant receptors, even a slight 
decrease in expression can result in hugely dysregulated downstream signalling e.g. 
mutations increasing receptor affinity for FGFs or chromosomal rearrangements 
causing fusion genes (Babina and Turner, 2017, Moasser and Krop, 2015).  If FGFR4 
is forming fusion genes similar to FGFR1/3-TACC1/3, seen in approximately 3.1% of 
GBM cases, there may be no increase in FGFR4 mRNA or protein expression but a 
Figure 5.7: Relative FGFR4 mRNA Expression  
Relative mRNA expression of FGFR4 was calculated using information from the REpository for 
Molecular BRAin Neoplasia DaTa (REMBRANT).  There was a significant decrease in relative 
mRNA expression in GBM samples when compared to normal samples.  The expression values 
were 136.5 for normal brain (n=20) and 130.5 for GBM (n=215), with a p-value of 0.03 using a 
Mann-Whitney U Test. 
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dysregulated signalling pathway which cannot be detected by qRT-PCR or 
immunohistochemistry (Di Stefano et al., 2015, Singh et al., 2012).  A previous study 
has also identified FGFR4 activating mutations in a small number of GBM samples 
by using The Cancer Genome Atlas, which again may not confer an increase in 
protein expression (TGCA)(Masica and Karchin, 2011).  
Rhabdomyosarcoma (RMS), a cancer of soft tissue (muscles, tendons, ligaments), 
has high FGFR4 expression in the tumours.  Activating mutations in FGFR4 have 
been studied in RMS, and it was found that an increase in FGFR4 signalling 
(detected by an increase in phosphorylation), caused an increase in both total and 
phosphorylated STAT3 (Taylor VI et al., 2009).  Similar findings have been shown in 
colorectal cancer where depleting cells of FGFR4 also decreased STAT3 activity 
(Turkington et al., 2014).  Activating mutations in FGFR4 were found to increase 
tumour proliferation in RMS cell lines and xenografts transplanted into nude mice 
(Taylor VI et al., 2009).  If similar mutations were present in the GBM cell lines used 
in this study, this could potentially have cause the chemo-sensitisation, however, as 
these mutations form a minor subset of all GBM tumours it is unlikely to have been 
present in all 3 GBM cell lines used. 
Regarding chemo-resistance, it has previously been found that breast cancer cells 
which are resistant to the chemotherapy doxorubicin over express FGFR4.  This 
overexpression has been shown to be responsible for chemo-resistance through 
upregulation of the anti-apoptotic pathways by the increased expression of BCL-xl 
(Roidl et al., 2009).  FGFR4 dysregulation has also been shown to activate other 
anti-apoptotic pathways such as Protein Kinase B (PKB/AKT) in breast cancer (Tiong 
et al., 2016).  These findings, although not specifically related to GBM, could 
potentially help us to understand why GBM stem cells (CD133+ve), which are a 
more chemo-resistant population, express more FGFR4 (Liu et al., 2006).  
As this is preliminary data, it would be interesting to investigate the mechanism of 
action further.  Similar assays used when exploring the mechanism of ERK5 in 
temozolomide resistance would be applied, particularly investigating the DNA 
damage response to the combination treatment.  FGFR4 depletion and treatment 
with chemotherapeutics (5-fluorouracil and oxaliplatin) have shown synergistic 
effects in colon cancer and STAT3 depleted cells have been shown to have a 
reduced DNA damage response when treated with UV-light and oxaliplatin 
chemotherapy (Barry et al., 2010, Turkington et al., 2014).  These findings may 
indicate a replication-associated mechanism of sensitisation, which potentially 
could be linked to temozolomide-mediated DNA lesions.   
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Treatment for GBM has remained unchanged for nearly 2 decades, since the 
approval of temozolomide for treating patients with recurrent glioblastoma  in 2001 
(Arney, 2013, NICE, 2001).  Temozolomide has improved 2 year survival from 10.4% 
to 26.5% in a phase II clinical trial (Stupp et al., 2005), however, GBM still remains a 
death sentence with most patients passing away only 18 months from diagnosis (Di 
Carlo et al., 2017).   
There are around 10,000 drugs currently in cancer clinical trials, however, the drop-
out rate is extremely high with failure to get from phase 0 clinical trials to phase I 
clinical trials as high as 95% (ClinicalTrials.gov, 2018, Kola and Landis, 2004).  For the 
compounds that are successful, it may have taken over 13 years before patients can 
receive this drug as part of their treatment regime (Paul et al., 2010).  This process 
is extremely costly not only for the pharmaceutical industry but also health care 
providers, such as the NHS, as the cost of purchasing successful drugs is inflated to 
cover the financial loss of failures (Sleire et al., 2017).  In order to target both poor 
productivity and expense of developing novel drugs, the Repurposing Drugs in 
Oncology (ReDO) Project has been developed.  This project focuses on repurposing 
non-oncology low-cost drugs which have a well-developed and safe 
pharmacokinetic profile.   
Studies investigating toxicity, absorption, distribution, metabolism and excretion 
are often available for drugs with the potential to be repurposed.  Phase I trials to 
establish maximum tolerated doses are still likely to be required when repurposing 
a drug, however, the risk of the drug failing is reduced as the pharmacokinetics are 
more likely to be better understood  (Pantziarka et al., 2014).  A successful example 
of drug repurposing is sildenafil.  This drug was initially developed to treat angina 
before being repurposed for treating erectile dysfunction and termed Viagra.  It has 
now been further developed and is used to treat pulmonary hypertension (Ghofrani 
et al., 2006).  
Collections of various pre-tested drugs have been compiled for high-throughput 
repurposing screens.  Itraconazole, first developed as anti-fungal, is one drug which 
has been identified by such screens.  Itraconazole was identified in a repurposing 
screen as an inhibitor of oncogenic hedgehog signalling in medulloblastoma (Kim et 
al., 2010).  It is now being tested in clinical trials for various cancers, having also 
shown synergistic effects with chemotherapeutics (ClinicalTrials.gov, 2018, Kim et 
al., 2010, Pounds et al., 2017).  
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During this study we conducted a screen of over 2000 compounds with the aim of 
identifying novel small molecule inhibitors able to sensitise GBM cells to treatment 
with temozolomide.  The compounds screened were from two libraries: a 
pharmacologically diverse selection of marketed drugs (Prestwick Chemical Library) 
and late phase clinical trial failures and natural compounds library targeted to CNS 
biology (Spectrum Collection Library). 
 
6.2 Small Molecule Screen Optimisation – Positive Control 
 
Seeding densities, which had been previously optimised for the siRNA screen 
(chapter 3), were used for the small molecule drug screen as the assays were to be 
carried out in the same 384-well format and duration.  A positive control able to 
generate a z-prime of >0.5 was also required for this screen.  O-6-benzylguanine 
(O6BG) is a small molecule inhibitor of MGMT, the enzyme responsible for repairing 
the most toxic lesion caused by temozolomide; methylation at the O6 position of 
guanine (Dolan et al., 1991).  O-6-benzylguanine was tested in combination with 
temozolomide (50µM) as a potential positive control.  DMSO was used as a 
negative control at the maximum concentration cells were exposed to in the 
positive control wells.  Positive and negative controls were added to a 384 well 
plate in a checker-board fashion to mitigate any intra-plate localisation effects on 
cell growth (figure 6.1).  On day 0 cells were plated, 24 hours later DMSO and O-6-
benzylguanine were added to the wells, before DMSO and temozolomide were 
added following a further 24 hours incubation.  The plates were then incubated for 
5 days before processing, imaging and analysing in an identical manner to the siRNA 
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10µM O-6-benzylguanine combined with 50µM temozolomide was able to generate 
significant cell death when compared to the negative DMSO control, giving a z-
prime of 0.61 (as calculated in chapter 3).  A score of >0.5 reflects a robust and 
reproducible assay (Bray and Carpenter, 2017).  This drug combination therefore 
was used as a subsequent positive control in the outer columns of every plate for 










Figure 6.1: 384 well plate checker-board representation  
24 hours after plating in a 384 well plate, T98G cells were treated with either DMSO or 10µM 
O6BG.  Following a further 24 hours incubation, cells were treated with DMSO or 50µM TMZ.  
DMSO and drugs were added the wells using a Labcyte Echo 500.  After 5 days, cells 
underwent staining, fixing and imaging and wells were analysed using a Multi Wavelength 
Cell Scoring application on MetaXpress which counted cells based on minimum and maximum 
microns and intensity above background.   
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6.3 Screen Optimisation – Negative Control 
 
All compounds in the library were diluted in DMSO to a concentration of 10mM 
before being dispersed by the Labcyte Echo 500 at the volume required for the 
selected concentration (e.g. 1µM or 10µM).  In order to ensure any effects on 
survival fractions were not due to increasing doses of DMSO, a DMSO dose 
response in T98G cells was conducted.  Doses ranged from 1-100µM either alone or 


















DMSO showed slightly toxicity (5-10%) at the highest concentration that would be 
used for dose responses of any potential hits.  At 10µM, the highest screen 
concentration, there was very minimal toxicity.  This was therefore deemed 
acceptable as a suitable negative control for the screen.  
 
Figure 6.2: Fraction of GBM cells treated with DMSO  
Cells were plated and allowed to adhere for 24 hours. Cells were treated with a range of 
volumes of DMSO equal to that dispersed for 0-100µM before being treated with 50µM TMZ 
24 hours later.  Drugs were added the wells using a Labcyte Echo 500.  After 5 days, cells 
underwent staining, fixing and imaging and wells were analysed using a Multi Wavelength 
Cell Scoring application on MetaXpress which counted cells based on minimum and maximum 
microns and intensity above background.  .  
 
A and B show the same data plotted against a different x-axis. 
 
Data shown is the surviving fraction +/- standard deviation from two independent biological 
repeat experiments. 
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6.4 Prestwick Chemical Library  
 
The Prestwick Chemical Library contains 1200 small molecule drugs, which form a 
diverse pharmacological collection.  Both 1µM and 10µM were selected as standard 
doses to perform the screen at.  Screening at 1µM did not highlight any particular 
compounds that sensitised the cells to temozolomide (data not shown).  However, 
when the library was screened at 10µM, 9 compounds were identified as potential 
‘hits’ (table 6.1). Hits were selected if they were able to reduce survival fraction by 
20% or greater when compared to DMSO negative control. 
 
Table 6.1 – Small molecules identified as sensitisers of GBM cells to temozolomide following 
initial screening at 10µM.  The compounds have a range of roles including: anti-bacterial, 
muscle relaxant, vasodilator, hypotensor and anti-psychotic. 
 
Increasing doses of the selected compounds (0-30µM) were then combined with 
50µM of temozolomide.  Out of all the compounds tested, only butamben was able 
to sensitise the cells to temozolomide (figure 6.3).  Butamben is a voltage 
dependent calcium channel blocker and an ATP sensitive potassium channel 
antagonist; used as a local anaesthetic (Beekwilder et al., 2006, Winkelman et al., 
2005).  It is not immediately obvious how this drug may affect cellular responses to 
temozolomide; however, it was decided to validate it further as a potential 
temozolomide sensitising agent.   
Thioridazine hydrochloride, an anti-psychotic agent which acts through inhibition of 
DRD2 receptors in the CNS, was subsequently identified as a sensitiser to 




Table 6.1: Prestwick Chemical Screen ‘hits’- 10µM 
Compound Survival Fraction 
Metronidazole 0.74 
Allantoin 0.75 
Atracurium besylate 0.80 
Dropropizine (R,S) 0.71 
Midodrine hydrochloride 0.76 
Perhexiline maleate 0.78 
Thioridazine hydrochloride 0.78 
Fluphenazine dihydrochloride 0.66 
Butamben 0.68 












Figure 6.3: Cytotoxicity curves of GBM cells treated with Prestwick Chemical Screen ‘hits’ 
and TMZ 
Cells were plated and allowed to adhere for 24 hours. Cells were treated with a range of doses 
of drugs (0-30µM) before being treated with TMZ 24 hours later.  Following 5 days incubation 
an MTT assay was performed.  Only T98G cells treated with butamben showed a reduced 
survival fraction when treated in combination with TMZ as opposed to drug alone, this 
reduction in survival was significant at 30µM (p=0.009). 
 
Data shown is the average surviving fraction (normalised to DMSO treated control) +/- 
standard deviation from 3 independent biological repeat experiments. 
**=P<0.005 using a Mann-Whitney U Test. 
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6.4.1 Validation of Butamben as a Temozolomide sensitising agent 
 
Fresh butamben was purchased from Selleck (S4583) and tested in increasing doses 
in T98G cells (0-30µM).  This fresh drug was inherently more toxic when compared 
to the Prestwick library stocks (most likely due to age-mediated degradation) but it 
was still able to sensitise the cells to temozolomide (figure 6.4).  Combinations of 
temozolomide and butamben ranging from 5µM to 17.5µM resulted in a significant 
decrease in survival fraction; however, this significance was lost when using ≥20µM 











Figure 6.4: Cytotoxicity curves of GBM cells treated with Butamben and TMZ 
Cells were plated and allowed to adhere for 24 hours. Cells were treated with a range of doses 
of butamben (0-30µM) before being treated with TMZ 24 hours later.  Following 5 days 
incubation an MTT assay was performed.  Butamben alone was slightly toxic at 7.5 µM and 
10µM with a significantly reduced survival fraction of 0.80 and 0.72, however, this increased 
dramatically with increasing doses (p=0.05 and 0.01 respectively using a Mann-Whitney U 
Test).  T98G cells treated with butamben showed a reduced survival fraction when treated in 
combination with TMZ as opposed to butamben alone. 
 
A and B show the same data plotted against a different x-axis. 
A x-axis Butamben B x-axis TMZ 
Data shown is the average surviving fraction (normalised to DMSO treated control) +/- 
standard deviation from 3 independent biological repeat experiments. 
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In order to determine whether this was a cell line specific effect, butamben was 
tested in combination with temozolomide in several additional cell lines; including 
some non-GBM cells (figure 6.5).  Butamben was also combined with temozolomide 
in clonogenic survival assays which are more sensitive than MTT assays (figure 6.6).  































Figure 6.5: Cytotoxicity curves for a range of cancer cells treated with Butamben and TMZ 
Cells were plated and allowed to adhere for 24 hours. Cells were treated with a range of doses 
of butamben (0-10µM) before being treated with TMZ 24 hours later.  Following 5 days 
incubation an MTT assay was performed.  All cells treated with butamben showed a reduced 
survival fraction when treated in combination with TMZ as opposed to butamben alone, 
however, this sensitivity varied between cell lines. 
 
Data shown is the surviving fraction (normalised to DMSO treated controls) +/- standard 



































Figure 6.6: Clonogenic survival curves for LN-18 cells treated with Butamben and TMZ 
Cells were plated and allowed to adhere for 24 hours. Cells were treated with DMSO, 5µM or 
10µM butamben before being treated with a range of doses of TMZ (0-400µM) 24 hours later.  
Cells were incubated for 12 days allowing colonies to form.  Cell colonies were fixed in 0.04% 
methylene blue in 100% ethanol for 30 minutes at room temperature.  >50 cells were counted 
as a colony.  Both 5µM and 10µM butamben combined with TMZ were more effective at 
killing cells when compared to TMZ alone  The higher dose of butamben was more effective at 
sensitising cells to TMZ.   
 
Data shown is the surviving fraction (normalised to DMSO treated controls) +/- standard 
deviation derived from two independent biological repeat experiments. 






















Figure 6.7: Cytotoxicity curves for a range of GBM cells treated with Butamben and TMZ 
Cells were plated and allowed to adhere for 24 hours. Cells were treated with a range of doses 
of butamben (0-10µM) before being treated with TMZ 24 hours later.  Following 5 days 
incubation an MTT assay was performed.  All cells treated with butamben showed a reduced 
survival fraction when treated in combination with TMZ as opposed to butamben alone; 
however, this sensitivity is only due to initial death caused by TMZ treatment. 
 
Data shown is the surviving fraction (normalised to DMSO treated controls) +/- standard 
deviation derived from 3 independent biological repeat experiments.  
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There were two GBM cell lines which did not sensitise to the combination of 
butamben and temozolomide (figure 6.7).  These were U-87 and U-251 cells which 
are both MGMT negative (figure 3.1A).  In order to test whether MGMT is required 
for butamben to sensitise cells to temozolomide, MGMT proficient cells were 
depleted using siRNA before being drug treated.    
Both control and MGMT siRNA treated T98G cells were sensitive to the 
combination of butamben and temozolomide (figure 6.8).  However, the 
combination treatment which caused a significant increase in cell death resulted in 
OD values near the sensitivity limit of the assay.  MGMT depletion combined with 
temozolomide caused almost 50% cell death which resulted in a much less dramatic 
sensitisation when additionally combined with butamben.  Expected values 
generated from combination treatment (B+T) were 0.38 for MGMT siRNA and 0.77 
for control siRNA, compared to the observed values of 0.18 and 0.23 respectively.  
Additional clonogenic survival assays would therefore be a more accurate measure 






























Figure 6.8: Survival Fraction of T98G cells treated with Butamben and siRNA 
Cells were reverse transfected for 48 hours before being treated with 10µM butamben.  24 
hours later cells were treated with 50µM TMZ.  Following 5 days incubation an MTT assay was 
performed.  Cells treated with MGMT siRNA were more sensitive to temozolomide treatment, 
a positive control for the assay. Both control and MGMT siRNA treated cells had a significant 
decrease in survival fraction when treated with the combination of butamben and 
temozolomide when compared to the respective DMSO control cells.  
 
Data shown is the surviving fraction (normalised to DMSO treated controls for control or 
MGMT siRNA) +/- standard deviation derived from two independent biological repeat 
experiments, 














































































6.4.2 Butamben and DNA damage 
 
In order to ascertain a potential mechanism by which butamben sensitised cells to 
temozolomide, comet assays were used to asses DNA damage caused by the 
combination of butamben and temozolomide.  These assays were carried out both 
a responding GBM cell line (T98G) and a non-responding GBM cell line (U-251).  The 
combination of butamben and temozolomide caused a modest, yet significant 
increase in tail moment (an established measure of DNA damage, see methods 
section for further details) in T98G cells when compared to temozolomide treated 














Figure 6.9: Assessing DNA damage using comet assays in GBM cells treated with butamben 
Cells were plated before being treated with DMSO or 10µM butamben.  24 hours later 200µM 
TMZ was added. Cells were collected for comet assays 24 hours post TMZ treatment. Comets 
were imaged and then analysed using CometScore.  50 cells were imaged for each condition, 
example images seen in B.  The combination of butamben and TMZ caused a significant 
increase in DNA damage in T98G cells (p=0.04) when compared to TMZ alone (A).  U-251 cells 
did not exhibit a significant increase in DNA damage in the combination treatment when 
compared to TMZ alone (p=0.47) (A), consistent with butamben not sensitising these cells to 
treatment with TMZ (figure 6.6). 
 
Data shown is the Tail Moment +/- standard deviation. 
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Unfortunately, due to time constraints the mechanism by which butamben 
sensitises GBM cells to temozolomide was not further studied. 
 
6.5 Spectrum Collection Library 
 
The Spectrum Collection library contains 1040 compounds including failures from 
late phase clinical trials, FDA approved drugs and natural compounds.  However, 
these have all been selected as compounds with the potential to target the CNS. 
The Spectrum Collection library was screened identically to the Prestwick Chemical 
Library, both at 1µM and 10µM.   Screening at 1µM identified two compounds 
which sensitised T98G cells to temozolomide; thalidomide and deoxysappanone B 
trimethyl ether.   
Thalidomide, which acts in as an anti-angiogenic, has previously been identified as a 
compound with the potential to sensitise GBM tumours to treatment with 
temozolomide and had a positive effect on survival in phase II clinical trials 
(Baumann et al., 2004).  It has also been trialled in other cancers where 
temozolomide is given as a chemotherapeutic, including melanoma, 
leiomyosarcoma and neuroblastoma (ClinicalTrials.gov, 2018).   
Deoxysappone B trimethyl ether is an inhibitor of TDP1, involved in the repair of 
DNA damage, and an inhibitor of CYP3A4 (National Center for Biotechnology 
Information, 2018a).  TDP1 depleted GBM cells have been shown to be more 
sensitive to temozolomide when compared to TDP1 proficient cells (Alagoz et al., 
2013).   
As both of the compounds identified in the 1µM screen had been previously 
identified as known sensitisers of GBM cells to temozolomide, this was positive 
reinforcement that the screen was a valid approach by which to identify novel 
temozolomide sensitising agents.  However, as these were the two targets 
identified from the screen at 1µM, an additional screen was carried out using 10µM 
of each compound within the library to try and identify initial hits.  
Two compounds were identified from the 10µM screen.  These were pyrvinium 
pamoate (PP) and d-penicillamine (D-pen).  Both drugs were relatively non-toxic at 
10µM with survival fractions of 0.97 and 0.71 respectively.  When combined with 
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6.5.1 Pyrvinium Pamoate 
 
Pyrvinium pamoate is an androgen receptor inhibitor.  Androgen receptors are 
activated by testosterone and dihydrotestosterone (DHT).  Pyrvinium pamoate has 
been investigated as a potential therapeutic in prostate cancer where androgen 
receptors are central to both the initial oncogenic development as well as 
progression into a more aggressive and advanced prostate cancer (Lim et al., 2014).   
Pyrvinium pamoate was purchased for a dose response in T98G cells (Sigma-Aldrich 
1592001).  This fresh drug was extremely toxic and over 90 percent of cells were 
dead at a dose of 1µM.  The combination of pyrvinium pamoate and temozolomide 
































































Figure 6.10: Cytotoxicity cruves of GBM cells treated with Pyrvinium Pamoate 
T98G cells were plated and allowed to adhere for 24 hours. Cells were treated with a range of 
doses of PP (A: 0-1µM, B: 0-10µM and C: 0-100µM) before being treated with TMZ 24 hours 
later.  Drugs were added the wells using a Labcyte Echo 500.  After 5 days, cells underwent 
staining, fixing and imaging and wells were analysed using a Multi Wavelength Cell Scoring 
application on MetaXpress which counted cells based on minimum and maximum microns and 
intensity above background.  
 
Survival fraction (A) shows T98G cells treated with a maximum dose of 1µM PP. 
Survival fraction (B) shows T98G cells treated with a maximum dose of 10µM PP. 
Survival fraction (C) shows T98G cells treated with a maximum dose of 100µM PP. 
A, B and C show the same data plotted against a different x-axis. 
 
Data shown is the average surviving fraction (normalised to DMSO treated controls) +/- 
standard deviation derived from 3 independent biological repeat experiments. 
 
 







                                        
 C 




Penicillamine is a chiral molecule which forms a mixture of both D- and L- 
penicillamine. These compounds are formed when penicillin degrades. 
Penicillamine is used as an anti-rheumatic and also as copper chelator in Wilson’s 
disease, where a fatal level of copper builds up in organs such as the brain and liver 
(Finney et al., 2009, National Center for Biotechnology Information, 2018b).  D-
penicillamine was purchased for a dose response in T98G cells (Sigma-Aldrich 
P4875) to validate it as a novel temozolomide sensitising agent.  This drug had a 
similar toxicity in both the library screen and dose response at 10µM, however, it 
was not able to sensitise T98G cells to temozolomide when used in combination 
(figure 6.11), suggesting that like pyrvinium pamoate, it too was a false positive hit 







































Figure 6.11: Cytotoxicity curves of GBM cells treated with D-Penicillamine 
T98G cells were plated and allowed to adhere for 24 hours. Cells were treated with a range of 
doses of D-Pen (A: 0-10µM and B: 0-100µM) before being treated with TMZ 24 hours later.  
Drugs were added the wells using a Labcyte Echo 500.  After 5 days, cells underwent staining, 
fixing and imaging and wells were analysed using a Multi Wavelength Cell Scoring application 
on MetaXpress which counted cells based on minimum and maximum microns and intensity 
above background.  .  
 
Survival fraction (A) shows T98G cells treated with a maximum dose of 10µM D-Pen. 
Survival fraction (B) shows T98G cells treated with a maximum dose of 100µM D-Pen. 
A and B show the same data plotted against a different x-axis. 
 
Data shown is the average surviving fraction (normalised to DMSO treated controls) +/- 
standard deviation derived from 3 independent biological repeat experiments. 
 
A                                                          B 




Repurposing drugs has become an attractive approach in oncology as there has 
been a gradual decline in the number of drugs approved for treatment each year 
since the 1990s (Sleire et al., 2017).  During this study we have identified butamben 
as a potential novel sensitiser of GBM cells to temozolomide.  Butamben is used as 
a topical anaesthetic and as an epidural for chronic pain.  Its anaesthetic properties 
are thought to be due to inhibition of voltage gated ion channels (sodium, calcium 
and potassium) linked to nociception (Beekwilder et al., 2006, Winkelman et al., 
2005, Van den Berg et al., 1995).  
Ion channels are known to be important in GBM as they help regulate proliferation 
via cell cycle checkpoints, and the sequencing of over 20,000 genes in 21 GBM 
patients revealed that over 90% had mutations in genes relating to transport of ions 
(Joshi et al., 2011).   
ATP-sensitive voltage gated potassium channel inhibitors are able to reduced cell 
proliferation in GBM cell line U-87 both in vitro and in vivo (xenograft nude mouse 
models) (Ru et al., 2014).  Furthermore, big conductance potassium channels (BK), 
which are activated by membrane potential changes and intracellular calcium, are 
over-expressed in GBM patients and are thought to contribute to the migratory 
properties of the tumour cells (Wondergem et al., 2008). 
GBM patients with mutations in sodium ion channels have a reduced overall 
survival when compared to patients with potassium or calcium ion channel 
mutations.  Additionally, patients with IDH1 mutations, which confers better 
survival, did not have any sodium ion channel mutations.  However, this study 
included only a small cohort of patients (n=21) and did not reach statistical 
significance (Di Stefano et al., 2015, Joshi et al., 2011). 
Mibefradil is an l-type and t-type (CaV 3.2) calcium channel blocker.  The l-type 
inhibition targets hypertension and that was the original target, however, 
repurposing has shown t-type inhibition to slow growth of glioma stem cells (GSCs) 
(Keir et al., 2013).  T-type channels are highly expressed in GSC population 
compared to the bulk tumour population, and under normal physiological 
conditions have important roles in cell cycle progression, cell growth and 
proliferation (Keir et al., 2013, Zhang et al., 2013). The combination of mibefradil 
and temozolomide was able to cause a decrease in both cell proliferation and 
increase in cell death detected by trypan blue (Zhang et al., 2017).  These findings 
translated into an orthotopic GSC xenograft model in immunocompromised mice, 
where the combination of treatment reduced tumour growth in an additive manner 
(Keir et al., 2013).  Butamben is also a t-type calcium channel inhibitor and may be 
acting in an identical manner to mibefradil, explaining the temozolomide 
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sensitisation seen (Beekwilder et al., 2006, Zhang et al., 2017), although at present 
the mechanism by which the two drugs interact is currently unknown.  This effect 
has not only been seen in GSCs, as U-87 cells have also shown reduced proliferation 
and migration in response to inhibition of t-type calcium currents (Zhang et al., 
2012).  Mibefradil has been recently tested in two phase I trials in patients with 
recurrent GBM, in combination with either radiotherapy or temozolomide, 
however, the result have not yet been published (ClinicalTrials.gov, 2018).  As 
butamben affects various ion channels, it would have been prudent to test 
sensitisation using alternative methods to MTT assays.  One example would be to 
use trypan blue, as this does not rely on metabolism, but it can be used to identify a 
non-viable cell population through the uptake of the blue dye.  Clonogenic survival 
assays which simply stain clonal cell colonies were used as an alternative measure 
of cell proliferation and were able to show similar temozolomide sensitisation seen 
using MTT assays. 
One key issue with the use of butamben is the anaesthetic property of the drug.  
Even if butamben was given directly into the tumour cavity during surgery, the 
compromised blood brain barrier seen in GBM patients means the anaesthetic is 
likely to reach systemic circulation thereby effecting normal tissues, making the 
combination of butamben and temozolomide highly unlikely to ever reach clinical 
trials.  This unfeasibility makes it difficult to see how such a drug would have been 
included in a small molecule library where compounds have been selected for 
repurposing.  If the target which enables butamben to sensitise GBM cells to 
temozolomide could be identified, inhibition with an alternative small molecule 
compound which does not have anaesthetic properties may have the potential for 
success in clinical trials. 
Not only have calcium channels been identified as potential targets for 
temozolomide sensitivity, one initial hit from the Prestwick Screen, fluphenazine 
dihydrochloride, is an anti-psychotic and an inhibitor of calcium-modulated protein 
(calmodulin) (Hait et al., 1987).  Calmodulin is activated by the binding of calcium 
ions (Ca2+) which enable it to act as a second messenger, binding to ion channels, 
enzymes and various other proteins relaying signalling information to pathways 
involved in apoptosis, smooth muscle contraction, metabolism and immunity (Chin 
and Means, 2000).  Calmodulin has been shown to be important for the growth of 
rat glioblastoma cells (C6 cells), with increasing inhibition of calmodulin correlating 
with reduced tumour cell growth (Lee and Hait, 1985).  Although the mechanism for 
this increased apoptosis is unclear, it may be via effects on calmodulin sensitive 
phosphodiesterases thus effecting cAMP and cGMP signalling (Lee and Hait, 1985).  
The degree of calmodulin inhibition does not completely explain the anti-
proliferative effects, but further studies showed a similar correlation regarding 
inhibition of sigma receptors (bind to anti-psychotropic drugs e.g. Xanax) (Vilner 
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and Bowen, 1993).   Calmodulin 3 (CALM3) and Calcium/Calmodulin Dependent 
Protein Kinase II Beta (CAMK2B), Calcium/Calmodulin-Dependent Protein Kinase 
Type 1B (PNCK) and two cAMP dependent kinases (PRKAR1A and PRKAR2B) were 
also initial hits in the primary OTP screen.  However, these were not taken forward 
as potential hits as they did not sensitise cells to temozolomide when depleted by 
siGENOME siRNA, however, as this was much less effective than OTP they could still 
be potential targets (chapter 3).  However, when a calmodulin inhibitor 
(trifluoperazine) was combined with chemotherapy (bleomycin) in 17 GBM patients 
in a Phase II trial, there was unfortunately no improvement with the combination.  
Although trifluoperazine is lipophilic and readily crosses the blood brain barrier, 
bleomycin is amphipathic and therefore potentially ineffective at treating GBM; 
possibly explaining why there was no sensitisation observed (Hait et al., 1990, 
Kristiansen et al., 1981). 
Thioridazine hydrochloride, an anti-psychotic, was also identified as an initial hit in 
the Prestwick Chemical Screen, however, the combination of thioridazine 
hydrochloride and temozolomide was unable to sensitise GBM cells in a series of 
dose response experiments.  Thioridazine hydrochloride has now been shown to 
sensitise GBM cells to temozolomide both in vitro and in vivo through inhibition of 
autophagy.  This results in the accumulation of autophagosomes and eventually cell 
death (Johannessen et al., 2018).  This publication, although strengthening the 
findings from the initial Prestwick Chemical Screen, highlights the difficulties in the 
reproducibility associated with screening such small drug volumes.  Due to this 
subsequent publication it would be interesting to revisit the compounds initially 
identified and retest them in combination with temozolomide in a different format.  
Both pyrvinium pamoate and d-penicillamine were identified as initial positive hits 
from the Spectrum Collection.  Pyrvinium pamoate has anti-oncogenic properties 
through its ability to inhibit wingless (Wnt) signalling (Venerando et al., 2013) and it 
is able to reduce proliferation of both prostate and breast cancer cells in vitro 
(Jones et al., 2009, Xu et al., 2016).  Wnt signalling is thought to increase chemo-
resistance possibly through maintaining GSC populations but also by its indirect 
effect on MGMT, which may possibly explain any sensitisation effects initially seen 
(Suwala et al., 2018, Wickström et al., 2015).  However, as the results were unable 
to be repeated, it is unknown if pyrvinium pamoate can sensitise GBM cells to 
temozolomide.   
Penicillamine is known to have anti-angiogenic properties due to its ability to 
chelate copper, which is a required factor for angiogenesis, and the use of 
penicillamine as a cancer therapeutic has been investigated for a long time.  In 
1990, penicillamine was used to deplete cells of copper in glioblastoma rat 
xenografts.  This depletion caused both a reduction in angiogenesis and a significant 
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reduction in  tumour growth and size (Brem et al., 1990a, Brem et al., 1990b).  
Penicillamine was used in a phase II trial in combination with radiotherapy in 
patients with glioblastoma multiforme.  Although the drug was well tolerated by 
the patients, there was no improvement in overall survival.  Unfeasibly, it was 
suggested that penicillamine may be more beneficial before the onset of GBM 
occurs as the successful animal models were treated with penicillamine before the 
tumour cells were implanted (Brem et al., 2005).  There are no trials that have 
investigated the use of penicillamine in combination with temozolomide, however, 
when penicillamine is prescribed, patients are warned not to take temozolomide 
due to the increased risk of haematological and renal toxicity (Prescribers' Digital 
Reference, 2018). 
However, further validation of these compounds showed that both were unable to 
sensitise GBM cells to temozolomide in a dose-response.  The initial sensitisation 
could potentially have been caused by activity of degradation products due to the 
age of the drugs in the screening library, however, the lack of sensitisation may 
simply have just been false positive hits generated.  However, there was some 
difficulty during this screen as the positive control of O-6-benzylguanine in 
combination with temozolomide was not always able to generate significant cell 
death detectable by the assay.  This may have been due to static charges 
preventing the drugs reaching the media/cells, causing the drugs to not be 
delivered by the Labcyte Echo 500 to the desired concentration.  In an attempt to 
control for this possibility, plates were gently tapped after drugs were added before 
being centrifuged to bring all liquid into the well bottom.  Additionally, drugs stocks 
were vortex thoroughly before being used and the dispensing report of the Labcyte 
Echo 500 was checked after every drug screen.  Unfortunately, all of the above 
solutions were unable to rectify the issues of the positive control failing.  This could 
have led to the false positive results, as the robustness and reproducibility of the 
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Chapter 7 – Conclusions  
 
In the UK, brain cancer kills around 5,000 people every year, reducing life 
expectancy by 20 years (Burnet et al., 2005), and in 2014, brain cancer was 
classified as a cancer of unmet need by Cancer Research UK.  This is because on 
average 50% of all patients diagnosed with cancer will achieve at least a 10 year 
survival, however, for patients with brain cancer, 10 year survival is only achieved 
by 13.5% (CancerResearchUK, 2011a, CancerResearchUK, 2011b).  GBM, the most 
common high-grade glioma, accounts for around half of all primary adult brain 
tumours (Adamson et al., 2009, Kleihues et al., 2000).   
Currently, the most aggressive treatment for GBM is de-bulking surgery followed by 
radiotherapy combined with both concomitant and adjuvant temozolomide (Stupp 
et al., 2009).  Between 2007 and 2011, almost 11,000 people were diagnosed with 
GBM in England, with a median survival of just over 6 months and a 5 year survival 
of only 3.4% (Brodbelt et al., 2015).  GBM tumours readily become resistant to 
temozolomide treatment and almost 90% of patients with recurrent GBM have 
tumours that have a complete lack of response to a second cycle of temozolomide 
(Oliva et al., 2010). The  constantly mutating and evolving tumour genome results in 
massive intratumoural heterogeneity and consequently treatment failure and 
disease recurrence (Qazi et al., 2017). As such, GMB is currently an incurable 
disease. 
Previous studies from several groups have aimed to develop treatments for GBM 
patients that augment the potency/cytotoxicity of temozolomide within cancer 
cells.  MGMT is a DNA repair enzyme that is able to directly repair the toxic lesions 
caused by temozolomide, as such, the activity of MGMT was targeted by the use of 
a specific inhibitor called O-6-benzylguanine, which was tested in clinical trials.  As 
MGMT is a suicide enzyme, once it has accepted a methyl group from DNA to repair 
the alkylation damage caused by temozolomide or accepted a benzyl group from O-
6-benzylguanine, it will then be targeted for degradation.  This means that DNA 
damage induced by temozolomide can accumulate if the levels of damage exceed 
the cellular levels of MGMT, which can be artificially reduced by O-6-benzylguanine. 
Unfortunately, there was no improvement in overall survival when patients 
received both O-6-benzylguanine and temozolomide, and haematological toxicity 
was a common side effect (Quinn et al., 2009), leading to the cessation of O-6-
benzylguanine trials.  
APNG, a BER protein, has also been investigated in relation to resistance to 
temozolomide in GBM; however, high expression has been shown to be both 
beneficial and detrimental to overall survival in patients (Agnihotri et al., 2012, 
Fosmark et al., 2017).  Inhibition of the BER pathway has been targeted in order to 
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attempt to sensitise temozolomide resistant ovarian and CRC tumour cells to 
temozolomide.  Methoxyamine, which binds to the abasic site inhibiting BER, did 
sensitise tumours cells to temozolomide alkylation damage (Fishel et al., 2007, 
Taverna et al., 2001).  There is currently a phase II clinical trial investigating the use 
of methoxyamine in combination with temozolomide in patients with recurrent 
GBM, however, the trial is still active and the results are yet to be published 
(ClinicalTrials.gov, 2018).  Inhibitors of PARP, a family of proteins also involved the 
BER pathway, are being investigated in clinical trials for patients with both 
recurrent (olaparib) and newly diagnosed GBM (veliparib), however, results have 
not yet been published as the recurrent GBM trial was only completed in July 2017 
and the trial in newly diagnosed GBM patients is still actively recruiting 
(ClinicalTrials.gov, 2018, Morales et al., 2014). There are also various other targets 
which are currently in trials for patients with GBM.  These include histone 
deacetylases, JAK1/2, PDGFR as well as pathways targeting survival, apoptosis and 
migration of tumour cells as well as improving the patient’s immune response to 
specifically target tumour cells (ClinicalTrials.gov, 2018). 
Nevertheless, there is still a desperate need to improve treatment and 
subsequently survival for GBM patients.  The ‘druggabiliy’ of kinases combined with 
the possibility of targeting master regulator unlocks the potential to target 
subsequent downstream signalling pathways and networks which may be 
fundamental to the development and progression of cancer (Manning, 2009).  
Given previous success, as seen with imatinib in CML, and the potential to target 
complex signalling networks combined with the fact GBM patient survival has 
remained unchanged for decades (Manning, 2009, Stupp et al., 2005), it was 
hypothesised that yet to be identified targets and/or pathways within the kinome 
could sensitise GBM cells to standard of care temozolomide treatment and that 
inhibitors of these novel targets could be developed into future adjuvant therapies.  
To investigate this hypothesis there were 5 aims, the first being carrying out an 
siRNA screen across the human kinome and completing two re-purposing small 
molecule drug screens in temozolomide resistant GBM cells.  The experimental 
steps taken to achieve the aims of the project are shown for both the siRNA and 
small molecule re-purposing screens in figure 7.1. Both siRNA screens and re-
purposing screens are well validated and established approaches to identify novel 
targets.  Both screens had robust positive controls established which were known 
sensitisers of temozolomide: MGMT siRNA and O-6-benzylguanine (Agarwala and 
Kirkwood, 2000, Quinn et al., 2005).  After optimisation, Z-prime values of >0.5 
were established using these positive controls in both assays and the screens were 
carried out.  There were no issues carrying out the siRNA kinome screen, with the 
positive control siRNA working well across all experimental repeats, resulting in a z-
prime of >0.5 on each 384 well plate screened.  However, the small molecule drug 
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screen positive control was not as successful and the assay robustness was lost.  
Attempts were made to rectify this loss including gently tapping plates to break any 
static charges, drugs stocks were vortex thoroughly before being used and the 
dispensing report of the Labcyte Echo 500 was checked after every drug screen.  
Unfortunately, all of the above solutions were unable to rectify the issues of the 



















The second aim was to validate the results from the siRNA kinome screen.  None of 
the hits from the initial kinome screen selected for validation using siGENOME 
siRNA were able to significantly sensitise GBM cells to temozolomide. However, 
even siGENOME siRNA targeting the well-established temozolomide sensitiser, 
MGMT, was unable to generate a significant increase in temozolomide sensitivity.  
ON-TARGETplus siRNA targeting MGMT was therefore used as a positive control to 
ensure the assay was working. This was less than ideal and consequently hits which 
Figure 7.1: Flowchart Summary of Studies 
The studies shown in  blue were all completed in order to investigate the hypothesis ‘inhibition 
of yet to be identified targets or pathways will enhance the cytotoxic effect of temozolomide 
in GBM’.  Those in red were unfortunately not completed within the timeframe. Flowchart A 
shows the steps taken for the siRNA kinome screen as well as the subsequent validation and 
mechanistic steps. Flowchart B shows the steps taken for the small-molecule drug screens as 
well as the validation and mechanistic steps.    
A                 B 
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reduced survival to less than 90% when both siRNA and temozolomide were 
combined were selected for further validation.  Validation using deconvoluted 
siRNA also resulted in some difficulties, with re-pooled siRNA in ineffectively 
depleting 4 out of 6 hits taken forward.   
Of the two hits that were successfully depleted by siRNA, only one (MAP3K3) was 
able to sensitise GBM cells to temozolomide.  MAP3K3 is over-expressed in almost 
two thirds of ovarian carcinomas (where expression is correlated with both grade 
and response to chemotherapy), and has also been shown to be amplified in up to 
20% of breast cancers, with shRNA depletion increasing sensitivity to both 
doxorubicin and 5-FU (Fan et al., 2014, Jia et al., 2016).  Although the inhibition of 
MAP3K3 would subsequently inhibit a whole pathway of downstream targets and 
signalling pathways, there are currently no specific MAP3K3 inhibitors reported.  
Therefore, downstream targets with inhibitors (MEK5/ERK5) were investigated 
further.  ERK5 depletion using siRNA or small molecule inhibition sensitised a panel 
of MGMT positive and MGMT negative GBM cell to temozolomide, particularly 
evident by data shown from the clonogenic survival assays.  Here, the LD10 for 
temozolomide alone was approximately 60µM in LN-18 cells; however, when 
combined with ERK5i, the LD10 was decreased to approximately 10µM, a 6 fold 
change temozolomide sensitivity.  This is comparable to the data from clonogenic 
survival assays originally published in 1996, which showed fold changes for 
temozolomide sensitivity in GBM cells, ranging from 2.1 in T98G cells up to 19.5 in 
SF767 cells following the inhibition of MGMT activity using O-6-benzylguanine 
(Bobola et al., 1996), the target which was used as the positive control for both the 
siRNA and small molecule drug screen. 
FGFR4 was the second hit which was selected following siGENOME validation as 
commercially inhibitors were available. FGFR4 was therefore validated using an 
alternative siRNA pool and an inhibitor, both showing an increase in temozolomide 
sensitivity in MGMT positive and MGMT negative GBM cell lines.  However, it would 
be prudent to investigate FGFR4 protein levels in GBM tumour samples compared 
to normal brain tissue in order to establish whether a therapeutic window to 
specifically target the tumour cells is present.  Pan-FGF inhibitors are currently 
undergoing clinical trials for HCC, however, pan-tyrosine kinase inhibitors, such as 
those used when treating CML, can have deleterious side effects such as anaemia, 
nausea, leukopenia and therefore may not be well tolerated by all patients (Tsai et 
al., 2018).  However, if selective FGFR4 inhibitors are successfully approved for 
treating HCC it would speed up entry in to a GBM clinical trial, but there are 
currently very few reports investigating the dysregulation of FGFR4 signalling in 
GBM.  As FGFR4 expression has been shown to correlate with erlotinib resistance in 
GBM cell lines it could indicate a substitute role for FGFR4 in oncogenic EGFR 
signalling pathways which are dysregulated in a high proportion of GBM patients  
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(Halatsch et al., 2009).  Therefore, investigation into crosstalk between these 
pathways could identify novel therapeutic targets which could improve patient 
survival.   
The third aim was to validate targets by investigating the mRNA and protein 
expression in brain tumours compared to healthy brain.  Due to time constraints, 
the investigation into FGFR4 was minimal and mRNA expression was simply 
investigated using an online dataset.  However, as FGFR family members are being 
investigated as potential therapeutic targets for a subset of GBM patients with 
activating fusion mutations and FGFR4 kinase activating mutations have also been 
identified in a subset of GBM patients, this increases the chances of a clinical trial, 
particularly if FGFR4 inhibitors become NICE approved for HCC (ClinicalTrials.gov, 
2018, Masica and Karchin, 2011).  However, GBM is very heterogeneous, both 
between patients and within tumours, it may have been unrealistically optimistic to 
hope to identify a therapeutic target which would sensitise all GBM patients across 
4 subgroups to temozolomide treatment (Qazi et al., 2017, Verhaak et al., 2010).   
The same dataset used to investigate FGFR4 mRNA expression in GBM was also 
used to investigate ERK5 mRNA expression, however, this which showed a 
significant increase in GBM tumours compared to normal brain.  ERK5 protein 
expression was next investigated using IHC and TMAs.  There was, again, a 
significant increase in ERK5 protein expression in GBM tumours compared to 
normal brain, with over-expression correlating with tumour grade, highlighting a 
potentially exploitable therapeutic window. However, although TMAs offer a large 
sample number which can all be processed identically, they only contain such small 
section of a tumour meaning intratumoural heterogeneity is readily lost which 
should be kept in mind when analysing results. One possible solution to this 
problem would be to take small sections from several locations within the tumour; 
however, this may not be feasible as it depends entirely on the resected tumour 
received for the initial TMA processing. 
The fourth aim was to validate any hits identified in the small molecule drug 
screens.  There was a high dropout rate for the initially identified compounds, with 
only 1 compound out of 9 (11%) sensitising GBM cells to temozolomide in dose-
escalation studies.  This may have been due to the loss of assay robustness 
highlighted by the failure of the positive control. The identified compound 
butamben was able to sensitise a panel of GBM and non-GBM cells to 
temozolomide but due to time constrains there was little mechanistic investigation 
carried out. However, as butamben is t-type calcium channel inhibitor, it was 
speculated that it may be acting in an identical manner to another t-type calcium 
channel inhibitor, mibefradil, which is a known sensitiser of GBM cells to 
temozolomide (Beekwilder et al., 2006, Zhang et al., 2017).  A major issue 
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associated with the use of butamben is the anaesthetic property of the drug.  This 
unfeasibility makes it difficult to see how such a drug would have been included in a 
small molecule library where compounds have been selected for repurposing.  If 
the target which enables butamben to sensitise GBM cells to temozolomide could 
be identified, inhibition with an alternative small molecule compound which does 
not have anaesthetic properties may have the potential for success in clinical trials.  
In order to improve the outcomes of small molecule screening, compound library 
maintenance, particularly long term storage of plates, must be improved.  This is 
highlighted by large changes in toxicity following the purchase of new compounds 
and subsequent irreproducibility of sensitisation, possibly due to the presence of 
degradation of compounds within the library.  
The final aim was to investigate the mechanisms by which GBM cells are sensitised 
to temozolomide. Here the role of ERK5 inhibition and temozolomide sensitivity 
was mainly investigated, showing an increase in 53BP1 foci and DNA-PK 
phosphorylation suggesting that combination treatment causes an increase in NHEJ 
(and a reduction in HR), which is activated as a result of an increase in DSBs. 
Potential hypotheses could be ‘ERK5 inhibition causes dysregulation of the DNA 
damage response pathways in GBM cells, sensitising them to temozolomide’ or 
‘ERK5 inhibition sensitises GBM cells to temozolomide in a mitosis dependent 
manner, enhancing DNA damage and dysregulating the DNA damage response 
pathways’.  However, ERK5-in-1 is now known to have off-target effects on BRD4, a 
protein which has been shown to decrease proliferation of GBM cells, dysregulate 
NHEJ and also increase sensitivity to temozolomide in GBM cells following 
inhibition, potentially contributing to the phenotype seen as a result of ERK5-in-1 
inhibition and temozolomide treatment (Lam et al., 2018, Pastori et al., 2014, Wang 
et al., 2018a).   
The sensitisation seen when combination treatment is used could also be TP53 
dependent as ERK5 is known to down-regulate TP53 expression and a study 
investigating 5-FU chemo-sensitivity in HCT116 colon cancer cells showed TP53 null 
mutants were not sensitised following ERK5 inhibition, unlike their wild type 
counterpart (Lim and Woo, 2011, Pereira et al., 2016, Yang et al., 2013b). In these 
studies both wild-type and mutant TP53 GBM cell lines were used: LN-18 has both 
mutant and wild-type TP53, T98G and U-251 cells have TP53 mutations and U-87 
cells are homozygous for TP53 which may suggest that the sensitisation seen is not 
TP53 dependent (Van Meir et al., 1994). U-138 cells which did not respond to 
combination treatment are TP53 wild-type (Van Meir et al., 1994). TP53 dependent 
ERK5 inhibition has also been shown to sensitise triple-negative breast cancer cells 
to the DNA cross-linking agent cisplatin (Ortiz-Ruiz et al., 2014). However, data 
investigating 5-FU sensitisation in CRC saw ERK5 inhibition resulted in minimal 
change to TP53 protein levels.  Instead, an increase in p21, a CDK inhibitor and 
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negative regulator of cell cycle progression, and an increase in PUMA, a pro-
apoptotic protein, both which are dependent on TP53 activity were identified as 
potential players in the increase in apoptosis and reduction in xenograft tumour 
size following ERK5 inhibition and 5-FU treatment (Pereira et al., 2016). 
Furthermore, a lack of cell cycle checkpoint regulation and dysregulated cell cycle 
progression through the G1 and G2 checkpoints could also be involved in 
chemotherapeutic sensitisation of cancer cells following ERK5 inhibition, potentially 
via NF-κB signalling (Cude et al., 2007, Pereira et al., 2016, Perez-Madrigal et al., 
2012).   
A potential mechanism may have been highlighted when the addition of 
nocodazole, which arrests cells in metaphase of mitosis, reduced the amount of 
DNA damage in combination treatment (Zieve et al., 1980). This suggests that the 
damage is mainly derived during mitotic progression, which is also consistent with 
the dramatic increase in MNi observed in cells treated with ERK5i and 
temozolomide.  The damage generated also seems to primarily activate the NHEJ 
pathway, which is particularly active in the G1 phase of the cell cycle. However, it 
has also been reported by several groups that deleterious activity of the NHEJ 
pathway outside of G1 can lead to DNA damage and chromosomal aberrations 
(Adamo et al., 2010, Pace et al., 2010).  This was coupled with a reduction in HR 
pathway activity, which is known to confer resistance to temozolomide when over-
activated, and could therefore be further potentiating the sensitisation induced by 
the combination treatment (del Alcazar et al., 2016).   
Further work to unravel the precise mechanism by which the increase in 
temozolomide sensitivity following ERK5 inhibition/depletion needs to be 
completed, potentially focusing on the increased DNA damage and the resulting cell 
death as a consequence of mitotic progression and the dysregulated DNA damage 
response, as well as further validation in patient derived primary cells, 3D culture 
and orthotopic animal studies.  However, as adult mice with an inducible ERK5 
knock out died 2-4 weeks after ERK5 depletion due to increased endothelial cell 
death which caused their vasculature to become ‘leaky’ resulting in massive 
haemorrhage (Hayashi et al., 2004), problems associated with vasculature may be 
an issue with ERK5 inhibitors in clinical trials.  Although in GBM cells, ERK5 
inhibition did not cause significantly more DNA damage or cell death when used as 
an individual agent, which if combined with temozolomide targeted directly to the 
tumour cells using nanoparticles, combining the treatments may be well tolerated 
by patients, with little normal tissue toxicity (Fang et al., 2015).  However, off-target 
effect of BRD4 inhibition must be investigated further as new generation ERK5 
specific inhibitors, such as AX 15836, have shown a dramatically reduce anti-
inflammatory and anti-proliferative actions in cancer cells suggesting BRD4 or ERK5 
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kinase independent mechanisms are responsible for these phenotypes (Lin et al., 
2016, Wang et al., 2018a).    
If ERK5 inhibition is shown to increase temozolomide sensitivity in GBM cells 
following research using new generation ERK5 inhibitors, such inhibitors would 
need to undergo investigation in clinical trials before being approved for treating 
patients.  As ERK5 was over-expressed in more than 93% of GBM patient cores and 
expression was significantly higher than normal brain tissue, it would most likely be 
a suitable drug target for all GBM patients.  ERK5 inhibitors could therefore be used 
alongside radiotherapy and temozolomide which are given post-surgery, but also in 
combination with subsequent cycles of temozolomide.  ERK5 inhibitors were able to 
sensitise both temozolomide resistant and non-resistant cell lines so by combining 
the treatments, the standard dose of temozolomide would be potentiated.  
Furthermore, as the combination of ERK5 inhibition and temozolomide induced 
more DNA damage in GBM cells, the effects of radiotherapy may also be enhanced, 
killing more tumour cells and improving the prospect of patient survival.  However, 
even if the potentiation of temozolomide is shown to be purely due to BRD4 
inhibition, ERK5 is still dysregulated in a vast array of cancers once clinical trial 
testing begins and both a safe and efficacious ERK5 inhibitor is identified, cancer 
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